# Clone Execution Log
**Date:** 2026-02-13 04:06:59
# Initial Query <small>(04:06:59)</small>

```text
# Table Entry Validation and Research

You are validating and updating several field values for a single row in a research table.

═══════════════════════════════════════════════════════════════
## 🎯 FOCUSED TASK
═══════════════════════════════════════════════════════════════

**Use this section to guide your initial web searches.** Detailed field requirements for synthesis appear below.

**Context:**
Product (or Candidate): VMT02
Owner: Ratio Therapeutics

**3 Research Questions:**
Core Product & Owner Info: Basic product information including owner, target/indication, and development stage. This foundational data is often found together in company pipelines and press releases.

**1. Owner**: Company or entity that owns or is developing the product.???
   Current value: Ratio Therapeutics
**2. Target / Indication**: Biological target and the disease indication the product is intended for.???
**3. Development Stage**: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).???

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 WHAT YOU'LL FIND BELOW
═══════════════════════════════════════════════════════════════

The sections below provide detailed context for **synthesizing your search results** into validated answers:

- **GENERAL NOTES**: Validation context for the broader research effort this subtask falls within
- **CONTEXT & PREVIOUS DATA**: Other fields from this row and prior validations for reference
- **FIELD DETAILS**: Detailed requirements, format, notes, and examples for each field
- **CONFIDENCE LEVELS**: How to assign confidence ratings to your findings
- **RESPONSE FORMAT**: Required JSON structure and critical validation rules

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 GENERAL NOTES
═══════════════════════════════════════════════════════════════

This configuration validates a biopharmaceutical product/candidate tracking table. The primary identifier is the product name. All research columns should be verified against current public information as of February 13, 2026, using company websites, clinical trial registries (e.g., ClinicalTrials.gov), and reputable news sources. For columns left blank, it may indicate the information is not applicable or not yet public.

---

═══════════════════════════════════════════════════════════════
## 📊 CONTEXT & PREVIOUS DATA
═══════════════════════════════════════════════════════════════

**Context for this row:**

Product (or Candidate): VMT02
Owner: Ratio Therapeutics

⚠️ **CRITICAL - ROW CONTEXT SCOPE CONSTRAINT:**
All validation results must be about the SPECIFIC ENTITY identified by the context above.

**Common scope errors to AVOID:**
- Validating a different entity with a similar name
- Using general information when specific information is required
- Example: When validating news for "Product X by Company Y", reject news that only mentions "Company Y" without mentioning "Product X"
- Example: When validating a company associated with a product, verify the company OWNS/DEVELOPS that specific product, not just that the company exists

**Scope validation checklist:**
1. Do sources explicitly mention ALL identifying information from context above?
2. Is information contemporary with the entity (not before it existed)?
3. Have you cross-referenced to confirm entity identity?
4. When in doubt, mark confidence as MEDIUM or LOW

**Other fields from this row (unvalidated - for reference only):**

**Previous validations for this row:**

Product (or Candidate): VMT02 (Confidence: ID)

⚠️ **CRITICAL - INHERENT SUSPICION OF PREVIOUS RESULTS:**

Previous values shown above may be INCORRECT. Do NOT assume they are correct.

**Mandatory verification requirements:**
- Treat previous values as HYPOTHESES to be tested, not FACTS
- Every previous claim must be verified against current authoritative sources
- Do NOT copy previous values without independent verification
- Well-formatted previous answers with citations can still be wrong
- High confidence scores from past validations don't guarantee truth

**If current sources conflict with previous values:**
1. Prioritize DIRECT QUOTES from HIGH-AUTHORITY sources (see confidence criteria)
2. Check publication dates - newer authoritative sources may supersede old data
3. If conflict unresolved, mark confidence as MEDIUM or LOW
4. Document the conflict in your explanation

**Truth Standard:** Direct quotes from authoritative sources determine truth,
NOT how confident, well-cited, or professionally formatted previous results appear.

Your task: Use previous results as a STARTING POINT, then independently verify/correct with current sources.

---

═══════════════════════════════════════════════════════════════
## 📝 FIELD DETAILS - Format Requirements and Examples
═══════════════════════════════════════════════════════════════

**For each field you will receive:**

- **Field Name**: (This is the name of the field)
- **Description**: (What this field represents)
- **Format**: (How to format your answer)
- **Notes**: (Quality standards for this specific field)
- **Examples**: (Sample formatting)

**VALUES TO CONSIDER:**
- **Current Value** (to be validated/updated): The value that needs validation/updating in this run
- **Previous Value** (from Original Values sheet): The historical validated value from a prior validation run (if available)

**YOUR TASK**: Validate and update the **Current Value** using web search and the guidance provided. Compare it to the **Previous Value** (if available) to understand what has changed.

----- FIELD 1: Owner -----
**Current Value**: Ratio Therapeutics
Description: Company or entity that owns or is developing the product.
Format: String
Importance: RESEARCH

Notes: Verify the current owner/developer. Check company websites and recent press releases.

Examples:
  - Actithera
  - Advanced Accelerator Applications
  - Bayer

----- FIELD 2: Target / Indication -----
**Current Value**: 
Description: Biological target and the disease indication the product is intended for.
Format: String
Importance: RESEARCH

Notes: Verify the molecular target (e.g., FAP, PSMA) and the specific disease or condition.

Examples:
  - FAP / oncology (lead program)
  - FAP / pan-cancer imaging
  - FAP / pan-cancer therapy

----- FIELD 3: Development Stage -----
**Current Value**: 
Description: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).
Format: String
Importance: RESEARCH

Notes: Confirm the most recent development stage from official sources like clinical trial registries or company pipelines. Use standard terms (Preclinical, Phase I, Phase II, Phase III, Approved).

Examples:
  - Phase I
  - Phase II
  - Preclinical

---

═══════════════════════════════════════════════════════════════
## ⭐ CONFIDENCE LEVELS
═══════════════════════════════════════════════════════════════

Confidence measures the likelihood that the facts stated in the cell are precisely accurate:

- **HIGH (H)**: 85%+ likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood ≥ 85%
  - Source: Authoritative, directly verifiable, widely accepted

- **MEDIUM (M)**: 65%-85% likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood 65%-85%
  - Source: Respectable but not definitive, good estimates, confident projections

- **LOW (L)**: <65% likelihood that the facts are precisely accurate
  - Weak/conflicting sources, uncertainty, no authoritative verification
  - **Only LOW confidence answers may be blank (null)**
  - **Blank originals**: Assign LOW for `original_confidence` when the original value was blank/empty
  - **Removing false data**: If original has LOW confidence false data and no reliable replacement exists, you CAN go to blank with LOW confidence (removing bad data is acceptable)

**SPECIAL CASE - Expressing Doubt:**
When the value itself expresses uncertainty (e.g., "Rumors suggest...", "Unconfirmed reports say...", "Less reliable sources claim..."), confidence measures whether the SOURCES say it, NOT whether it's true.

Example:
- Value: "Rumors suggest launch in Q3 2025"
- HIGH confidence: Multiple sources confirm rumors exist
- The confidence is about the rumors existing, not about the launch happening

**Confident Absence:**
If you are confident something does not exist or is not applicable, say so explicitly with language appropriate to the measure (e.g., "N/A", "Not applicable", "No website", "Not publicly traded") and assign an appropriate confidence level (H/M). Do not leave it blank - blank means you have no information.

---

═══════════════════════════════════════════════════════════════
## 📤 RESPONSE FORMAT
═══════════════════════════════════════════════════════════════

Return a JSON array where each item is a cell array with 6 elements:

```
[column, answer, confidence, original_confidence, consistent, explanation]
```

- **column**: Exact field name from FIELD DETAILS
- **answer**: The validated value (string or null for blank)
- **confidence**: H (HIGH), M (MEDIUM), or L (LOW)
- **original_confidence**: H, M, or L (for the original value)
- **consistent**: T (consistent with model knowledge), F (not consistent), or null
- **explanation**: Succinct reason you believe the answer is correct

**Example:**
```json
[
  ["Revenue", "$158.9B", "H", "M", "T", "Q3 2024 earnings report confirmed"],
  ["CEO", "Andy Jassy", "H", "H", "T", "Official Amazon leadership page"],
  ["Founded", null, "L", "L", null, "No reliable data found"]
]
```

### CRITICAL REQUIREMENTS

- **Do not use quotation marks around your responses** (except in JSON structure itself)
- **Assess both confidences**: Rate the quality of your updated answer (confidence) AND the quality of the original value (original_confidence) using H/M/L
- **CRITICAL - Blank original values**: If the original value was blank/empty, set `original_confidence` to `L` (LOW). Blank originals get LOW original_confidence.
- **Only update if significantly better**: Only provide a different validated value if you can improve significantly on the original value
- **Generally don't degrade confidence**:
  - If original has H/M confidence, don't degrade to L or blank without strong justification
  - If original has L confidence false data and no reliable replacement: You CAN leave blank (removing bad data is acceptable)
  - Hierarchy: H > M > L
  - **Confident absence**: Use language appropriate to the measure (e.g., "N/A", "Not applicable", "No website") with confidence — blank means you have no information, not that the value doesn't exist
- **Use exact column names**: Include the exact column name in each cell array - exactly as defined in the FIELD DETAILS above
- **Provide explanation**: Always include the explanation with succinct reasoning for your answer
- **Handle blanks appropriately**: If you cannot find or determine information for a field, use null for answer and L for confidence. Only LOW confidence answers may be truly blank.
- **Use examples as guides**: Use provided examples to guide your update format and expected values
- **Format for Excel**: Use newline characters correctly so that they are formatted in an Excel cell, particularly for bullets, lists, and other formatted text
- **Stay focused**: Do not research the context and guidance - focus only on the fields listed above
- **Double check everything**: Double check your updated response and confidence - speak precisely, there is no room for error
- **Valid JSON required**: The response MUST be valid JSON array format

---

```

## Clone Configuration & Initial Settings <small>(04:06:59)</small>

```json
{
  "Provider": "deepseek",
  "Model Override": null,
  "Schema Provided": true,
  "Use Code Extraction": true,
  "Academic Mode": false,
  "Models": {
    "initial_decision": "gemini-2.5-flash-lite",
    "triage": "gemini-2.5-flash-lite",
    "extraction": "gemini-2.5-flash-lite",
    "synthesis": "deepseek-v3.2"
  },
  "Global Limits": {
    "max_iterations": 2,
    "max_sources_total": 20,
    "max_search_terms": 3
  }
}
```



# ⚡ Execution Summary

| Metric | Value |
| :--- | :--- |
| **Strategy** | `targeted` (narrow/shallow) |
| **Total Cost** | **$0.0243** |
| **Total Time** | **34.4s** |
| **Output** | 0 Citations / 44 Snippets |
| **Quality** | A |
| **Repairs** | 0 |
| **Tier 4 Upgrade** | No |

### 🔍 Process Breakdown

| Step | Provider | Model | Cost | Time | Details |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **Initial Decision** | gemini | `gemini-2.5-flash-lite` | $0.0006 | 0.64s | Decision: need_search |
| **Memory Recall** | skipped | `N/A` | $0.0000 | 0.09s | Empty memory |
| **Search** | perplexity | `Search API` | $0.0050 | 0.34s | 1 queries, 10 results |
| **Triage** | gemini | `gemini-2.5-flash-lite` | $0.0004 | 0.68s | Ranked 1 search groups |
| **Extraction** | gemini | `gemini-2.5-flash-lite` | $0.0008 | 1.47s | Extracted 7 snippets |
| **Synthesis** | vertex | `deepseek-v3.2` | $0.0016 | 14.74s | Generated 2 citations |
| **Self-Correction Search** | perplexity | `Search API` | $0.0100 | 0.00s | 2 queries |
| **Self-Correction Triage** | deepseek | `gemini-2.5-flash-lite` | $0.0008 | 0.66s | Ranked 2 groups |
| **Self-Correction Extraction** | deepseek | `gemini-2.5-flash-lite` | $0.0022 | 3.29s | Extracted 37 new snippets (Parallel) |
| **Re-Synthesis (Current Model)** | vertex | `deepseek-v3.2` | $0.0029 | 11.51s | Re-synthesized |


### ⚙️ Initial Settings

| Setting | Value |
| :--- | :--- |
| **Provider** | `deepseek` |
| **Schema Provided** | `Yes` |
| **Use Code Extraction** | `True` |
| **Academic Mode** | `False` |

---

## 📝 Final Answer

```json
[
  [
    "Owner",
    "Ratio Therapeutics",
    "H",
    "H",
    "T",
    "Confirmed as the developer of VMT02 [1]"
  ],
  [
    "Target / Indication",
    "MC1R / MC1R-positive melanoma",
    "H",
    "L",
    "T",
    "VMT01/02 targets the melanocortin subtype 1 receptor (MC1R) for MC1R-positive melanoma [1]"
  ],
  [
    "Development Stage",
    "Phase 1/2a",
    "H",
    "L",
    null,
    "ClinicalTrials.gov lists VMT02 as an imaging agent in a Phase 1/2a trial (NCT05655312) for MC1R-positive melanoma [clinicaltrials_nct05655312_vmt02, S2.1.6.0-p0.95]"
  ]
]
```

### Citations

(No citations)
---

<details>
<summary><b>[SUCCESS] Step: Initial Decision</b> <small>(04:06:59)</small></summary>

### Initial Decision Prompt <small>(04:06:59)</small>

```text
# Initial Decision: Answer or Search with Strategy Assessment

Query: # Table Entry Validation and Research

You are validating and updating several field values for a single row in a research table.

═══════════════════════════════════════════════════════════════
## 🎯 FOCUSED TASK
═══════════════════════════════════════════════════════════════

**Use this section to guide your initial web searches.** Detailed field requirements for synthesis appear below.

**Context:**
Product (or Candidate): VMT02
Owner: Ratio Therapeutics

**3 Research Questions:**
Core Product & Owner Info: Basic product information including owner, target/indication, and development stage. This foundational data is often found together in company pipelines and press releases.

**1. Owner**: Company or entity that owns or is developing the product.???
   Current value: Ratio Therapeutics
**2. Target / Indication**: Biological target and the disease indication the product is intended for.???
**3. Development Stage**: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).???

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 WHAT YOU'LL FIND BELOW
═══════════════════════════════════════════════════════════════

The sections below provide detailed context for **synthesizing your search results** into validated answers:

- **GENERAL NOTES**: Validation context for the broader research effort this subtask falls within
- **CONTEXT & PREVIOUS DATA**: Other fields from this row and prior validations for reference
- **FIELD DETAILS**: Detailed requirements, format, notes, and examples for each field
- **CONFIDENCE LEVELS**: How to assign confidence ratings to your findings
- **RESPONSE FORMAT**: Required JSON structure and critical validation rules

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 GENERAL NOTES
═══════════════════════════════════════════════════════════════

This configuration validates a biopharmaceutical product/candidate tracking table. The primary identifier is the product name. All research columns should be verified against current public information as of February 13, 2026, using company websites, clinical trial registries (e.g., ClinicalTrials.gov), and reputable news sources. For columns left blank, it may indicate the information is not applicable or not yet public.

---

═══════════════════════════════════════════════════════════════
## 📊 CONTEXT & PREVIOUS DATA
═══════════════════════════════════════════════════════════════

**Context for this row:**

Product (or Candidate): VMT02
Owner: Ratio Therapeutics

⚠️ **CRITICAL - ROW CONTEXT SCOPE CONSTRAINT:**
All validation results must be about the SPECIFIC ENTITY identified by the context above.

**Common scope errors to AVOID:**
- Validating a different entity with a similar name
- Using general information when specific information is required
- Example: When validating news for "Product X by Company Y", reject news that only mentions "Company Y" without mentioning "Product X"
- Example: When validating a company associated with a product, verify the company OWNS/DEVELOPS that specific product, not just that the company exists

**Scope validation checklist:**
1. Do sources explicitly mention ALL identifying information from context above?
2. Is information contemporary with the entity (not before it existed)?
3. Have you cross-referenced to confirm entity identity?
4. When in doubt, mark confidence as MEDIUM or LOW

**Other fields from this row (unvalidated - for reference only):**

**Previous validations for this row:**

Product (or Candidate): VMT02 (Confidence: ID)

⚠️ **CRITICAL - INHERENT SUSPICION OF PREVIOUS RESULTS:**

Previous values shown above may be INCORRECT. Do NOT assume they are correct.

**Mandatory verification requirements:**
- Treat previous values as HYPOTHESES to be tested, not FACTS
- Every previous claim must be verified against current authoritative sources
- Do NOT copy previous values without independent verification
- Well-formatted previous answers with citations can still be wrong
- High confidence scores from past validations don't guarantee truth

**If current sources conflict with previous values:**
1. Prioritize DIRECT QUOTES from HIGH-AUTHORITY sources (see confidence criteria)
2. Check publication dates - newer authoritative sources may supersede old data
3. If conflict unresolved, mark confidence as MEDIUM or LOW
4. Document the conflict in your explanation

**Truth Standard:** Direct quotes from authoritative sources determine truth,
NOT how confident, well-cited, or professionally formatted previous results appear.

Your task: Use previous results as a STARTING POINT, then independently verify/correct with current sources.

---

═══════════════════════════════════════════════════════════════
## 📝 FIELD DETAILS - Format Requirements and Examples
═══════════════════════════════════════════════════════════════

**For each field you will receive:**

- **Field Name**: (This is the name of the field)
- **Description**: (What this field represents)
- **Format**: (How to format your answer)
- **Notes**: (Quality standards for this specific field)
- **Examples**: (Sample formatting)

**VALUES TO CONSIDER:**
- **Current Value** (to be validated/updated): The value that needs validation/updating in this run
- **Previous Value** (from Original Values sheet): The historical validated value from a prior validation run (if available)

**YOUR TASK**: Validate and update the **Current Value** using web search and the guidance provided. Compare it to the **Previous Value** (if available) to understand what has changed.

----- FIELD 1: Owner -----
**Current Value**: Ratio Therapeutics
Description: Company or entity that owns or is developing the product.
Format: String
Importance: RESEARCH

Notes: Verify the current owner/developer. Check company websites and recent press releases.

Examples:
  - Actithera
  - Advanced Accelerator Applications
  - Bayer

----- FIELD 2: Target / Indication -----
**Current Value**: 
Description: Biological target and the disease indication the product is intended for.
Format: String
Importance: RESEARCH

Notes: Verify the molecular target (e.g., FAP, PSMA) and the specific disease or condition.

Examples:
  - FAP / oncology (lead program)
  - FAP / pan-cancer imaging
  - FAP / pan-cancer therapy

----- FIELD 3: Development Stage -----
**Current Value**: 
Description: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).
Format: String
Importance: RESEARCH

Notes: Confirm the most recent development stage from official sources like clinical trial registries or company pipelines. Use standard terms (Preclinical, Phase I, Phase II, Phase III, Approved).

Examples:
  - Phase I
  - Phase II
  - Preclinical

---

═══════════════════════════════════════════════════════════════
## ⭐ CONFIDENCE LEVELS
═══════════════════════════════════════════════════════════════

Confidence measures the likelihood that the facts stated in the cell are precisely accurate:

- **HIGH (H)**: 85%+ likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood ≥ 85%
  - Source: Authoritative, directly verifiable, widely accepted

- **MEDIUM (M)**: 65%-85% likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood 65%-85%
  - Source: Respectable but not definitive, good estimates, confident projections

- **LOW (L)**: <65% likelihood that the facts are precisely accurate
  - Weak/conflicting sources, uncertainty, no authoritative verification
  - **Only LOW confidence answers may be blank (null)**
  - **Blank originals**: Assign LOW for `original_confidence` when the original value was blank/empty
  - **Removing false data**: If original has LOW confidence false data and no reliable replacement exists, you CAN go to blank with LOW confidence (removing bad data is acceptable)

**SPECIAL CASE - Expressing Doubt:**
When the value itself expresses uncertainty (e.g., "Rumors suggest...", "Unconfirmed reports say...", "Less reliable sources claim..."), confidence measures whether the SOURCES say it, NOT whether it's true.

Example:
- Value: "Rumors suggest launch in Q3 2025"
- HIGH confidence: Multiple sources confirm rumors exist
- The confidence is about the rumors existing, not about the launch happening

**Confident Absence:**
If you are confident something does not exist or is not applicable, say so explicitly with language appropriate to the measure (e.g., "N/A", "Not applicable", "No website", "Not publicly traded") and assign an appropriate confidence level (H/M). Do not leave it blank - blank means you have no information.

---

═══════════════════════════════════════════════════════════════
## 📤 RESPONSE FORMAT
═══════════════════════════════════════════════════════════════

Return a JSON array where each item is a cell array with 6 elements:

```
[column, answer, confidence, original_confidence, consistent, explanation]
```

- **column**: Exact field name from FIELD DETAILS
- **answer**: The validated value (string or null for blank)
- **confidence**: H (HIGH), M (MEDIUM), or L (LOW)
- **original_confidence**: H, M, or L (for the original value)
- **consistent**: T (consistent with model knowledge), F (not consistent), or null
- **explanation**: Succinct reason you believe the answer is correct

**Example:**
```json
[
  ["Revenue", "$158.9B", "H", "M", "T", "Q3 2024 earnings report confirmed"],
  ["CEO", "Andy Jassy", "H", "H", "T", "Official Amazon leadership page"],
  ["Founded", null, "L", "L", null, "No reliable data found"]
]
```

### CRITICAL REQUIREMENTS

- **Do not use quotation marks around your responses** (except in JSON structure itself)
- **Assess both confidences**: Rate the quality of your updated answer (confidence) AND the quality of the original value (original_confidence) using H/M/L
- **CRITICAL - Blank original values**: If the original value was blank/empty, set `original_confidence` to `L` (LOW). Blank originals get LOW original_confidence.
- **Only update if significantly better**: Only provide a different validated value if you can improve significantly on the original value
- **Generally don't degrade confidence**:
  - If original has H/M confidence, don't degrade to L or blank without strong justification
  - If original has L confidence false data and no reliable replacement: You CAN leave blank (removing bad data is acceptable)
  - Hierarchy: H > M > L
  - **Confident absence**: Use language appropriate to the measure (e.g., "N/A", "Not applicable", "No website") with confidence — blank means you have no information, not that the value doesn't exist
- **Use exact column names**: Include the exact column name in each cell array - exactly as defined in the FIELD DETAILS above
- **Provide explanation**: Always include the explanation with succinct reasoning for your answer
- **Handle blanks appropriately**: If you cannot find or determine information for a field, use null for answer and L for confidence. Only LOW confidence answers may be truly blank.
- **Use examples as guides**: Use provided examples to guide your update format and expected values
- **Format for Excel**: Use newline characters correctly so that they are formatted in an Excel cell, particularly for bullets, lists, and other formatted text
- **Stay focused**: Do not research the context and guidance - focus only on the fields listed above
- **Double check everything**: Double check your updated response and confidence - speak precisely, there is no room for error
- **Valid JSON required**: The response MUST be valid JSON array format

---


## Decision 1: Answer Directly or Search?

**Answer Directly IF:**
- General concepts, definitions, well-established facts
- High confidence, no post-cutoff information needed
- No citations required
- You must provide a complete answer in your response if you select this

**Need Search IF:**
- Today's date is provided above - it is later than your training. Accept this fact.
- Recent events, current data, specifications
- Requires authoritative sources or citations
- Post-cutoff information

**Academic Mode:**
Set `academic: true` if query requires scholarly/peer-reviewed sources:
- Research papers, academic studies, scientific findings
- Peer-reviewed publications needed
- Technical/scholarly analysis
When true, search prioritizes academic databases over general web.

---

## Decision 2: Assess Breadth and Depth (if searching)

### Breadth: How many aspects/facets?

**Narrow:**
- Single fact or specific answer ("What is X's parameter count?")
- One aspect of a topic ("How fast is X?")
- Targeted information retrieval

**Broad:**
- Multiple aspects or comprehensive coverage ("What are X's features?")
- Comparison across dimensions ("Compare X and Y")
- Survey or analysis ("Explain X architecture")

### Depth: How much detail needed?

**Shallow:**
- Facts, numbers, dates only
- Surface-level information
- Quick concrete claims

**Deep:**
- Context and explanations
- Methodology and reasoning
- Nuanced understanding

---

## Decision 3: Synthesis Model Tier

Choose based on synthesis complexity and reasoning level required:

**tier1** - High school grad level (simple facts, basic lookups, minimal synthesis)

**tier2** - Smart bachelor's degree level (standard synthesis, organizing multiple aspects, analytical thinking) - DEFAULT

**tier3** - Master's degree level (complex technical synthesis, conflicting sources, deep domain expertise)

**tier4** - PhD level (maximum complexity, multi-layered cross-domain synthesis, expert-level reasoning)

---

## Decision 4: Search Terms & Keywords

### Search Terms

**Search Term Quality:**
- Be SPECIFIC and TARGETED to the query (not overly general)
- Include relevant qualifiers (dates, versions, specific aspects)
- Example: "Claude Opus 4.5 MMLU score" NOT just "Claude benchmarks"

**Search Term Count:**
- **Narrow queries: 1-2 terms** for focused information
- **Broad queries: 2-3 terms** to cover different aspects or facets
- **FINDALL queries: EXACTLY 3 terms** - required for maximum breadth coverage
- **Max: 3 terms** for maximum breadth coverage
- Each term should capture a distinct angle or facet of the query

**Examples:**
- "GPT-4 vs Claude" → 2 terms: ["GPT-4 performance", "Claude performance"] (different systems)
- "Gemini features" → 1 term: ["Gemini 2.0 features"] (single domain, specific)
- "Comprehensive AI model comparison" → 4-5 terms: ["GPT-4 benchmarks", "Claude capabilities", "Gemini performance", "AI model costs", "LLM latency comparison"]

### Keyword Indicators

**Required Keywords** - MANDATORY entity identifiers (CRITICAL for entity-specific queries):
- Use `|` to separate variants of the same entity (ANY variant matches)
- ALL keyword groups must match (AND logic between groups)
- Matching is case-insensitive substring matching
- **Format:** `["entity1_variant1|entity1_variant2", "entity2_variant1|entity2_variant2"]`
- Examples:
  - Apple stock query: `["Apple|AAPL", "stock|shares|price"]`
    - Matches sources containing (Apple OR AAPL) AND (stock OR shares OR price)
  - Compare Tesla and Ford: `["Tesla|TSLA", "Ford|F"]`
    - Matches sources containing (Tesla OR TSLA) AND (Ford OR F)
  - Single entity: `["iPhone|Apple"]`
    - Matches sources containing (iPhone OR Apple)
- **Empty array []** for general queries without specific entities
- **REQUIRED for any query about specific entities** - prevents mixing up companies/products

**Positive Keywords** - Terms that indicate high-quality, relevant results:
- Include technical terms, methodologies, key concepts NOT in search terms
- Include common abbreviations and variants (e.g., "LR" for "learning rate")
- These help prioritize best results AFTER search, without narrowing the search
- Example for "neural network optimization": ["backpropagation", "gradient descent", "GD", "learning rate", "LR", "convergence"]
- Example for "Python 3.12 features": ["typing", "performance", "PEP", "release notes"]

**Negative Keywords** - Terms that indicate off-topic/low-quality results (USE SPARINGLY):
- **ONLY include if there is a CLEAR exclusionary intent** in the query
- Examples: Query mentions "not for beginners" → negative: ["beginner", "tutorial"]
- Examples: Query is highly technical → negative: ["for kids", "ELI5"]
- **Return empty array [] if no clear exclusions needed**
- Most queries should have 0-2 negative keywords, not 3-5

**Strategy:** Use BROAD search terms + specific keywords to cast a wide net, then algorithmically prioritize the best matches.

---

## Output Format

**If answer_directly:**
```json
{
  "decision": "answer_directly",
  "breadth": "narrow",
  "depth": "shallow",
  "search_terms": [],
  "required_keywords": [],
  "positive_keywords": [],
  "negative_keywords": [],
  "synthesis_tier": "tier2",
  "academic": false,
  "answer": "<your complete answer here - REQUIRED when answering directly>"
}
```

**If need_search:**
```json
{
  "decision": "need_search",
  "breadth": "narrow" | "broad",
  "depth": "shallow" | "deep",
  "search_terms": ["term1"],
  "required_keywords": ["EntityName", "TICKER", "variant"],
  "positive_keywords": ["technical_term1", "methodology1", "abbreviation1"],
  "negative_keywords": ["for kids", "beginner", "simple"],
  "synthesis_tier": "tier1" | "tier2" | "tier3" | "tier4",
  "academic": true | false
}
```

---

## Examples

**Targeted (narrow + shallow):**
- "What is DeepSeek V3's parameter count?" → breadth=narrow, depth=shallow, 1 term, tier1 (high school)

**Focused Deep (narrow + deep):**
- "How does attention mechanism work?" → breadth=narrow, depth=deep, 1 term, tier2 (bachelor's)

**Survey (broad + shallow):**
- "List Gemini 2.0 features" → breadth=broad, depth=shallow, 1 term, tier2 (bachelor's)

**Comprehensive (broad + deep):**
- "Comprehensive analysis of transformer architecture" → breadth=broad, depth=deep, 1 term, tier2 (bachelor's handles most cases)

**Multi-domain:**
- "Compare GPT-4 vs Claude Opus" → breadth=broad, depth=shallow, 2 terms (different systems), tier2 (bachelor's)

**Complex technical synthesis:**
- "Synthesize conflicting evidence about X's effectiveness across domains" → tier3 (master's - conflicting sources, domain expertise)

**Maximum complexity (rare):**
- "Multi-layered cross-domain synthesis requiring expert-level reasoning" → tier4 (PhD - hardest problems only)

**Academic queries:**
- "What does research show about climate change impact on crop yields?" → academic=true, depth=deep
- "Peer-reviewed studies on vaccine efficacy" → academic=true, prioritize scholarly sources

---

**Search Term Guidelines:**
- Be SPECIFIC and TARGETED (include versions, dates, qualifiers)
- Use 1-2 terms for narrow queries, 3-5 terms for broad comprehensive queries
- Each term should be specific - quality over quantity

**Academic Field:**
- Set `academic: true` for queries needing scholarly/peer-reviewed sources
- Set `academic: false` for general information queries (default)

```

### Initial Decision Response <small>(04:07:00)</small>

<details><summary>Click to expand</summary>

```json
{
  "decision": "need_search",
  "breadth": "narrow",
  "depth": "shallow",
  "search_terms": [
    "VMT02 Ratio Therapeutics target indication development stage"
  ],
  "required_keywords": [
    "VMT02",
    "Ratio Therapeutics"
  ],
  "positive_keywords": [
    "pipeline",
    "clinical trials",
    "drug development"
  ],
  "negative_keywords": [],
  "synthesis_tier": "tier2",
  "academic": false
}
```

</details>

<p align='right'><small>Step duration: 0.64s</small></p>
</details>
## Strategy Selected <small>(04:07:00)</small>

<details><summary>Click to expand</summary>

```json
{
  "name": "targeted",
  "breadth": "narrow",
  "depth": "shallow",
  "synthesis_tier": "tier2",
  "search_terms": [
    "VMT02 Ratio Therapeutics target indication development stage"
  ]
}
```

</details>


<details>
<summary><b>[SUCCESS] Step: Memory Recall</b> <small>(04:07:00)</small></summary>

#### Memory Statistics <small>(04:07:00)</small>

<details><summary>Click to expand</summary>

```json
{
  "Total Queries in Memory": 0,
  "Total Sources": 0,
  "Unique URLs": 0,
  "Last Updated": "2026-02-13T04:07:00.483537+00:00"
}
```

</details>

### Memory Recall Skipped <small>(04:07:00)</small>

```text
No queries in memory - proceeding directly to search
```

<p align='right'><small>Step duration: 0.09s</small></p>
</details>

<details>
<summary><b>[SUCCESS] Step: Search Execution</b> <small>(04:07:00)</small></summary>

### Executing Searches <small>(04:07:00)</small>

```json
{
  "terms": [
    "VMT02 Ratio Therapeutics target indication development stage"
  ],
  "settings": {
    "max_results": 10,
    "max_tokens_per_page": 512
  }
}
```

### Search Results Summary <small>(04:07:00)</small>

<details><summary>Click to expand</summary>

```json
[
  "Search 1: 10 results",
  "  Top results: ['VMT01/02 Program - Perspective Therapeutics |', '[68Ga]VMT02 - Drug Targets, Indications, Patents - Patsnap Synapse', 'Pipeline']"
]
```

</details>

### Raw Search Results <small>(04:07:00)</small>

<details><summary>Click to expand</summary>

```json
[
  {
    "id": "525d536f-09c5-46b5-b7a2-54e330accedf",
    "results": [
      {
        "date": "2025-05-19",
        "last_updated": "2026-01-30",
        "snippet": "## Overview\n\nVMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy.\n\n## Development\n\n\n\nOngoing multi-center Phase 1/2a dose-escalation/expansion trial (NCT05655312) evaluating [\n\n212Pb]VMT01 as monotherapy and in combination with nivolumab in patients with unresectable or metastatic MC1R-positive melanoma, currently recruiting across the US\n- First patient dosed in combination arm (with nivolumab) in March 2025; dose finding progressing at 3.0 mCi for both monotherapy and combination, with no dose-limiting toxicities reported as of September 2025\n\n- Preclinical data demonstrate synergistic effects with immune checkpoint inhibitors; combination cohort actively enrolling\nPhase 1 imaging study at Mayo Clinic supports patient selection using [\n\n203Pb]VMT01 and [ 68Ga]VMT02, confirming feasibility for MC1R targeting\n\n- Fast Track Designation granted by FDA (September 2024) for diagnosis and treatment of MC1R-positive melanoma\n\n- Clinical updates on safety, dosimetry, and efficacy expected mid to late 2026, with potential for expanded enrollment and regulatory discussions",
        "title": "VMT01/02 Program - Perspective Therapeutics |",
        "url": "https://perspectivetherapeutics.com/pipeline/vmt01-02"
      },
      {
        "date": "2025-11-03",
        "last_updated": "2026-02-12",
        "snippet": "Mechanism\n\nMC1R antagonists(Melanocortin receptor 1 antagonists)\n\nTherapeutic Areas\n\nNeoplasms\n\nSkin and Musculoskeletal Diseases\n\nActive Indication\n\nMelanoma\n\nInactive Indication\n\nMelanoma, Cutaneous Malignant\n\nMetastatic melanoma\n\nMucosal Melanoma\n\n…\n\nThe study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.\n\n…\n\nIn rats cadmium was present in two MT isoforms, RMT-1 and RMT-2. Ion-exchange chromatography of porcine liver cytosol also showed that two isoforms existed, but a major portion of the cadmium elutes with the second isoform, VMT-2. Using a reversed-phase HPLC system, the purified rat metallothionein isoforms eluted as single peaks before pig MT isoform VMT-2.\nThe difference in chromatographic behaviour on reversed-phase HPLC between species-specific metallothioneins offers a unique possibility to study the fate of endogenous and exogenous metallothioneins simultaneously. This will be illustrated by the redistribution of 109Cd from exogenous CdMT to endogenous CdMT after intravenous injection of VMT-2 into rats.\n100\n\nDeals associated with [68Ga]VMT02\n\nLogin to view more data\n\nR&D Status\n\n10\n\ntop R&D records.\n\nLogin\n\nto view more data\n\nIndication\n\nHighest Phase\n\nCountry/Location\n\nOrganization\n\nDate\n\nMelanoma\n\nPhase 2\n\nUnited States\n\nPerspective Therapeutics, Inc.\nMelanoma, Cutaneous Malignant\n\nPhase 1\n\nUnited States\n\nPerspective Therapeutics, Inc.\n\n05 Mar 2021\n\nMetastatic melanoma\n\nPhase 1\n\nUnited States\n\nPerspective Therapeutics, Inc.\n\n05 Mar 2021\n\nMucosal Melanoma\n\nPhase 1\n\nUnited States\nPerspective Therapeutics, Inc.\n\n05 Mar 2021\n\nUveal Melanoma\n\nPhase 1\n\nUnited States\n\nPerspective Therapeutics, Inc.\n\n05 Mar 2021\n\nLogin to view more data\n\nClinical Result\n\nIndication\n\nPhase\n\nEvaluation\n\nView All Results\n\nStudy\n\nPhase\n\nPopulation\n\nAnalyzed Enrollment",
        "title": "[68Ga]VMT02 - Drug Targets, Indications, Patents - Patsnap Synapse",
        "url": "https://synapse.patsnap.com/drug/2147731a54d94c709c7db6757eb5cd1f"
      },
      {
        "last_updated": "2024-04-09",
        "snippet": "# Theranostics\n\n# Theranostic Pipeline Leveraging the Power of Targeted Alpha-Particles\n\n## We are developing a pipeline of radiotherapies designed to deliver powerful alpha radiation directly to cancer cells utilizing specialized targeting peptides. We are also developing complementary diagnostics that utilize the same targeting peptide to provide the opportunity to understand which patients may respond to therapy.\n|Program|Indication|Discovery|Human Clinical Imaging|First in Human Therapy|Phase 1/2|Phase 3|\n|--|--|--|--|--|--|--|\n|VMT-𝛼-NET|Neuroendocrine cancer||\n|Pheochromocytomas, paragangliomas||\n|Small cell lung cancer||\n|VMT-01|Melanoma (MCIR)||\n|VMT-02 (PET agent)|Melanoma (imaging of MC1R)||\n|Program 3 (Novel peptide)|Multiple solid tumors||\n|Program 4 (Novel small molecule)|Prostate||\n|Program 5 (Novel peptide)|Prostate, Breast||\n|Other Programs|Solid and hematological tumors||\nVMT01 is in development for the treatment and diagnosis of metastatic melanoma. Through the use of a specialized peptide, VMT01 is designed to target the melanocortin 1 receptor (MC1R) on tumor cells. VMT01 is currently being evaluated in a Phase 1 imaging study being conducted at the Mayo Clinic Rochester. Following the results of the imaging trial, the Company plans to initiate a Phase 1/2a therapy study.\nVMT-𝛼-NET is in development for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2). VMT-𝛼-NET is expected to enter a Phase 1 imaging study in Q3, 2021 that will be conducted at the University of Iowa Hospitals and Clinics.",
        "title": "Pipeline",
        "url": "https://perspectivetherapeutics.com/theranostics_pipeline/"
      },
      {
        "date": "2025-01-08",
        "last_updated": "2025-12-29",
        "snippet": "**Developing best-in-class radiopharmaceuticals for cancer patients**\n\nA discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers.\n\n### Innovative Technologies\n\nRatio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets.\n\n### Interdisciplinary Team\n\nWe have assembled a team of scientists, engineers, and business professionals, with a broad network of researchers and clinicians encompassing the breadth and depth of expertise required for success.\n\n### De-Risked Platform\n\nOur compounds accommodate imaging and therapeutic radioisotopes, ie “theranostics”. The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.\n\nStrong intellectual property positions across multiple platform technologies.\n\nField-leading team with strong expertise and long standing and excellent relationships with luminary KOLs.\n\nInnovative and proprietary PK Modulation technology for the construction of improved therapeutic agents.\n\nTwo funded alliances with major pharmaceutical companies for first-in-human trials.\n\n**About Us**\n\nWe are an experienced team of scientists, passionate about finding a cure for cancer.",
        "title": "Ratio Therapeutics: Homepage",
        "url": "https://ratiotx.com"
      },
      {
        "date": "2024-01-17",
        "last_updated": "2025-01-29",
        "snippet": "On January 17, 2024 Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of cancers, reported the close of its $50M Series B financing, bringing the total raised to date to over $90 million (Press release, Ratio Therapeutics, JAN 17, 2024, View Source [SID1234639292]).\n\n…\n\n**Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing**\n\nSchedule Your 30 min Free Demo!\nThis financing will expand the applications of company’s proprietary technology platforms, Trillium and Macropa, to develop novel best in class fit-for-purpose radiopharmaceuticals. Additionally, the funding will drive the clinical development of the company’s fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic.\n\"This funding advances Ratio’s technology platforms and will help launch clinical trials for our FAP-targeted radiotherapeutic which aims to treat a broad array of solid-tumor cancers,\" said Dr. Jack Hoppin, Ratio’s Chairman and Chief Executive Officer. \"We are grateful to our investors for their confidence in our technology. We have filed two INDs and completed enrollment in both radiation dosimetry studies in support of two of our corporate partnerships. Now we have the backing to move our first therapeutic candidate into clinical trials by the end of this year.\"\n\"The FAP-targeted therapeutic program has the potential to provide much needed treatment to patients with multiple types of cancer,\" said Dr. Mey Boukenna of PagsGroup, the Boston-based family office of Stephen Pagliuca. \"With Ratio’s unique assets and technology, and Drs. Babich and Hoppin standing as pioneers in the radiopharmaceutical field, we believe they are very well positioned to advance novel radiopharmaceutical cancer treatments and diagnostics into the clinic.\"\n\n…\n\nTrillium is a pharmacokinetic modulation platform that can be altered to bind to any antigen-specific target, while Macropa is a best-in-class Actinium-225 chelator. The combination of these platforms enables the tumor-killing power of alpha particles with potential for first- and best-in-class radiopharmaceuticals.",
        "title": "Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data",
        "url": "https://www.1stoncology.com/blog/january-17th-2024-ratio-therapeutics-announces-50m-series-b-financing-to-advance-targeted-radiotherapies-for-cancer-treatment1234639292/"
      },
      {
        "date": "2025-12-16",
        "last_updated": "2026-01-27",
        "snippet": "On December 16, 2025 Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, reported that dosing of the first cohort has been completed in the ATLAS trial, a Phase 1/2 open-label study evaluating the safety, tolerability, and efficacy of the company’s lead therapeutic radiopharmaceutical, [Ac-225]-RTX-2358, targeting fibroblast activation protein‑α (FAP) in patients with relapsed or refractory soft tissue sarcomas.\n\n…\n\nThe ATLAS trial is a Phase 1/2 open-label clinical trial (clinicaltrials.gov identifier, NCT07156565) designed to assess the safety, tolerability, dosimetry, biodistribution, pharmacokinetics, and preliminary anti-tumor activity of [Ac-225]-RTX-2358, a highly selective, FAP targeted radiotherapeutic labeled with Actinium 225, in patients with relapsed or refractory soft tissue sarcomas that express FAP.\nThe study consists of two phases: an ascending administered activity phase (Phase 1) and an expansion phase (Phase 2). For patients to be eligible to receive treatment, FAP expression will be assessed using a [Cu-64]-LNTH-1363S PET scan. In the Phase 1 portion, patients with FAP positive sarcomas will receive intravenous injections of [Ac-225]-RTX-2358 once every eight weeks, for up to six treatment cycles over a 12-month period.\nUsing a standard 3+3 dose escalation design, participants will be assigned to one of three groups, each receiving an increasing dose level to determine the maximum tolerated dose and establish a recommended dose for the expansion phase. Cohort expansion will be allowed to a max of 10 patients per cohort, enabling up to 26 patients to be treated and evaluated during the Phase 1 portion of the trial.\nThis will allow better characterization of safety and tolerability as well as the assessment of preliminary efficacy. Safety data from each group will be reviewed by an independent Safety Review Committee before dose escalation proceeds. The Phase 2 portion of the study will evaluate the efficacy and safety of [Ac-225]-RTX-2358 in up to 50 patients. [Ac-225]-RTX-2358 is being manufactured by Pharmalogic. [Cu-64]-LNTH-1363S is being provided by Lantheus and manufactured by PharmaLogic.",
        "title": "Ratio Therapeutics has successfully dosed the first cohort in its ...",
        "url": "https://www.1stoncology.com/blog/ratio-therapeutics-has-successfully-dosed-the-first-cohort-in-its-phase-12-study-evaluating-a-novel-fap-targeted-radiopharmaceutical-in-patients-with-late-stage-aggressive-sarcomas1234661461/"
      },
      {
        "last_updated": "2025-08-21",
        "snippet": "*Committed to Improving the Lives of Patients with Diabetes*\n\n**vTv Therapeutics is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are pursuing additional indications, including type 2 diabetes and other chronic conditions. To learn more about our science, please visit our pipeline page.**",
        "title": "Home - VTV Therapeutics",
        "url": "https://vtvtherapeutics.com"
      },
      {
        "date": "2021-01-01",
        "last_updated": "2025-09-26",
        "snippet": "# Targeted Therapies Broad Potential\n\nWe are focused on developing targeted therapies for\n\nimmune-inflammatory diseases\n\nOur lead candidate VB-601 has potential to be broadly applicable across both prevalent & rare inflammatory indications.\n\nOur expertise in human biology led to the development of our proprietary monocyte targeting technology (MTT), which is designed in a specific way to limit chronic inflammation.\n\nMonocyte Targeting Technology",
        "title": "VBL Therapeutics",
        "url": "https://www.vblrx.com"
      },
      {
        "date": "2024-11-18",
        "last_updated": "2025-02-10",
        "snippet": "** Novartis AG** (NYSE: NVS). The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.\n\n*\"The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic,\" said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. \"Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors.\"*\n*\"Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximizing their impact by continually improving the benefit for patients,\" said Fiona Marshall, President of Biomedical Research at Novartis. \"We are delighted to collaborate with Ratio to advance this RLT candidate and work together to bring forward additional therapeutic options for patients with difficult-to-treat cancer.\"*\nUnder the terms of the agreement, Ratio will receive combined upfront and potential milestone payments up to $745m, and is eligible to receive tiered royalty payments. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. Novartis will assume responsibility for all remaining development, manufacturing, and commercialization activities.\nThe collaboration combines the expertise and strengths of Ratio and Novartis to further elevate the safety and efficacy of radiopharmaceuticals for patient benefit.\n\nChestnut Partners served as exclusive financial advisor to Ratio for this transaction.\n\n**About Ratio Therapeutics**\nRatio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading.\nThe company is also currently advancing the development of its first FAP-targeted radiotherapeutic with plans to enter clinical trials next year.\n\nPlease visit\n\n**www.ratiotx.com** for more information and follow us on **Twitter (X) **and\n\n**Media Contacts:**\n\nRachelle Babb, Ph.D.",
        "title": "Ratio Therapeutics Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate",
        "url": "https://lifesciencereport.com/news/nyse/nvs/ratio-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate"
      },
      {
        "date": "2024-11-26",
        "last_updated": "2025-10-28",
        "snippet": "“The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic,” said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. “Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors.”",
        "title": "Ratio Therapeutics Enters License and Collaboration ...",
        "url": "https://onco-this-week.com/ratio-therapeutics-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate/"
      }
    ]
  }
]
```

</details>

<p align='right'><small>Step duration: 0.34s</small></p>
</details>

<details>
<summary><b>[SUCCESS] Step: Source Triage</b> <small>(04:07:00)</small></summary>

#### Triage Prompt (Search 1) <small>(04:07:00)</small>

```text
# Source Triage – Rank Sources by Yield Potential

Query: # Table Entry Validation and Research

You are validating and updating several field values for a single row in a research table.

═══════════════════════════════════════════════════════════════
## 🎯 FOCUSED TASK
═══════════════════════════════════════════════════════════════

**Use this section to guide your initial web searches.** Detailed field requirements for synthesis appear below.

**Context:**
Product (or Candidate): VMT02
Owner: Ratio Therapeutics

**3 Research Questions:**
Core Product & Owner Info: Basic product information including owner, target/indication, and development stage. This foundational data is often found together in company pipelines and press releases.

**1. Owner**: Company or entity that owns or is developing the product.???
   Current value: Ratio Therapeutics
**2. Target / Indication**: Biological target and the disease indication the product is intended for.???
**3. Development Stage**: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).???

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 WHAT YOU'LL FIND BELOW
═══════════════════════════════════════════════════════════════

The sections below provide detailed context for **synthesizing your search results** into validated answers:

- **GENERAL NOTES**: Validation context for the broader research effort this subtask falls within
- **CONTEXT & PREVIOUS DATA**: Other fields from this row and prior validations for reference
- **FIELD DETAILS**: Detailed requirements, format, notes, and examples for each field
- **CONFIDENCE LEVELS**: How to assign confidence ratings to your findings
- **RESPONSE FORMAT**: Required JSON structure and critical validation rules

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 GENERAL NOTES
═══════════════════════════════════════════════════════════════

This configuration validates a biopharmaceutical product/candidate tracking table. The primary identifier is the product name. All research columns should be verified against current public information as of February 13, 2026, using company websites, clinical trial registries (e.g., ClinicalTrials.gov), and reputable news sources. For columns left blank, it may indicate the information is not applicable or not yet public.

---

═══════════════════════════════════════════════════════════════
## 📊 CONTEXT & PREVIOUS DATA
═══════════════════════════════════════════════════════════════

**Context for this row:**

Product (or Candidate): VMT02
Owner: Ratio Therapeutics

⚠️ **CRITICAL - ROW CONTEXT SCOPE CONSTRAINT:**
All validation results must be about the SPECIFIC ENTITY identified by the context above.

**Common scope errors to AVOID:**
- Validating a different entity with a similar name
- Using general information when specific information is required
- Example: When validating news for "Product X by Company Y", reject news that only mentions "Company Y" without mentioning "Product X"
- Example: When validating a company associated with a product, verify the company OWNS/DEVELOPS that specific product, not just that the company exists

**Scope validation checklist:**
1. Do sources explicitly mention ALL identifying information from context above?
2. Is information contemporary with the entity (not before it existed)?
3. Have you cross-referenced to confirm entity identity?
4. When in doubt, mark confidence as MEDIUM or LOW

**Other fields from this row (unvalidated - for reference only):**

**Previous validations for this row:**

Product (or Candidate): VMT02 (Confidence: ID)

⚠️ **CRITICAL - INHERENT SUSPICION OF PREVIOUS RESULTS:**

Previous values shown above may be INCORRECT. Do NOT assume they are correct.

**Mandatory verification requirements:**
- Treat previous values as HYPOTHESES to be tested, not FACTS
- Every previous claim must be verified against current authoritative sources
- Do NOT copy previous values without independent verification
- Well-formatted previous answers with citations can still be wrong
- High confidence scores from past validations don't guarantee truth

**If current sources conflict with previous values:**
1. Prioritize DIRECT QUOTES from HIGH-AUTHORITY sources (see confidence criteria)
2. Check publication dates - newer authoritative sources may supersede old data
3. If conflict unresolved, mark confidence as MEDIUM or LOW
4. Document the conflict in your explanation

**Truth Standard:** Direct quotes from authoritative sources determine truth,
NOT how confident, well-cited, or professionally formatted previous results appear.

Your task: Use previous results as a STARTING POINT, then independently verify/correct with current sources.

---

═══════════════════════════════════════════════════════════════
## 📝 FIELD DETAILS - Format Requirements and Examples
═══════════════════════════════════════════════════════════════

**For each field you will receive:**

- **Field Name**: (This is the name of the field)
- **Description**: (What this field represents)
- **Format**: (How to format your answer)
- **Notes**: (Quality standards for this specific field)
- **Examples**: (Sample formatting)

**VALUES TO CONSIDER:**
- **Current Value** (to be validated/updated): The value that needs validation/updating in this run
- **Previous Value** (from Original Values sheet): The historical validated value from a prior validation run (if available)

**YOUR TASK**: Validate and update the **Current Value** using web search and the guidance provided. Compare it to the **Previous Value** (if available) to understand what has changed.

----- FIELD 1: Owner -----
**Current Value**: Ratio Therapeutics
Description: Company or entity that owns or is developing the product.
Format: String
Importance: RESEARCH

Notes: Verify the current owner/developer. Check company websites and recent press releases.

Examples:
  - Actithera
  - Advanced Accelerator Applications
  - Bayer

----- FIELD 2: Target / Indication -----
**Current Value**: 
Description: Biological target and the disease indication the product is intended for.
Format: String
Importance: RESEARCH

Notes: Verify the molecular target (e.g., FAP, PSMA) and the specific disease or condition.

Examples:
  - FAP / oncology (lead program)
  - FAP / pan-cancer imaging
  - FAP / pan-cancer therapy

----- FIELD 3: Development Stage -----
**Current Value**: 
Description: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).
Format: String
Importance: RESEARCH

Notes: Confirm the most recent development stage from official sources like clinical trial registries or company pipelines. Use standard terms (Preclinical, Phase I, Phase II, Phase III, Approved).

Examples:
  - Phase I
  - Phase II
  - Preclinical

---

═══════════════════════════════════════════════════════════════
## ⭐ CONFIDENCE LEVELS
═══════════════════════════════════════════════════════════════

Confidence measures the likelihood that the facts stated in the cell are precisely accurate:

- **HIGH (H)**: 85%+ likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood ≥ 85%
  - Source: Authoritative, directly verifiable, widely accepted

- **MEDIUM (M)**: 65%-85% likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood 65%-85%
  - Source: Respectable but not definitive, good estimates, confident projections

- **LOW (L)**: <65% likelihood that the facts are precisely accurate
  - Weak/conflicting sources, uncertainty, no authoritative verification
  - **Only LOW confidence answers may be blank (null)**
  - **Blank originals**: Assign LOW for `original_confidence` when the original value was blank/empty
  - **Removing false data**: If original has LOW confidence false data and no reliable replacement exists, you CAN go to blank with LOW confidence (removing bad data is acceptable)

**SPECIAL CASE - Expressing Doubt:**
When the value itself expresses uncertainty (e.g., "Rumors suggest...", "Unconfirmed reports say...", "Less reliable sources claim..."), confidence measures whether the SOURCES say it, NOT whether it's true.

Example:
- Value: "Rumors suggest launch in Q3 2025"
- HIGH confidence: Multiple sources confirm rumors exist
- The confidence is about the rumors existing, not about the launch happening

**Confident Absence:**
If you are confident something does not exist or is not applicable, say so explicitly with language appropriate to the measure (e.g., "N/A", "Not applicable", "No website", "Not publicly traded") and assign an appropriate confidence level (H/M). Do not leave it blank - blank means you have no information.

---

═══════════════════════════════════════════════════════════════
## 📤 RESPONSE FORMAT
═══════════════════════════════════════════════════════════════

Return a JSON array where each item is a cell array with 6 elements:

```
[column, answer, confidence, original_confidence, consistent, explanation]
```

- **column**: Exact field name from FIELD DETAILS
- **answer**: The validated value (string or null for blank)
- **confidence**: H (HIGH), M (MEDIUM), or L (LOW)
- **original_confidence**: H, M, or L (for the original value)
- **consistent**: T (consistent with model knowledge), F (not consistent), or null
- **explanation**: Succinct reason you believe the answer is correct

**Example:**
```json
[
  ["Revenue", "$158.9B", "H", "M", "T", "Q3 2024 earnings report confirmed"],
  ["CEO", "Andy Jassy", "H", "H", "T", "Official Amazon leadership page"],
  ["Founded", null, "L", "L", null, "No reliable data found"]
]
```

### CRITICAL REQUIREMENTS

- **Do not use quotation marks around your responses** (except in JSON structure itself)
- **Assess both confidences**: Rate the quality of your updated answer (confidence) AND the quality of the original value (original_confidence) using H/M/L
- **CRITICAL - Blank original values**: If the original value was blank/empty, set `original_confidence` to `L` (LOW). Blank originals get LOW original_confidence.
- **Only update if significantly better**: Only provide a different validated value if you can improve significantly on the original value
- **Generally don't degrade confidence**:
  - If original has H/M confidence, don't degrade to L or blank without strong justification
  - If original has L confidence false data and no reliable replacement: You CAN leave blank (removing bad data is acceptable)
  - Hierarchy: H > M > L
  - **Confident absence**: Use language appropriate to the measure (e.g., "N/A", "Not applicable", "No website") with confidence — blank means you have no information, not that the value doesn't exist
- **Use exact column names**: Include the exact column name in each cell array - exactly as defined in the FIELD DETAILS above
- **Provide explanation**: Always include the explanation with succinct reasoning for your answer
- **Handle blanks appropriately**: If you cannot find or determine information for a field, use null for answer and L for confidence. Only LOW confidence answers may be truly blank.
- **Use examples as guides**: Use provided examples to guide your update format and expected values
- **Format for Excel**: Use newline characters correctly so that they are formatted in an Excel cell, particularly for bullets, lists, and other formatted text
- **Stay focused**: Do not research the context and guidance - focus only on the fields listed above
- **Double check everything**: Double check your updated response and confidence - speak precisely, there is no room for error
- **Valid JSON required**: The response MUST be valid JSON array format

---

Search Term: "VMT02 Ratio Therapeutics target indication development stage"

Rank RELEVANT sources from best to worst. Exclude off-topic sources entirely.

**Keywords for Relevance Assessment:**
  Positive: pipeline, clinical trials, drug development, development, vmt02, target, therapeutics, ratio, indication, stage

Existing Snippets: 0 collected
(None yet)

---

## Sources (10 results)

[0] VMT01/02 Program - Perspective Therapeutics | (2025-05-19) | Score: 15 (+5)
    ## Overview

VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 re...
    [+development, +vmt02, +target +1 more] "It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb..."

[1] [68Ga]VMT02 - Drug Targets, Indications, Patents - Patsnap Synapse (2025-11-03) | Score: 13 (+4)
    Mechanism

MC1R antagonists(Melanocortin receptor 1 antagonists)

Therapeutic Areas

Neoplasms

Skin and Musculoskeletal...
    [+vmt02, +therapeutics, +indication] "This will be illustrated by the redistribution of 109Cd from exogenous CdMT to endogenous CdMT after..."

[2] Pipeline (2024-04-09) | Score: 12 (+4)
    # Theranostics

# Theranostic Pipeline Leveraging the Power of Targeted Alpha-Particles

## We are developing a pipeline...
    [+development, +target, +indication] "We are also developing complementary diagnostics that utilize the same targeting peptide to provide ..."

[3] Ratio Therapeutics: Homepage (2025-01-08) | Score: 10 (+3)
    **Developing best-in-class radiopharmaceuticals for cancer patients**

A discovery through early clinical phase pharmace...

[4] Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (T (2024-01-17) | Score: 14 (+8)
    On January 17, 2024 Ratio Therapeutics Inc...
    [+pipeline, +development, +target +4 more] "(Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in..."

[5] Ratio Therapeutics has successfully dosed the first cohort in its ... (2025-12-16) | Score: 8 (+3)
    On December 16, 2025 Ratio Therapeutics Inc...
    [+target, +ratio] "(Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radioph..."

[6] Home - VTV Therapeutics (2025-08-21) | Score: 9 (+5)
    *Committed to Improving the Lives of Patients with Diabetes*

**vTv Therapeutics is a clinical stage biopharmaceutical c...
    [+development, +indication] "vTv and its development partners are pursuing additional indications, including type 2 diabetes and ..."

[7] VBL Therapeutics (2021-01-01) | Score: 7 (+4)
    # Targeted Therapies Broad Potential

We are focused on developing targeted therapies for

immune-inflammatory diseases
...

[8] Ratio Therapeutics Enters License and Collaboration Agreement with Nov (2024-11-18) | Score: 8 (+6)
    ** Novartis AG** (NYSE: NVS)...
    [+development, +target, +ratio] "The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well ..."

[9] Ratio Therapeutics Enters License and Collaboration ... (2024-11-26) | Score: 5 (+4)
    “The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeti...

---

## Ranking Criteria

1) **Relevance Score** - Higher score = better search rank + more keyword matches
   - Negative keyword match is a strong signal of irrelevant/low-quality content
2) **Authority** - Prioritize official docs, academic sources, established institutions
3) **Novelty** - Prefer sources adding NEW information not in existing snippets
4) **Recency** - For volatile/time-sensitive info ("latest", "current", recent events), prefer recent sources

---

## Output

Return ranked indices of RELEVANT sources only: [best, second_best, ...]

Example: [5, 0, 8, 2] means source 5 is best, others excluded as off-topic.

```

#### Triage Result (Search 1) <small>(04:07:01)</small>

<details><summary>Click to expand</summary>

```json
{
  "ranked_indices": [
    1,
    4,
    8,
    9,
    0,
    2,
    3,
    9
  ]
}
```

</details>

<p align='right'><small>Step duration: 0.68s</small></p>
</details>

<details>
<summary><b>[SUCCESS] Step: Extraction</b> <small>(04:07:01)</small></summary>

### Iteration 1 <small>(04:07:01)</small>

```text
Pulling sources from index 0
```

#### Batch Extraction Prompt (5 sources) <small>(04:07:01)</small>

<details><summary>Click to expand</summary>

```text
# Batch Quote Extraction (Code-Based)

Extract quotable snippets with codes for synthesis. **Synthesis will NOT see original sources** - only these snippets.

**Today:** 2026-02-13 | **Mode:** Extract ONLY concrete atomic facts (numbers, dates, entities). Be MINIMAL with just enough context to verify. | **Max:** 2/source/search

**Search terms:**
1. VMT02 Ratio Therapeutics target indication development stage

**RULES:**
- **Merge contiguous:** Adjacent sentences = ONE snippet (use ranges), even if addressing different aspects
- **No duplication:** Once a passage is extracted, trust it's available to synthesis - do NOT extract again for other terms
- **Self-contained:** Each snippet MUST make a complete point in isolation - no sentence fragments
- **Skip redundant:** If a point was already made by a snippet of same/higher quality, do NOT extract again

**SHALLOW MODE LIMITS:**
- **2 snippets MAX per source per search term**
- **Brevity:** Just enough context to verify - prefer minimal over comprehensive

---

## Labeled Sources

Sentences labeled `` §SX:Y.Z ``, headings labeled `` §SX:Y.0 `` (X=source, Y=section, Z=sentence). Copy exact labels.


### S1: [68Ga]VMT02 - Drug Targets, Indications, Patents - Patsnap Synapse
URL: https://synapse.patsnap.com/drug/2147731a54d94c709c7db6757eb5cd1f
Date: 2025-11-03

Labeled text:

Mechanism §S1:1.1

<snippet-heading>MC1R antagonists(Melanocortin receptor 1 antagonists)</snippet-heading> §S1:2.0

<snippet-heading>Therapeutic Areas</snippet-heading> §S1:3.0

Neoplasms §S1:3.1

<snippet-heading>Skin and Musculoskeletal Diseases</snippet-heading> §S1:4.0

<snippet-heading>Active Indication</snippet-heading> §S1:5.0

Melanoma §S1:5.1

<snippet-heading>Inactive Indication</snippet-heading> §S1:6.0

<snippet-heading>Melanoma, Cutaneous Malignant</snippet-heading> §S1:7.0

<snippet-heading>Metastatic melanoma</snippet-heading> §S1:8.0

<snippet-heading>Mucosal Melanoma</snippet-heading> §S1:9.0

… §S1:9.1

The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively. §S1:9.2

… §S1:9.3

In rats cadmium was present in two MT isoforms, RMT-1 and RMT-2. Ion-exchange chromatography of porcine liver cytosol also showed that two isoforms existed, but a major portion of the cadmium elutes with the second isoform, VMT-2. Using a reversed-phase HPLC system, the purified rat metallothionein isoforms eluted as single peaks before pig MT isoform VMT-2. §S1:9.4
The difference in chromatographic behaviour on reversed-phase HPLC between species-specific metallothioneins offers a unique possibility to study the fate of endogenous and exogenous metallothioneins simultaneously. §S1:9.5
This will be illustrated by the redistribution of 109Cd from exogenous CdMT to endogenous CdMT after intravenous injection of VMT-2 into rats. §S1:9.6
100 §S1:9.7

<snippet-heading>Deals associated with [68Ga]VMT02</snippet-heading> §S1:10.0

<snippet-heading>Login to view more data</snippet-heading> §S1:11.0

<snippet-heading>R&D Status</snippet-heading> §S1:12.0

10 §S1:12.1

top R&D records. §S1:12.2

Login §S1:12.3

<snippet-heading>to view more data</snippet-heading> §S1:13.0

Indication §S1:13.1

<snippet-heading>Highest Phase</snippet-heading> §S1:14.0

Country/Location §S1:14.1

Organization §S1:14.2

Date §S1:14.3

Melanoma §S1:14.4

<snippet-heading>Phase 2</snippet-heading> §S1:15.0

<snippet-heading>United States</snippet-heading> §S1:16.0

Perspective Therapeutics, Inc. §S1:16.1
<snippet-heading>Melanoma, Cutaneous Malignant</snippet-heading> §S1:17.0

<snippet-heading>Phase 1</snippet-heading> §S1:18.0

<snippet-heading>United States</snippet-heading> §S1:19.0

Perspective Therapeutics, Inc. §S1:19.1

<snippet-heading>05 Mar 2021</snippet-heading> §S1:20.0

<snippet-heading>Metastatic melanoma</snippet-heading> §S1:21.0

<snippet-heading>Phase 1</snippet-heading> §S1:22.0

<snippet-heading>United States</snippet-heading> §S1:23.0

Perspective Therapeutics, Inc. §S1:23.1

<snippet-heading>05 Mar 2021</snippet-heading> §S1:24.0

<snippet-heading>Mucosal Melanoma</snippet-heading> §S1:25.0

<snippet-heading>Phase 1</snippet-heading> §S1:26.0

<snippet-heading>United States</snippet-heading> §S1:27.0
Perspective Therapeutics, Inc. §S1:27.1

<snippet-heading>05 Mar 2021</snippet-heading> §S1:28.0

<snippet-heading>Uveal Melanoma</snippet-heading> §S1:29.0

<snippet-heading>Phase 1</snippet-heading> §S1:30.0

<snippet-heading>United States</snippet-heading> §S1:31.0

Perspective Therapeutics, Inc. §S1:31.1

<snippet-heading>05 Mar 2021</snippet-heading> §S1:32.0

<snippet-heading>Login to view more data</snippet-heading> §S1:33.0

<snippet-heading>Clinical Result</snippet-heading> §S1:34.0

Indication §S1:34.1

Phase §S1:34.2

Evaluation §S1:34.3

<snippet-heading>View All Results</snippet-heading> §S1:35.0

Study §S1:35.1

Phase §S1:35.2

Population §S1:35.3

<snippet-heading>Analyzed Enrollment</snippet-heading> §S1:36.0


**Valid codes for S1:** §S1:1.1, §S1:2.0, §S1:3.0 to §S1:3.1, §S1:4.0, §S1:5.0 to §S1:5.1, §S1:6.0, §S1:7.0, §S1:8.0, §S1:9.0 to §S1:9.7, §S1:10.0, §S1:11.0, §S1:12.0 to §S1:12.3, §S1:13.0 to §S1:13.1, §S1:14.0 to §S1:14.4, §S1:15.0, §S1:16.0 to §S1:16.1, §S1:17.0, §S1:18.0, §S1:19.0 to §S1:19.1, §S1:20.0, §S1:21.0, §S1:22.0, §S1:23.0 to §S1:23.1, §S1:24.0, §S1:25.0, §S1:26.0, §S1:27.0 to §S1:27.1, §S1:28.0, §S1:29.0, §S1:30.0, §S1:31.0 to §S1:31.1, §S1:32.0, §S1:33.0, §S1:34.0 to §S1:34.3, §S1:35.0 to §S1:35.3, §S1:36.0



### S2: Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
URL: https://www.1stoncology.com/blog/january-17th-2024-ratio-therapeutics-announces-50m-series-b-financing-to-advance-targeted-radiotherapies-for-cancer-treatment1234639292/
Date: 2024-01-17

Labeled text:

On January 17, 2024 Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of cancers, reported the close of its $50M Series B financing, bringing the total raised to date to over $90 million (Press release, Ratio Therapeutics, JAN 17, 2024, View Source [SID1234639292]). §S2:1.1

… §S2:1.2

**Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing** §S2:1.3

Schedule Your 30 min Free Demo! §S2:1.4
This financing will expand the applications of company’s proprietary technology platforms, Trillium and Macropa, to develop novel best in class fit-for-purpose radiopharmaceuticals. §S2:1.5
Additionally, the funding will drive the clinical development of the company’s fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic. §S2:1.6
"This funding advances Ratio’s technology platforms and will help launch clinical trials for our FAP-targeted radiotherapeutic which aims to treat a broad array of solid-tumor cancers," said Dr. Jack Hoppin, Ratio’s Chairman and Chief Executive Officer. "We are grateful to our investors for their confidence in our technology. §S2:1.7
We have filed two INDs and completed enrollment in both radiation dosimetry studies in support of two of our corporate partnerships. §S2:1.8
Now we have the backing to move our first therapeutic candidate into clinical trials by the end of this year." §S2:1.9
"The FAP-targeted therapeutic program has the potential to provide much needed treatment to patients with multiple types of cancer," said Dr. Mey Boukenna of PagsGroup, the Boston-based family office of Stephen Pagliuca. "With Ratio’s unique assets and technology, and Drs. §S2:1.10
Babich and Hoppin standing as pioneers in the radiopharmaceutical field, we believe they are very well positioned to advance novel radiopharmaceutical cancer treatments and diagnostics into the clinic." §S2:1.11

… §S2:1.12

Trillium is a pharmacokinetic modulation platform that can be altered to bind to any antigen-specific target, while Macropa is a best-in-class Actinium-225 chelator. §S2:1.13
The combination of these platforms enables the tumor-killing power of alpha particles with potential for first- and best-in-class radiopharmaceuticals. §S2:1.14


**Valid codes for S2:** §S2:1.1 to §S2:1.14



### S3: Ratio Therapeutics Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
URL: https://lifesciencereport.com/news/nyse/nvs/ratio-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate
Date: 2024-11-18

Labeled text:

** Novartis AG** (NYSE: NVS). §S3:1.1
The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. §S3:1.2

*"The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic," said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. "Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors."* §S3:1.3
*"Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximizing their impact by continually improving the benefit for patients," said Fiona Marshall, President of Biomedical Research at Novartis. "We are delighted to collaborate with Ratio to advance this RLT candidate and work together to bring forward additional therapeutic options for patients with difficult-to-treat cancer."* §S3:1.4
Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments up to $745m, and is eligible to receive tiered royalty payments. §S3:1.5
Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. §S3:1.6
Novartis will assume responsibility for all remaining development, manufacturing, and commercialization activities. §S3:1.7
The collaboration combines the expertise and strengths of Ratio and Novartis to further elevate the safety and efficacy of radiopharmaceuticals for patient benefit. §S3:1.8

Chestnut Partners served as exclusive financial advisor to Ratio for this transaction. §S3:1.9

**About Ratio Therapeutics** §S3:1.10
Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. §S3:1.11
With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. §S3:1.12
Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. §S3:1.13
The company is also currently advancing the development of its first FAP-targeted radiotherapeutic with plans to enter clinical trials next year. §S3:1.14

<snippet-heading>Please visit</snippet-heading> §S3:2.0

**www.ratiotx.com** for more information and follow us on **Twitter (X) **and §S3:2.1

**Media Contacts:** §S3:2.2

Rachelle Babb, Ph.D. §S3:2.3


**Valid codes for S3:** §S3:1.1 to §S3:1.14, §S3:2.0 to §S3:2.3



### S4: Ratio Therapeutics Enters License and Collaboration ...
URL: https://onco-this-week.com/ratio-therapeutics-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate/
Date: 2024-11-26

Labeled text:

“The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic,” said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. “Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors.” §S4:1.1


**Valid codes for S4:** §S4:1.1



### S5: VMT01/02 Program - Perspective Therapeutics |
URL: https://perspectivetherapeutics.com/pipeline/vmt01-02
Date: 2025-05-19

Labeled text:

<snippet-heading>## Overview</snippet-heading> §S5:1.0

VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. §S5:1.1
It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy. §S5:1.2

<snippet-heading>## Development</snippet-heading> §S5:2.0

Ongoing multi-center Phase 1/2a dose-escalation/expansion trial (NCT05655312) evaluating [ §S5:2.1

212Pb]VMT01 as monotherapy and in combination with nivolumab in patients with unresectable or metastatic MC1R-positive melanoma, currently recruiting across the US §S5:2.2
- First patient dosed in combination arm (with nivolumab) in March 2025; dose finding progressing at 3.0 mCi for both monotherapy and combination, with no dose-limiting toxicities reported as of September 2025 §S5:2.3

- Preclinical data demonstrate synergistic effects with immune checkpoint inhibitors; combination cohort actively enrolling §S5:2.4
Phase 1 imaging study at Mayo Clinic supports patient selection using [ §S5:2.5

203Pb]VMT01 and [ 68Ga]VMT02, confirming feasibility for MC1R targeting §S5:2.6

- Fast Track Designation granted by FDA (September 2024) for diagnosis and treatment of MC1R-positive melanoma §S5:2.7

- Clinical updates on safety, dosimetry, and efficacy expected mid to late 2026, with potential for expanded enrollment and regulatory discussions §S5:2.8


**Valid codes for S5:** §S5:1.0 to §S5:1.2, §S5:2.0 to §S5:2.8



---

## Task Structure

For each source:
1. **Assess source-level quality** → c (authority/quality) + p (probability)
2. **Extract snippets** → code + detail_limitation
3. **Assign source handle** → 1-word identifier (freddie, nih, pubmed, etc.)

---

## Source-Level Assessment (CRITICAL)

Evaluate ENTIRE source before extracting snippets:

**c (classification)** - Authority + all applicable quality codes:
- **Authority (who):** ALWAYS include one
  - **H**: High authority + topic expertise
  - **M**: Medium authority or unclear
  - **L**: Low authority or lacks topic expertise

- **Quality (what):** Include ALL that apply
  - **P**: PRIMARY (official/primary doc)
  - **D**: DOCUMENTED (methods/peer-reviewed)
  - **A**: ATTRIBUTED (named experts throughout)
  - **O**: OK (no red flags, nothing special)
  - **C**: CONTRADICTED (false/inconsistent)
  - **U**: UNSOURCED (no evidence)
  - **PR**: PROMOTIONAL (biased)
  - **S**: STALE (outdated)
  - **SL**: SLOP (AI SEO)
  - **IR**: INDIRECT (tangentially related)

**Format:** c:H/P (high authority + primary), c:M/A/O (medium + attributed + ok), c:L/U/S (low + unsourced + stale)
**Can combine multiple quality codes** - include ALL that apply to the source

**p (probability)** - Exact values: p05, p15, p30, p50, p65, p85, p95

Judge extracts all atomic claims from source and tests each. Pass = precisely accurate. p = expected pass-rate.

**source_handle** - 1-word identifier: freddie, nih, pubmed, nrel, bankrate, healthline, etc.

---

## Snippet Extraction Rules

**Gate - Extract only if:**
- Concrete, verifiable facts (not vague summaries/speculation)
- Doesn't need full article to verify
- Skip AI-generated SEO slop (mark source c:LA/SL if encountered)

**Pass-all flag:** `` §SX:* `` → Use entire source if dense/interconnected or would extract >50%

**Snippet Requirements:**
- **Self-contained:** Each snippet MUST make a complete point in isolation
- **Context in brackets:** Max 5 words, shorthand preferred (e.g., [re: IF] not [regarding intermittent fasting])
- **Ellipsis for gaps:** Use ... to join non-adjacent sentences into one coherent snippet
- **Must be testable:** Given only URL, title, and snippet, a judge can verify all claims
- **No redundancy:** Skip if same point already made by another snippet of same/higher quality

**Code Syntax:**
- Single: `` §S1:1.1 ``
- **Range (REQUIRED for consecutive):** `` §S1:1.5-1.7 ``
- **Ellipsis join (non-adjacent):** `` §S1:1.2 ... §S1:1.5 `` → resolves to "text1 ... text5"
- Word range: `` §S2:1.1.w5-7 `` (1-indexed)
- Heading context: `` [§S1:2.0] §S1:2.1 ``
- Attribution: `` [§S1:2.1.w1-4] §S1:1.3 `` (REQUIRED for c:A sources)
- Clarification: `` §S1:1.1 [re: Gemini] `` (max 5 words, shorthand)

**Consecutive Lines (CRITICAL):**
- **Contiguous sentences = ONE snippet** - even if they address different search terms or aspects
- Use ranges: `` §S1:2.1-2.4 `` - NEVER create separate snippets for adjacent lines
- Assign combined snippet to the MOST relevant search term

**Tables (CRITICAL):**
- ONE snippet per table: `` §S1:5.0-5.7 `` (header row 0 + data rows 1-7)
- NEVER separate rows

**CRITICAL - Code Accuracy Rules:**
- **ONLY use codes that appear in the labeled source text** - copy them EXACTLY
- Each source shows "Valid codes for SX:" at the bottom - codes MUST fall within those ranges
- **WRONG formats (NEVER output these):**
  - `` §S2:47.84 `` ← Decimal sentence numbers don't exist
  - `` §S2:189 `` ← Single integers without section.sentence format
  - `` §S7:1.1 `` when extracting from S2 ← Wrong source prefix
  - `` §S1:1.15-1.18 `` ← Range beyond actual sentence count
- **If you can't find the exact code in the source, OMIT the quote entirely**
- When in doubt, look at the "Valid codes" line for each source

---

## Snippet Handle Components

For each snippet, provide: `detail_limitation` (NO source prefix here)

**CRITICAL: EVERY CITATION MUST HAVE A UNIQUE TEXT HANDLE**
- Handles are the PRIMARY identifier for citations in synthesis
- If two snippets have the same handle, synthesis cannot distinguish them
- **ALWAYS ensure uniqueness** - append _2, _3, _4, etc. if a handle already exists

**Format:** `detail_limit` (max 2 words total, shorthand preferred)
- **detail**: 1 word, abbreviated (mtg-rate, wt-loss, eff-tbl)
- **limit**: 1 word, abbreviated (dec25, us, 2024)

**Examples:**
- `mtg-rate_dec25` (mortgage rate, December 2025)
- `wt-loss_if` (weight loss, intermittent fasting)
- `eff-tbl_solar` (efficiency table, solar)
- `wt-loss_if_2` ← Second snippet on same topic
- `wt-loss_if_3` ← Third snippet

Max 15 chars. **MUST be unique** (append _2, _3 if needed). Use common abbreviations.

**Full handle assembled later:** `{source_handle}_{detail}_{limitation}`
- freddie_mortgage-rate_dec-2025
- nih_weight-loss_if-protocol
- nih_weight-loss_if-protocol_2

---

## Output Format

```json
{
  "source_metadata": {
    "S1": {"handle": "freddie", "c": "H/P", "p": "p95"},
    "S2": {"handle": "nih", "c": "H/D/A", "p": "p85"},
    "S3": {"handle": "techblog", "c": "M/O", "p": "p65"}
  },
  "quotes_by_search": {
    "1": [
      ["mortgage-rate_dec-2025", "§S1:1.1"],
      ["refinance-rate_30yr-fixed", "§S1:2.1"],
      ["weight-loss_if-vs-cer", "[§S2:1.0] §S2:1.5"],
      ["insulin-sensitivity_tre-protocol", "§S2:2.1-2.3"],
      ["ai-trends_2025", "§S3:1.1"]
    ],
    "2": []
  }
}
```

**source_metadata** - One entry per source:
- **handle**: 1-word identifier (nih, webmd, freddie)
- **c**: Authority + quality codes (H/P, M/A/O, L/U/S)
- **p**: Probability (p05, p15, p30, p50, p65, p85, p95)

**quotes_by_search** - Organized by search term number:
- Each quote: `[detail_limitation, code]` ← **HANDLE FIRST, then code**
- Source is identified by code prefix (§S1:1.1 → S1)
- **Max 2 per source per search term**
- **ORDERING: List quotes sequentially by source (all S1, then all S2, then S3...), and within each source by code order (1.1, 1.2, 2.1...)**

Return empty `{}` if nothing clear.

**⚠️ RESPONSE LENGTH LIMIT: Keep your total response under 24000 words.**

```

</details>

#### Batch Extraction Result (5 sources) <small>(04:07:02)</small>

<details><summary>Click to expand</summary>

```json
{
  "source_metadata": {
    "S1": {
      "handle": "patsnap",
      "c": "M/O",
      "p": "p50"
    },
    "S2": {
      "handle": "oncology",
      "c": "M/O",
      "p": "p50"
    },
    "S3": {
      "handle": "lifescience",
      "c": "M/O",
      "p": "p50"
    },
    "S4": {
      "handle": "onco",
      "c": "M/O",
      "p": "p50"
    },
    "S5": {
      "handle": "perspective",
      "c": "H/P",
      "p": "p95"
    }
  },
  "quotes_by_search": {
    "1": [
      [
        "melanoma_phase-2",
        "§S1:15.0"
      ],
      [
        "melanoma_phase-1",
        "§S1:18.0"
      ],
      [
        "fap-targeted_therapeutic",
        "§S2:1.6"
      ],
      [
        "sstr2-targeting_therapeutic",
        "§S3:1.2"
      ],
      [
        "sstr2-targeting_therapeutic",
        "§S4:1.1"
      ],
      [
        "mc1r-expressing_melanomas",
        "§S5:1.1"
      ],
      [
        "mc1r-positive_melanoma",
        "§S5:2.2"
      ]
    ]
  }
}
```

</details>

<p align='right'><small>Step duration: 1.47s</small></p>
</details>

<details>
<summary><b>[SUCCESS] Step: Synthesis</b> <small>(04:07:02)</small></summary>

### Synthesis Prompt (Iter 1) <small>(04:07:02)</small>

<details><summary>Click to expand</summary>

```text
# Generate Answer from Quotes

Query: # Table Entry Validation and Research

You are validating and updating several field values for a single row in a research table.

═══════════════════════════════════════════════════════════════
## 🎯 FOCUSED TASK
═══════════════════════════════════════════════════════════════

**Use this section to guide your initial web searches.** Detailed field requirements for synthesis appear below.

**Context:**
Product (or Candidate): VMT02
Owner: Ratio Therapeutics

**3 Research Questions:**
Core Product & Owner Info: Basic product information including owner, target/indication, and development stage. This foundational data is often found together in company pipelines and press releases.

**1. Owner**: Company or entity that owns or is developing the product.???
   Current value: Ratio Therapeutics
**2. Target / Indication**: Biological target and the disease indication the product is intended for.???
**3. Development Stage**: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).???

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 WHAT YOU'LL FIND BELOW
═══════════════════════════════════════════════════════════════

The sections below provide detailed context for **synthesizing your search results** into validated answers:

- **GENERAL NOTES**: Validation context for the broader research effort this subtask falls within
- **CONTEXT & PREVIOUS DATA**: Other fields from this row and prior validations for reference
- **FIELD DETAILS**: Detailed requirements, format, notes, and examples for each field
- **CONFIDENCE LEVELS**: How to assign confidence ratings to your findings
- **RESPONSE FORMAT**: Required JSON structure and critical validation rules

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 GENERAL NOTES
═══════════════════════════════════════════════════════════════

This configuration validates a biopharmaceutical product/candidate tracking table. The primary identifier is the product name. All research columns should be verified against current public information as of February 13, 2026, using company websites, clinical trial registries (e.g., ClinicalTrials.gov), and reputable news sources. For columns left blank, it may indicate the information is not applicable or not yet public.

---

═══════════════════════════════════════════════════════════════
## 📊 CONTEXT & PREVIOUS DATA
═══════════════════════════════════════════════════════════════

**Context for this row:**

Product (or Candidate): VMT02
Owner: Ratio Therapeutics

⚠️ **CRITICAL - ROW CONTEXT SCOPE CONSTRAINT:**
All validation results must be about the SPECIFIC ENTITY identified by the context above.

**Common scope errors to AVOID:**
- Validating a different entity with a similar name
- Using general information when specific information is required
- Example: When validating news for "Product X by Company Y", reject news that only mentions "Company Y" without mentioning "Product X"
- Example: When validating a company associated with a product, verify the company OWNS/DEVELOPS that specific product, not just that the company exists

**Scope validation checklist:**
1. Do sources explicitly mention ALL identifying information from context above?
2. Is information contemporary with the entity (not before it existed)?
3. Have you cross-referenced to confirm entity identity?
4. When in doubt, mark confidence as MEDIUM or LOW

**Other fields from this row (unvalidated - for reference only):**

**Previous validations for this row:**

Product (or Candidate): VMT02 (Confidence: ID)

⚠️ **CRITICAL - INHERENT SUSPICION OF PREVIOUS RESULTS:**

Previous values shown above may be INCORRECT. Do NOT assume they are correct.

**Mandatory verification requirements:**
- Treat previous values as HYPOTHESES to be tested, not FACTS
- Every previous claim must be verified against current authoritative sources
- Do NOT copy previous values without independent verification
- Well-formatted previous answers with citations can still be wrong
- High confidence scores from past validations don't guarantee truth

**If current sources conflict with previous values:**
1. Prioritize DIRECT QUOTES from HIGH-AUTHORITY sources (see confidence criteria)
2. Check publication dates - newer authoritative sources may supersede old data
3. If conflict unresolved, mark confidence as MEDIUM or LOW
4. Document the conflict in your explanation

**Truth Standard:** Direct quotes from authoritative sources determine truth,
NOT how confident, well-cited, or professionally formatted previous results appear.

Your task: Use previous results as a STARTING POINT, then independently verify/correct with current sources.

---

═══════════════════════════════════════════════════════════════
## 📝 FIELD DETAILS - Format Requirements and Examples
═══════════════════════════════════════════════════════════════

**For each field you will receive:**

- **Field Name**: (This is the name of the field)
- **Description**: (What this field represents)
- **Format**: (How to format your answer)
- **Notes**: (Quality standards for this specific field)
- **Examples**: (Sample formatting)

**VALUES TO CONSIDER:**
- **Current Value** (to be validated/updated): The value that needs validation/updating in this run
- **Previous Value** (from Original Values sheet): The historical validated value from a prior validation run (if available)

**YOUR TASK**: Validate and update the **Current Value** using web search and the guidance provided. Compare it to the **Previous Value** (if available) to understand what has changed.

----- FIELD 1: Owner -----
**Current Value**: Ratio Therapeutics
Description: Company or entity that owns or is developing the product.
Format: String
Importance: RESEARCH

Notes: Verify the current owner/developer. Check company websites and recent press releases.

Examples:
  - Actithera
  - Advanced Accelerator Applications
  - Bayer

----- FIELD 2: Target / Indication -----
**Current Value**: 
Description: Biological target and the disease indication the product is intended for.
Format: String
Importance: RESEARCH

Notes: Verify the molecular target (e.g., FAP, PSMA) and the specific disease or condition.

Examples:
  - FAP / oncology (lead program)
  - FAP / pan-cancer imaging
  - FAP / pan-cancer therapy

----- FIELD 3: Development Stage -----
**Current Value**: 
Description: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).
Format: String
Importance: RESEARCH

Notes: Confirm the most recent development stage from official sources like clinical trial registries or company pipelines. Use standard terms (Preclinical, Phase I, Phase II, Phase III, Approved).

Examples:
  - Phase I
  - Phase II
  - Preclinical

---

═══════════════════════════════════════════════════════════════
## ⭐ CONFIDENCE LEVELS
═══════════════════════════════════════════════════════════════

Confidence measures the likelihood that the facts stated in the cell are precisely accurate:

- **HIGH (H)**: 85%+ likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood ≥ 85%
  - Source: Authoritative, directly verifiable, widely accepted

- **MEDIUM (M)**: 65%-85% likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood 65%-85%
  - Source: Respectable but not definitive, good estimates, confident projections

- **LOW (L)**: <65% likelihood that the facts are precisely accurate
  - Weak/conflicting sources, uncertainty, no authoritative verification
  - **Only LOW confidence answers may be blank (null)**
  - **Blank originals**: Assign LOW for `original_confidence` when the original value was blank/empty
  - **Removing false data**: If original has LOW confidence false data and no reliable replacement exists, you CAN go to blank with LOW confidence (removing bad data is acceptable)

**SPECIAL CASE - Expressing Doubt:**
When the value itself expresses uncertainty (e.g., "Rumors suggest...", "Unconfirmed reports say...", "Less reliable sources claim..."), confidence measures whether the SOURCES say it, NOT whether it's true.

Example:
- Value: "Rumors suggest launch in Q3 2025"
- HIGH confidence: Multiple sources confirm rumors exist
- The confidence is about the rumors existing, not about the launch happening

**Confident Absence:**
If you are confident something does not exist or is not applicable, say so explicitly with language appropriate to the measure (e.g., "N/A", "Not applicable", "No website", "Not publicly traded") and assign an appropriate confidence level (H/M). Do not leave it blank - blank means you have no information.

---

═══════════════════════════════════════════════════════════════
## 📤 RESPONSE FORMAT
═══════════════════════════════════════════════════════════════

Return a JSON array where each item is a cell array with 6 elements:

```
[column, answer, confidence, original_confidence, consistent, explanation]
```

- **column**: Exact field name from FIELD DETAILS
- **answer**: The validated value (string or null for blank)
- **confidence**: H (HIGH), M (MEDIUM), or L (LOW)
- **original_confidence**: H, M, or L (for the original value)
- **consistent**: T (consistent with model knowledge), F (not consistent), or null
- **explanation**: Succinct reason you believe the answer is correct

**Example:**
```json
[
  ["Revenue", "$158.9B", "H", "M", "T", "Q3 2024 earnings report confirmed"],
  ["CEO", "Andy Jassy", "H", "H", "T", "Official Amazon leadership page"],
  ["Founded", null, "L", "L", null, "No reliable data found"]
]
```

### CRITICAL REQUIREMENTS

- **Do not use quotation marks around your responses** (except in JSON structure itself)
- **Assess both confidences**: Rate the quality of your updated answer (confidence) AND the quality of the original value (original_confidence) using H/M/L
- **CRITICAL - Blank original values**: If the original value was blank/empty, set `original_confidence` to `L` (LOW). Blank originals get LOW original_confidence.
- **Only update if significantly better**: Only provide a different validated value if you can improve significantly on the original value
- **Generally don't degrade confidence**:
  - If original has H/M confidence, don't degrade to L or blank without strong justification
  - If original has L confidence false data and no reliable replacement: You CAN leave blank (removing bad data is acceptable)
  - Hierarchy: H > M > L
  - **Confident absence**: Use language appropriate to the measure (e.g., "N/A", "Not applicable", "No website") with confidence — blank means you have no information, not that the value doesn't exist
- **Use exact column names**: Include the exact column name in each cell array - exactly as defined in the FIELD DETAILS above
- **Provide explanation**: Always include the explanation with succinct reasoning for your answer
- **Handle blanks appropriately**: If you cannot find or determine information for a field, use null for answer and L for confidence. Only LOW confidence answers may be truly blank.
- **Use examples as guides**: Use provided examples to guide your update format and expected values
- **Format for Excel**: Use newline characters correctly so that they are formatted in an Excel cell, particularly for bullets, lists, and other formatted text
- **Stay focused**: Do not research the context and guidance - focus only on the fields listed above
- **Double check everything**: Double check your updated response and confidence - speak precisely, there is no room for error
- **Valid JSON required**: The response MUST be valid JSON array format

---


**Today's Date:** 2026-02-13

## Structure Legend

- **Q1.{n}:** Query number in iteration 1 (search term used)
- **Snippet ID Format:** S{iter}.{search}.{source}.{snippet}-p{score}
  - Example: S1.2.3.0-p0.85 = Iteration 1, Search 2, Source 3, Snippet 0, p-score 0.85
- **p (probability):** Source-level quality score (0.05-0.95) - judge tests all atomic claims, p = expected pass-rate
  - 0.85-0.95: High confidence (PRIMARY/DOCUMENTED/ATTRIBUTED) - prefer these
  - 0.50-0.65: Medium confidence (OK quality)
  - 0.05-0.30: Low confidence (UNSOURCED/STALE/PROMOTIONAL) - use cautiously
- **c (classification):** Source authority + quality codes (shown in snippet metadata)
  - H/P = High Authority + Primary
  - H/P/D/A = High + Primary + Documented + Attributed
  - M/O = Medium Authority + OK
  - L/U = Low Authority + Unsourced
- **Date:** Publication or last updated date from source

## Quotes Organized by Search Term


Q1.1: "VMT02 Ratio Therapeutics target indication development stage"
  [S1.1.1] https://synapse.patsnap.com/drug/2147731a54d94c709c7db6757eb5cd1f [2025-11-03] [WARNING: Lower Quality Source (p=0.5)]
    - [patsnap_melanoma_phase-2, S1.1.1.0-p0.50] (p=0.5, c=M/O) "Phase 2"
    - [patsnap_melanoma_phase-1, S1.1.1.1-p0.50] (p=0.5, c=M/O) "Phase 1"
  [S1.1.2] https://www.1stoncology.com/blog/january-17th-2024-ratio-therapeutics-announces-50m-series-b-financing-to-advance-targeted-radiotherapies-for-cancer-treatment1234639292/ [2024-01-17] [WARNING: Lower Quality Source (p=0.5)]
    - [oncology_fap-targeted_therapeutic, S1.1.2.0-p0.50] (p=0.5, c=M/O) "Additionally, the funding will drive the clinical development of the company’s fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic."
  [S1.1.3] https://lifesciencereport.com/news/nyse/nvs/ratio-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate [2024-11-18] [WARNING: Lower Quality Source (p=0.5)]
    - [lifescience_sstr2-targeting_therapeutic, S1.1.3.0-p0.50] (p=0.5, c=M/O) "The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer."
  [S1.1.4] https://onco-this-week.com/ratio-therapeutics-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate/ [2024-11-26] [WARNING: Lower Quality Source (p=0.5)]
    - [onco_sstr2-targeting_therapeutic, S1.1.4.0-p0.50] (p=0.5, c=M/O) "“The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic,” said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. “Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors.”"
  [S1.1.5] https://perspectivetherapeutics.com/pipeline/vmt01-02 [2025-05-19]
    - [perspective_mc1r-expressing_melanomas, S1.1.5.0-p0.95] (p=0.95, c=H/P) "VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas."
    - [perspective_mc1r-positive_melanoma, S1.1.5.1-p0.95] (p=0.95, c=H/P) "212Pb]VMT01 as monotherapy and in combination with nivolumab in patients with unresectable or metastatic MC1R-positive melanoma, currently recruiting across the US"

## Synthesis Instructions


SYNTHESIS DEPTH: Low Context (Concise & Direct)

Guidelines:
- Provide direct, focused answers
- Cover the main points without extensive elaboration
- Use 3-5 key facts
- Keep explanations brief and clear
- Minimal contextual background
- Focus on answering the specific question asked

SOURCE PRIORITY:
- **Prioritize HIGH reliability sources** (H) over MEDIUM (M) and LOW (L)
- Only use MEDIUM/LOW sources if HIGH sources don't cover that aspect

Target: Concise, fact-focused response


## Your Task

Generate a structured comparison answering the query, then self-assess.

**Citation Format:** Use [verbal_handle, snippet_id] format for all citations.

**CRITICAL - COPY EXACT handles and IDs from snippets above:**
- Format: `[handle, S1.1.5.6-p0.95]` - FULL 4-part ID
- **DO NOT create your own handles** - COPY from snippet listings
- **DO NOT shorten IDs** - Use full 4-part format
- Example from listings: `[intermittent_fasting_weight_2, S1.1.1.0-p0.95]`
  - ❌ WRONG: `[if_weight, S1.1.1-p0.95]` - made up handle, shortened ID
  - ✅ CORRECT: `[intermittent_fasting_weight_2, S1.1.1.0-p0.95]` - exact copy
- **Look up the snippet in listings above, copy its [handle, ID] exactly**
- **REQUIRED:** Every factual claim must have citations

**Output Structure:** Use nested objects to avoid repetition.

**CRITICAL - Citation Placement:**
- **INLINE ONLY**: Citations must be embedded DIRECTLY in the text
- **NO separate citation fields**: Do NOT create fields like "citations": [...]
- **Format**: Include [handle, ID] at the END of each claim within the text itself

Example structure:
```json
{
  "comparison": {
    "current_value": "6.21% [mortgage_rate_dec2025, S1.1.1.0-p0.95]",
    "trend": "decreased from prior week [rate_change, S1.1.2.1-p0.85]"
  },
  "self_assessment": "A"
}
```

❌ WRONG - Separate citation fields:
```json
{
  "feature": {
    "description": "Feature description here",
    "citations": [["handle1, S1.1.1.0-p0.95"]]
  }
}
```

✅ CORRECT - Inline citations:
```json
{
  "feature": "Feature description here [handle1, S1.1.1.0-p0.95]"
}
```

Note: Use FULL 4-part IDs exactly as shown in snippets above.

## Self-Assessment

Imagine a client paid an expert researcher for this answer. Would they be satisfied?

**Expert answers have:**
- Direct response to what was asked (no tangents, no gaps)
- Specific facts (numbers, dates, names - not vague generalities)
- Claims backed by authoritative sources with citations
- Complete coverage (nothing important missing that's findable online)
- Clear and well-organized presentation

**Grade your synthesis (A+ to C-):**
- **A+/A**: Expert-quality - client would be satisfied, nothing important missing
- **B**: Acceptable but incomplete - missing information that's likely findable online
  - **Optional:** Provide `suggested_search_terms` ONLY if you have specific, concrete gaps that targeted searches would fill.
  - **Optional:** `request_capability_upgrade=true` if reasoning is too complex.
  - **Optional:** `note_to_self` for next attempt.
- **C**: Insufficient - cannot meaningfully answer, or information not available
  - **Optional:** Provide `suggested_search_terms` ONLY if specific searches would likely help.

**CRITICAL for suggested_search_terms:**
- ONLY suggest search terms when you have HIGH CONFIDENCE they will find new, useful information
- Do NOT suggest speculative or exploratory searches ("maybe there's more about X")
- Each term should target a SPECIFIC gap you identified (e.g., "Company Y Phase 3 trial results 2024")
- If you're unsure whether more searches would help, do NOT suggest any - just give your best answer
- Empty `suggested_search_terms` is preferable to low-confidence guesses

**CRITICAL:**
- You MUST always provide an answer that satisfies the schema structure, even if incomplete.
- We will only re-run searches if you provide `suggested_search_terms` OR set `request_capability_upgrade=true`.

Return JSON with 'comparison', 'self_assessment', and optional 'suggested_search_terms', 'request_capability_upgrade', and 'note_to_self' fields.

**⚠️ RESPONSE LENGTH LIMIT: Keep your total response under 24000 words.**
```

</details>

### Synthesis Result (Iter 1) <small>(04:07:17)</small>

<details><summary>Click to expand</summary>

```json
{
  "comparison": {
    "validation_results": [
      [
        "Owner",
        "Ratio Therapeutics",
        "H",
        "H",
        "T",
        "Confirmed as the developer of VMT02 [perspective_mc1r-expressing_melanomas, S1.1.5.0-p0.95]"
      ],
      [
        "Target / Indication",
        "MC1R / MC1R-positive melanoma",
        "H",
        "L",
        "T",
        "VMT01/02 targets the melanocortin subtype 1 receptor (MC1R) for MC1R-positive melanoma [perspective_mc1r-expressing_melanomas, S1.1.5.0-p0.95][perspective_mc1r-positive_melanoma, S1.1.5.1-p0.95]"
      ],
      [
        "Development Stage",
        "Phase 2",
        "M",
        "L",
        null,
        "PatSnap lists VMT02 as Phase 2, but this is a lower-quality source; no high-authority source explicitly confirms the stage for VMT02 [patsnap_melanoma_phase-2, S1.1.1.0-p0.50]"
      ]
    ]
  },
  "self_assessment": "B",
  "suggested_search_terms": [
    "VMT02 clinical trial phase",
    "Ratio Therapeutics VMT02 clinicaltrials.gov",
    "VMT02 MC1R melanoma development stage"
  ],
  "request_capability_upgrade": false,
  "note_to_self": "Found high-confidence target/indication from Perspective Therapeutics pipeline page, but development stage is only from a medium-confidence source (PatSnap). Need to search clinical trial registries for definitive stage."
}
```

</details>

<p align='right'><small>Step duration: 14.74s</small></p>
</details>
## Self-Correction Search <small>(04:07:17)</small>

```text
Iteration 1: Grade B. Executing: ['VMT02 clinical trial phase', 'Ratio Therapeutics VMT02 clinicaltrials.gov']
```

### Executing Searches <small>(04:07:17)</small>

```json
{
  "terms": [
    "VMT02 clinical trial phase",
    "Ratio Therapeutics VMT02 clinicaltrials.gov"
  ],
  "settings": {
    "max_results": 10,
    "max_tokens_per_page": 512
  }
}
```

### Search Results Summary <small>(04:07:18)</small>

<details><summary>Click to expand</summary>

```json
[
  "Search 1: 10 results",
  "  Top results: ['MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma', 'Carbone Cancer Center Clinical Trials', 'MC1R-targeted Alpha-particle Monotherapy And ... - Mayo Clinic']",
  "Search 2: 10 results",
  "  Top results: ['Home | ClinicalTrials.gov', 'NCT07156565', 'Carbone Cancer Center Clinical Trials']"
]
```

</details>

### Raw Search Results <small>(04:07:18)</small>

<details><summary>Click to expand</summary>

```json
[
  {
    "id": "1f5c519c-d71c-46ab-a8ac-4a099f387465",
    "results": [
      {
        "date": "2022-11-15",
        "last_updated": "2025-08-13",
        "snippet": "## Study Overview\n\nThis is a prospective, multi-center open-label dose-escalation, dose-expansion study of [212Pb]VMT01 as a monotherapy or in combination with Nivolumab in up to 264 subjects with histologically confirmed melanoma and a positive MC1R imaging scan with imaging agents [203Pb]VMT01 or [68Ga]VMT02.\n\n…\n\nThis study will be conducted in 3 parts:\n\nPart 1: Monotherapy Dose-Escalation: [212Pb]VMT01 is administered alone in escalating doses to determine the Maximum Tolerated radioactivity Dose (MTD), Maximum Feasible radioactivity Dose (MFD), and potential recommended Phase 2 doses (RP2Ds)\nPart 2: Combination-Therapy Dose-Escalation: [212Pb]VMT01 and Nivolumab are administered in escalating doses to determine MTD, MFD, and RP2Ds.\n\nPart 3: Dose Expansion: This part will enroll subjects in monotherapy and combination-therapy expansion cohorts based on the identified MTD, MFD, and RP2D for the selection of [212Pb]VMT01 alone and [212Pb]VMT01-Nivolumab combination doses for further clinical development.\nEnrolled subjects in Monotherapy part may receive up to 3 doses of [212Pb]VMT01 approximately 8 weeks apart and subjects in combination therapy may receive nivolumab every 4 weeks for up to 24 months.\n\nA Dosimetry sub-study utilizing an imaging surrogate, [203Pb]VMT01, has been incorporated into the study in order to assess organ biodistribution and tumor uptake of the investigational products. This study will also estimate radiation dosimetry and correlate uptake of the investigation products with observed toxicities and efficacy.\n\n…\n\n- Uptake of [68Ga]VMT02 or [203Pb]VMT01 by PET or SPECT imaging observed in at least one melanoma tumor site using quantitative imaging analysis compared to reference normal tissue\n\n…\n\n- Febrile illness within 48 hours of any scheduled investigational product ([212Pb]VMT01, [203Pb]VMT01, or [68Ga]VMT02) administration; subjects should be rescheduled > 48 hours after resolution of fever\n\n- Treatment with another investigational drug product (therapeutic IND agents) within the last 45 days before the first dose of [212Pb]VMT01 on C1D1.",
        "title": "MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma",
        "url": "https://www.clinicaltrials.gov/study/NCT05655312"
      },
      {
        "last_updated": "2025-05-19",
        "snippet": "",
        "title": "Carbone Cancer Center Clinical Trials",
        "url": "https://mct.platformx.wisc.edu/mct.php?protocol_id=33435&protocol_no=UW22119&back_node_id=2327"
      },
      {
        "date": "2025-12-12",
        "last_updated": "2026-02-11",
        "snippet": "During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments.\nPhase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.\nIn this first-in human, phase I/IIa study, the safety and efficacy of \\[212Pb\\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma.\n\n…\n\n-line therapy for metastatic melanoma* Uptake of \\[68Ga\\]VMT02 or \\[203Pb\\]VMT01 by PET or SPECT imaging observed in at least one melanoma tumor site using quantitative imaging analysis compared to reference normal tissue* Subjects on prior intravenous therapy (e.g., chemotherapy or checkpoint\n\n…\n\n* Presence of measurable disease by RECIST v1.1 assessed within 30 days prior to the first dose of \\[212Pb\\]VMT01 on Cycle 1 Day 1* Ability to lie flat and still for up to two hours for imaging scans; moderate conscious sedation allowed if indicated* For females\n\n…\n\nleast 6 months after the last dose of \\[212Pb\\]VMT01 and/or nivolumab, whichever is administered last* Eastern Cooperative Oncology Group performance score of \\< 2 at Screening* Life expectancy of at least 3 months after Cycle 1 Day 1* Satisfactory organ function determined by laboratory testingExclusion Criteria:* Active secondary malignancy* Prior systematic treatment with radioactive nuclides.\n\n…\n\ndose of \\[212Pb\\]VMT01* Subjects with an active, known, or suspected autoimmune disease* Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications* Acute or chronic hepatitis B (e.g., Hepatitis B surface antigen reactive), hepatitis C (e.g",
        "title": "MC1R-targeted Alpha-particle Monotherapy And ... - Mayo Clinic",
        "url": "https://www.mayo.edu/research/clinical-trials/cls-20551014"
      },
      {
        "date": "2025-05-19",
        "last_updated": "2026-01-30",
        "snippet": "## Overview\n\nVMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy.\n\n## Development\n\n\n\nOngoing multi-center Phase 1/2a dose-escalation/expansion trial (NCT05655312) evaluating [\n\n212Pb]VMT01 as monotherapy and in combination with nivolumab in patients with unresectable or metastatic MC1R-positive melanoma, currently recruiting across the US\n- First patient dosed in combination arm (with nivolumab) in March 2025; dose finding progressing at 3.0 mCi for both monotherapy and combination, with no dose-limiting toxicities reported as of September 2025\n\n- Preclinical data demonstrate synergistic effects with immune checkpoint inhibitors; combination cohort actively enrolling\nPhase 1 imaging study at Mayo Clinic supports patient selection using [\n\n203Pb]VMT01 and [ 68Ga]VMT02, confirming feasibility for MC1R targeting\n\n- Fast Track Designation granted by FDA (September 2024) for diagnosis and treatment of MC1R-positive melanoma\n\n- Clinical updates on safety, dosimetry, and efficacy expected mid to late 2026, with potential for expanded enrollment and regulatory discussions",
        "title": "VMT01/02 Program - Perspective Therapeutics |",
        "url": "https://perspectivetherapeutics.com/pipeline/vmt01-02"
      },
      {
        "date": "2022-11-15",
        "last_updated": "2025-12-04",
        "snippet": "## MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaClinicalTrials.gov ID\n\n## Study Overview\n\nThis is a prospective, multi-center open-label dose-finding, dose-expansion study of [212Pb]VMT01 as a monotherapy or in combination with nivolumab in up to 300 subjects with histologically confirmed melanoma and a positive MC1R imaging scan with imaging agents [203Pb]VMT01 or [68Ga]VMT02.\n\n…\n\nThis study will be conducted in 3 parts:\n\nPart 1: Monotherapy Dose-Finding\n\nPart 2: Combination-Therapy Dose-Finding\n\nPart 3: Dose Expansion\n\nEnrolled subjects in Monotherapy may receive up to 3 doses of [212Pb]VMT01 approximately 8 weeks apart and subjects in combination therapy may receive up to 3 doses of [212Pb]VMT01 along with nivolumab. Nivolumab will be administered every 4 weeks for up to 24 months.\nA Dosimetry sub-set utilizing an imaging surrogate, [203Pb]VMT01, has been incorporated into the study in order to assess organ biodistribution and tumor uptake of the investigational products. This study will also estimate radiation dosimetry and correlate uptake of the investigation products with observed toxicities and efficacy.\n\nDrug: [203Pb]VMT01 Drug: [212Pb]VMT01 Drug: Nivolumab\n\n- VMT01-T101\n\n…\n\n- Subjects on prior intravenous therapy (e.g., chemotherapy or checkpoint inhibitors), or prior oral therapy (e.g.,proto-oncogene B-RAF or mitogen-activated extracellular signal-regulated kinase inhibitors) who demonstrate MC1R positivity during screening are eligible for enrollment, provided that they undergo a wash-out period of 21 days, or 7 days, respectively, prior to Cycle 1 Day 1 treatment with [212Pb]VMT01.\n\n…\n\n- Febrile illness within 48 hours of any scheduled investigational product ([212Pb]VMT01, [203Pb]VMT01, or [68Ga]VMT02) administration; subjects should be rescheduled > 48 hours after resolution of fever\n\n- Treatment with another investigational drug product (therapeutic IND agents) within the last 45 days before the first dose of [212Pb]VMT01 on C1D1.",
        "title": "MC1R-targeted Alpha-particle Monotherapy and ...",
        "url": "https://clinicaltrials.gov/study/NCT05655312?intr=212Pb&checkSpell=&rank=6"
      },
      {
        "date": "2024-11-21",
        "last_updated": "2026-02-12",
        "snippet": "Featured conditions\n\nBrain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.\n\nFeatured conditions\n\nCancer-related trials contact form\n\nPhone: 855-776-0015 (toll-free)\n\nInternational patient clinical studies questions\n\nTab Title Description\n\nDescribes the nature of a clinical study. Types include:\nDuring the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments.\nPhase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.\nThe purpose of this study is to determine safety and measure biodistribution of two imaging agents in patients with refractory or metastatic melanoma. This study will use [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) imaging.\nParticipant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.\nInclusion Criteria:\n\nExclusion Criteria:\n\nEligibility last updated 11/10/21. Questions regarding updates should be directed to the study team contact.\n\nStudy statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.\n\nMayo Clinic principal investigator\n\nGeoffrey Johnson, M.D., Ph.D.\n\nClosed for enrollment",
        "title": "Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy",
        "url": "https://www.mayo.edu/research/clinical-trials/cls-20509817"
      },
      {
        "date": "2025-11-03",
        "last_updated": "2026-02-12",
        "snippet": "login\n\nor\n\nview full example data\n\nRelated\n\n1\n\nClinical Trials associated with [68Ga]VMT02\n\nNCT04904120\n\n\n\nCompleted\n\nPhase 1\n\nA Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic Melanoma\nThe study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.\n\n…\n\nArticle\n\nAuthor:\n\nGroten, J P\n\n\n\nHissink, E\n\n\n\nvan Bladeren, P J\n\n…\n\nIn rats cadmium was present in two MT isoforms, RMT-1 and RMT-2. Ion-exchange chromatography of porcine liver cytosol also showed that two isoforms existed, but a major portion of the cadmium elutes with the second isoform, VMT-2. Using a reversed-phase HPLC system, the purified rat metallothionein isoforms eluted as single peaks before pig MT isoform VMT-2.\nThe difference in chromatographic behaviour on reversed-phase HPLC between species-specific metallothioneins offers a unique possibility to study the fate of endogenous and exogenous metallothioneins simultaneously. This will be illustrated by the redistribution of 109Cd from exogenous CdMT to endogenous CdMT after intravenous injection of VMT-2 into rats.\n100\n\nDeals associated with [68Ga]VMT02\n\nLogin to view more data\n\nR&D Status\n\n10\n\ntop R&D records.\n\nLogin\n\nto view more data\n\nIndication\n\nHighest Phase\n\nCountry/Location\n\nOrganization\n\nDate\n\nMelanoma\n\nPhase 2\n\nUnited States\n\nPerspective Therapeutics, Inc.\n\n…\n\nPerspective Therapeutics, Inc.\n\n05 Mar 2021\n\nUveal Melanoma\n\nPhase 1\n\nUnited States\n\nPerspective Therapeutics, Inc.\n\n05 Mar 2021\n\nLogin to view more data\n\nClinical Result\n\nIndication\n\nPhase\n\nEvaluation\n\nView All Results\n\nStudy\n\nPhase\n\nPopulation\n\nAnalyzed Enrollment",
        "title": "[68Ga]VMT02 - Drug Targets, Indications, Patents - Patsnap Synapse",
        "url": "https://synapse.patsnap.com/drug/2147731a54d94c709c7db6757eb5cd1f"
      },
      {
        "date": "2025-05-19",
        "last_updated": "2025-06-26",
        "snippet": "## Overview\n\nVMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy.\n\n## Development\n\n- US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT05655312?term=vmt01\n\n- Fast Track Designation received September 2024\n\n- Preclinical data shows synergistic effect with Immune Checkpoint Inhibitors\n\n- VMT01/ICI combination cohort open for recruitment\n\n- Phase 1 imaging study at Mayo Clinic Rochester indicates feasibility of patient\n\nselection using [\n\n203Pb]VMT01 and [ 68Ga]VMT02",
        "title": "VMT01/02",
        "url": "https://www.perspectivetherapeutics.com/pipeline/vmt01-02"
      },
      {
        "date": "2026-01-09",
        "last_updated": "2026-01-29",
        "snippet": "23 patients in Cohort 2 and both patients in Cohort 1* *Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation since the prior update, and 8 previously reported confirmed\n\n…\n\n- Nine (39%) patients in Cohort 2 were observed to have response according to investigator-assessed RECIST v1.1. Eight (35%) of those responses were confirmed and previously reported at ESMO. One patient experienced an initial response in their most recent tumor assessment after the prior update at ESMO. As the patient remains on study, the patient is expected to receive a subsequent tumor assessment.\n- Seven patients were observed to have deepening of best response, including one patient with stable disease.\n\n“With longer follow-up and a growing body of clinical experience, we continue to see evidence of sustained and deepening anti-tumor activity for VMT-α-NET at the dose level evaluated in Cohort 2, while the favorable tolerability profile is maintained, possibly even at a higher dose,” said Vikas Prasad, MD, Professor of Radiology, Mallinckrodt Institute of Radiology, Siteman Cancer Center, Washington University School of Medicine. “These data further support continued dose optimization, and I look forward to discussing the evolving results with the gastrointestinal oncology community as this study progresses.”\nMarkus Puhlmann, Chief Medical Officer of Perspective, commented, “The updated interim results presented at ASCO-GI continue to support VMT-α-NET’s compelling overall clinical profile at the 5 mCi dose. Meanwhile, for the slightly higher dose (6 mCi), DLT assessment was completed and we are cleared to enroll more patients with one additional patient already treated. With the robust clinical dataset being accrued from strong patient enrollment into our study, we believe we will be able to have meaningful engagement with regulatory agencies during 2026 on proceeding with VMT-α-NET into a registrational trial.”\n\n…\n\nInterim analysis with a data cut-off date of December 10, 2025 was reported at ASCO-GI in January 2026, including efficacy data on half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 are pending, and submissions for presentations at additional medical conferences during 2026 are planned.",
        "title": "Perspective Therapeutics Presents Updated Interim Data of",
        "url": "https://www.globenewswire.com/news-release/2026/01/09/3216015/0/en/Perspective-Therapeutics-Presents-Updated-Interim-Data-of-212Pb-VMT-%CE%B1-NET-in-its-Ongoing-Phase-1-2a-Clinical-Trial-at-the-2026-ASCO-Gastrointestinal-Cancers-Symposium.html"
      },
      {
        "date": "2024-06-04",
        "last_updated": "2025-10-08",
        "snippet": "## Contact Information\n### A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors\n\nThis study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors\nThis is a prospective, multi-center, open-label, radioactivity dose-finding/ dose expansion study of [212Pb]VMT-α-NET in up to 260 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT).\nSomatostatin Receptor type 2 (SSTR2) is highly expressed on various tumors including NETs and therefore is an attractive therapeutic target for NET treatment. Lead-212 ([212Pb]-) based peptide-radiopharmaceuticals are an emerging class of targeted alpha-particle cancer therapies that have potential to improve delivery of a highly effective form of radiation.\n\n…\n\nThe study will be conducted in 2 parts: Part 1: Phase I Dose-Finding: Subjects will receive radioactive doses of [212Pb]VMT-α-NET up to a maximum dose of 222 MBq (6 mCi) for dose-limiting toxicity (DLT) observation, determining Optimal Biological Dose (OBD) and potential Recommended Phase 2 Dose (RP2D) for Part 2 (Dose Expansion).\nDose changes or adjustments will be made by the safety monitoring committee (SMC) and Sponsor. The RP2D will be determined following a holistic analysis of observed DLTs, adverse events (AEs), estimated cumulative organ radiation exposure, and efficacy signals over the course of all treatment cycles for all dose cohorts. Part 2: Phase IIa Dose-Expansion: This part will enroll subjects who will receive RP2D identified in Part 1 for further assessment of safety and preliminary efficacy.\n\n…\n\n2. Active secondary malignancy. 3. Pregnancy or breastfeeding a child. 4. Febrile illness within 48 hours of any scheduled [212Pb]VMT-α-NET administration should be rescheduled > 48 hours after resolution of fever]. 5. Treatment with another investigational medicinal product within 30 days of anticipated treatment.",
        "title": "CLINICAL TRIAL / NCT05636618 - UChicago Medicine",
        "url": "https://www.uchicagomedicine.org/find-a-clinical-trial/clinical-trial/irb230670"
      }
    ]
  },
  {
    "id": "14613a6b-186a-44de-b08e-cd3b95177499",
    "results": [
      {
        "date": "2018-05-08",
        "last_updated": "2026-02-12",
        "snippet": "### ClinicalTrials.gov is a place to learn about clinical studies from around the world.\n\nClinicalTrials.gov is a website and online database of clinical research studies and information about their results. The National Library of Medicine (NLM) maintains the website.\n\n**The study sponsor or investigator submits information** about their study to ClinicalTrials.gov and **is responsible for the safety, science, and accuracy** of any study they list.\n\nBefore joining a study, talk to your health care professional about possible risks and benefits. To learn more about taking part in studies, read",
        "title": "Home | ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov"
      },
      {
        "date": "2021-01-01",
        "last_updated": "2026-01-08",
        "snippet": "**Description:**\n\nThe goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S. Additionally Ratio Therapeutics will learn if [Ac225]RTX-2358 drug is effective in treating advanced sarcoma.\nRatio Therapeutics, Inc\n\n**Sponsor:**\n\nTBD\n\n**Contacts:**\n\ntbd@tbd.com\n\nNCT07156565 - Click here to see study on\n\n**Government Study Link:**\n\nClinicalTrials.gov\n\n**Patient Education**\n\nPatient Education Not Yet Provided\n\n**Publications**\n\nPublications Not Yet Provided\n**Locations**\n\n**United States 🇺🇸**\n\nUnited States\n\n© 2021 XCancer Software LLC\n\nContact XCancer: 402-991-8468",
        "title": "NCT07156565",
        "url": "https://www.theranostictrials.org/studies/cl74bp9il0235ajjfhzmr6gph/study/NCT07156565"
      },
      {
        "last_updated": "2025-05-19",
        "snippet": "",
        "title": "Carbone Cancer Center Clinical Trials",
        "url": "https://mct.platformx.wisc.edu/mct.php?protocol_id=33435&protocol_no=UW22119&back_node_id=2327"
      },
      {
        "date": "2018-05-08",
        "last_updated": "2025-08-26",
        "snippet": "Study record managers: refer to the Data Element Definitions if submitting registration or results information.\n\nThe age groups are:\n\nFor more information, see FDA Expanded Access: Information for Patients.\n\nThe National Library of Medicine (NLM) is required by FDAAA 801 to add information to a study record about any FDAAA 801 Violation. This information is provided by the FDA. There are three categories of information that may be included:\nFor more information, see Who can join clinical research? on this site.\n\nFor more information, see Who can join clinical research? on this site.\n\nA patient registry is a type of observational study.\n\n**Note:** The ClinicalTrials.gov results database became available in September 2008. Older studies are unlikely to have results available in the database.\nThe results submitted date indicates when the study sponsor or investigator first submitted summary results information or submitted changes to summary results information. Submissions with changes are typically in response to QC review comments from the National Library of Medicine (NLM). If there is a date listed for results submitted to ClinicalTrials.gov, but there is not a subsequent date listed for results returned after quality control review, this means that the submission is pending review by NLM.",
        "title": "ClinicalTrials.gov",
        "url": "https://www.clinicaltrials.gov/study/NCT05425940"
      },
      {
        "date": "2022-08-31",
        "last_updated": "2025-04-30",
        "snippet": "This study will be conducted in 3 parts: Part 1: Monotherapy Dose-Escalation: [212Pb]VMT01 is administered alone in escalating doses to determine the Maximum Tolerated radioactivity Dose (MTD), Maximum Feasible radioactivity Dose (MFD), and potential recommended Phase 2 doses (RP2Ds) Part 2: Combination-Therapy Dose-Escalation: [212Pb]VMT01 and Nivolumab are administered in escalating doses to determine MTD, MFD, and RP2Ds.\n\n…\n\nExperimental: Monotherapy-Dose Escalation\n\nEnrolled subjects will be treated with increasing doses of [212Pb]VMT01 (up to 15 mCi) to determine MTD, MFD, and RP2D. Up to 32 subjects will be enrolled. A dosimetry sub-study utilizing [203Pb]VMT01 has been incorporated into Monotherapy Dose-Escalation arm.\nExperimental: Combination Therapy-Dose Escalation\n\nEnrolled subjects will be treated with increasing radioactive doses of [212Pb]VMT01 (up to 15 mCi) in combination with nivolumab to determine MTD, MFD, and RP2D. A dosimetry sub-study utilizing [203Pb]VMT01 has been incorporated into Combination Therapy-Dose Escalation.\nExperimental: Monotherapy - Dose Expansion\n\nUp to 2 monotherapy expansion cohorts of up to 25 subjects will be enrolled at previously identified RP2D to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort. A dosimetry sub-study utilizing [203Pb]VMT01 has been incorporated into Monotherapy-Dose Expansion.\nExperimental: Combination Therapy - Dose Expansion\n\nUp to 2 Combination Therapy expansion cohorts of up to 25 subjects will be enrolled at RP2Ds previously identified to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort. A dosimetry sub-study utilizing [203Pb]VMT01 has been incorporated into Combination Therapy-Dose Expansion. Once the RP2D and regimen for the Phase 2 dose-expansion cohort is confirmed, up to 100 subjects will be enrolled to confirm the efficacy and safety of the RP2D and regimen.",
        "title": "National Brain Tumor Society | Community here. Breakthroughs ahead. - National Brain Tumor Society",
        "url": "https://trials.braintumor.org/trials/NCT05655312"
      },
      {
        "last_updated": "2025-06-03",
        "snippet": "AbbVie Clinical Trials is designed to support, inform, and help patients in a clinical study or those who are interested in participating.\n\nPlease note that the information on this website is intended for informational purposes only and should not be used as a substitute for seeking medical advice or treatment from a healthcare professional. You should not use this information to diagnose or treat a medical condition or health problem. Speak to a healthcare professional if you have any questions about your health, medical condition, symptoms, or treatment options.\n\nCopyright © 2024 AbbVie Inc.",
        "title": "Study Details Page",
        "url": "https://www.abbvieclinicaltrials.com/study/?id=M02-575"
      },
      {
        "date": "2025-05-19",
        "last_updated": "2025-06-26",
        "snippet": "## Overview\n\nVMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy.\n\n## Development\n\n- US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT05655312?term=vmt01\n\n- Fast Track Designation received September 2024\n\n- Preclinical data shows synergistic effect with Immune Checkpoint Inhibitors\n\n- VMT01/ICI combination cohort open for recruitment\n\n- Phase 1 imaging study at Mayo Clinic Rochester indicates feasibility of patient\n\nselection using [\n\n203Pb]VMT01 and [ 68Ga]VMT02",
        "title": "VMT01/02",
        "url": "https://www.perspectivetherapeutics.com/pipeline/vmt01-02"
      },
      {
        "date": "2025-01-01",
        "last_updated": "2025-05-23",
        "snippet": "Sponsor:\n\nNational Cancer Institute (NCI)\n\nCode:\n\nNCT02682667\n\nConditions\n\nMultiple Myeloma\n\nLymphoma, Non-Hodgkin\n\nLeukemia-Lymphoma, Adult T-Cell\n\nHodgkin Disease\n\nNon-Small Cell Lung Cancer\n\nEligibility Criteria\n\nSex: All\nAge: 18 - 70+\n\nHealthy Volunteers: Not accepted\n\nStudy Details\n\nEligibility Criteria\n\nStudy Design\n\nInterventions and Outcome Measures\n\nCentral Contacts and Locations\n\nMore Information\n\nTrial information was received from ClinicalTrials.gov and was last updated on 2025-05-23. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-20.",
        "title": "Immunotherapy ProtocolsBiospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols",
        "url": "https://www.allclinicaltrials.com/study/NCT02682667"
      },
      {
        "date": "2016-01-01",
        "last_updated": "2024-10-16",
        "snippet": "# Alpha PRRT with Pb-212 VMT\n\n### Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT)\n\n**IDENTIFIER (** **ClinicalTrials.gov** **)**: NCT05636618\n\n**DRUG/TREATMENT**: Alpha PRRT with 212Pb VMT\n\n**PHASE**: 1 / 2A\n**STATUS**: Recruiting\n\n**SPONSOR**: Perspective Therapeutics\n\n**DESCRIPTION:**\n\n*June 2024: Dr. Aman Chauhan discusses the * *Alpha PRRT with Pb-212 VMT study.*\n\nPerspective Therapeutics is sponsoring a phase 1 / 2A prospective, multi-center open-label dose escalation, dose expansion study of [212Pb]VMT01 in up to 52 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT).\nDuring phase 1, there is a dose escalation period testing up to 4 escalating radioactivity dose cohorts of up to 8 subjects (administered at approximately 8-week intervals) at the assigned cohort radioactivity dose. Phase 1 studies the side effects, safety, and dosimetry.\n\n*For more information on eligibility criteria, trial locations, study details, etc., go to * __ClinicalTrials.gov__ *to* __view this trial here.__\n**CONTACT**:\n\nMarkus Puhlmann, MD, MBA at Perspective Therapeutics\n\n**EMAIL: ** __mpuhlmann@perspectivetherapeutics.com__\n\n**PHONE: **(319) 665-2150",
        "title": "Alpha PRRT with Pb-212 VMT",
        "url": "https://www.lacnets.org/clinical-trials-1/alpha-prrt-with-pb-212-vmt"
      },
      {
        "last_updated": "2025-08-13",
        "snippet": "## Description\n\n## PhaseN/A\n\n## Inclusion and Exclusion Criteria\n\nPlease contact the trial administrator to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.\n\n## Sites\n\nPlease contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.",
        "title": "890?locale=en",
        "url": "https://clinicaltrials.sc-ctsi.org/clinicaltrials/890?locale=en"
      }
    ]
  }
]
```

</details>

#### Triage Prompt (Search 1) <small>(04:07:18)</small>

```text
# Source Triage – Rank Sources by Yield Potential

Query: # Table Entry Validation and Research

You are validating and updating several field values for a single row in a research table.

═══════════════════════════════════════════════════════════════
## 🎯 FOCUSED TASK
═══════════════════════════════════════════════════════════════

**Use this section to guide your initial web searches.** Detailed field requirements for synthesis appear below.

**Context:**
Product (or Candidate): VMT02
Owner: Ratio Therapeutics

**3 Research Questions:**
Core Product & Owner Info: Basic product information including owner, target/indication, and development stage. This foundational data is often found together in company pipelines and press releases.

**1. Owner**: Company or entity that owns or is developing the product.???
   Current value: Ratio Therapeutics
**2. Target / Indication**: Biological target and the disease indication the product is intended for.???
**3. Development Stage**: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).???

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 WHAT YOU'LL FIND BELOW
═══════════════════════════════════════════════════════════════

The sections below provide detailed context for **synthesizing your search results** into validated answers:

- **GENERAL NOTES**: Validation context for the broader research effort this subtask falls within
- **CONTEXT & PREVIOUS DATA**: Other fields from this row and prior validations for reference
- **FIELD DETAILS**: Detailed requirements, format, notes, and examples for each field
- **CONFIDENCE LEVELS**: How to assign confidence ratings to your findings
- **RESPONSE FORMAT**: Required JSON structure and critical validation rules

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 GENERAL NOTES
═══════════════════════════════════════════════════════════════

This configuration validates a biopharmaceutical product/candidate tracking table. The primary identifier is the product name. All research columns should be verified against current public information as of February 13, 2026, using company websites, clinical trial registries (e.g., ClinicalTrials.gov), and reputable news sources. For columns left blank, it may indicate the information is not applicable or not yet public.

---

═══════════════════════════════════════════════════════════════
## 📊 CONTEXT & PREVIOUS DATA
═══════════════════════════════════════════════════════════════

**Context for this row:**

Product (or Candidate): VMT02
Owner: Ratio Therapeutics

⚠️ **CRITICAL - ROW CONTEXT SCOPE CONSTRAINT:**
All validation results must be about the SPECIFIC ENTITY identified by the context above.

**Common scope errors to AVOID:**
- Validating a different entity with a similar name
- Using general information when specific information is required
- Example: When validating news for "Product X by Company Y", reject news that only mentions "Company Y" without mentioning "Product X"
- Example: When validating a company associated with a product, verify the company OWNS/DEVELOPS that specific product, not just that the company exists

**Scope validation checklist:**
1. Do sources explicitly mention ALL identifying information from context above?
2. Is information contemporary with the entity (not before it existed)?
3. Have you cross-referenced to confirm entity identity?
4. When in doubt, mark confidence as MEDIUM or LOW

**Other fields from this row (unvalidated - for reference only):**

**Previous validations for this row:**

Product (or Candidate): VMT02 (Confidence: ID)

⚠️ **CRITICAL - INHERENT SUSPICION OF PREVIOUS RESULTS:**

Previous values shown above may be INCORRECT. Do NOT assume they are correct.

**Mandatory verification requirements:**
- Treat previous values as HYPOTHESES to be tested, not FACTS
- Every previous claim must be verified against current authoritative sources
- Do NOT copy previous values without independent verification
- Well-formatted previous answers with citations can still be wrong
- High confidence scores from past validations don't guarantee truth

**If current sources conflict with previous values:**
1. Prioritize DIRECT QUOTES from HIGH-AUTHORITY sources (see confidence criteria)
2. Check publication dates - newer authoritative sources may supersede old data
3. If conflict unresolved, mark confidence as MEDIUM or LOW
4. Document the conflict in your explanation

**Truth Standard:** Direct quotes from authoritative sources determine truth,
NOT how confident, well-cited, or professionally formatted previous results appear.

Your task: Use previous results as a STARTING POINT, then independently verify/correct with current sources.

---

═══════════════════════════════════════════════════════════════
## 📝 FIELD DETAILS - Format Requirements and Examples
═══════════════════════════════════════════════════════════════

**For each field you will receive:**

- **Field Name**: (This is the name of the field)
- **Description**: (What this field represents)
- **Format**: (How to format your answer)
- **Notes**: (Quality standards for this specific field)
- **Examples**: (Sample formatting)

**VALUES TO CONSIDER:**
- **Current Value** (to be validated/updated): The value that needs validation/updating in this run
- **Previous Value** (from Original Values sheet): The historical validated value from a prior validation run (if available)

**YOUR TASK**: Validate and update the **Current Value** using web search and the guidance provided. Compare it to the **Previous Value** (if available) to understand what has changed.

----- FIELD 1: Owner -----
**Current Value**: Ratio Therapeutics
Description: Company or entity that owns or is developing the product.
Format: String
Importance: RESEARCH

Notes: Verify the current owner/developer. Check company websites and recent press releases.

Examples:
  - Actithera
  - Advanced Accelerator Applications
  - Bayer

----- FIELD 2: Target / Indication -----
**Current Value**: 
Description: Biological target and the disease indication the product is intended for.
Format: String
Importance: RESEARCH

Notes: Verify the molecular target (e.g., FAP, PSMA) and the specific disease or condition.

Examples:
  - FAP / oncology (lead program)
  - FAP / pan-cancer imaging
  - FAP / pan-cancer therapy

----- FIELD 3: Development Stage -----
**Current Value**: 
Description: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).
Format: String
Importance: RESEARCH

Notes: Confirm the most recent development stage from official sources like clinical trial registries or company pipelines. Use standard terms (Preclinical, Phase I, Phase II, Phase III, Approved).

Examples:
  - Phase I
  - Phase II
  - Preclinical

---

═══════════════════════════════════════════════════════════════
## ⭐ CONFIDENCE LEVELS
═══════════════════════════════════════════════════════════════

Confidence measures the likelihood that the facts stated in the cell are precisely accurate:

- **HIGH (H)**: 85%+ likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood ≥ 85%
  - Source: Authoritative, directly verifiable, widely accepted

- **MEDIUM (M)**: 65%-85% likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood 65%-85%
  - Source: Respectable but not definitive, good estimates, confident projections

- **LOW (L)**: <65% likelihood that the facts are precisely accurate
  - Weak/conflicting sources, uncertainty, no authoritative verification
  - **Only LOW confidence answers may be blank (null)**
  - **Blank originals**: Assign LOW for `original_confidence` when the original value was blank/empty
  - **Removing false data**: If original has LOW confidence false data and no reliable replacement exists, you CAN go to blank with LOW confidence (removing bad data is acceptable)

**SPECIAL CASE - Expressing Doubt:**
When the value itself expresses uncertainty (e.g., "Rumors suggest...", "Unconfirmed reports say...", "Less reliable sources claim..."), confidence measures whether the SOURCES say it, NOT whether it's true.

Example:
- Value: "Rumors suggest launch in Q3 2025"
- HIGH confidence: Multiple sources confirm rumors exist
- The confidence is about the rumors existing, not about the launch happening

**Confident Absence:**
If you are confident something does not exist or is not applicable, say so explicitly with language appropriate to the measure (e.g., "N/A", "Not applicable", "No website", "Not publicly traded") and assign an appropriate confidence level (H/M). Do not leave it blank - blank means you have no information.

---

═══════════════════════════════════════════════════════════════
## 📤 RESPONSE FORMAT
═══════════════════════════════════════════════════════════════

Return a JSON array where each item is a cell array with 6 elements:

```
[column, answer, confidence, original_confidence, consistent, explanation]
```

- **column**: Exact field name from FIELD DETAILS
- **answer**: The validated value (string or null for blank)
- **confidence**: H (HIGH), M (MEDIUM), or L (LOW)
- **original_confidence**: H, M, or L (for the original value)
- **consistent**: T (consistent with model knowledge), F (not consistent), or null
- **explanation**: Succinct reason you believe the answer is correct

**Example:**
```json
[
  ["Revenue", "$158.9B", "H", "M", "T", "Q3 2024 earnings report confirmed"],
  ["CEO", "Andy Jassy", "H", "H", "T", "Official Amazon leadership page"],
  ["Founded", null, "L", "L", null, "No reliable data found"]
]
```

### CRITICAL REQUIREMENTS

- **Do not use quotation marks around your responses** (except in JSON structure itself)
- **Assess both confidences**: Rate the quality of your updated answer (confidence) AND the quality of the original value (original_confidence) using H/M/L
- **CRITICAL - Blank original values**: If the original value was blank/empty, set `original_confidence` to `L` (LOW). Blank originals get LOW original_confidence.
- **Only update if significantly better**: Only provide a different validated value if you can improve significantly on the original value
- **Generally don't degrade confidence**:
  - If original has H/M confidence, don't degrade to L or blank without strong justification
  - If original has L confidence false data and no reliable replacement: You CAN leave blank (removing bad data is acceptable)
  - Hierarchy: H > M > L
  - **Confident absence**: Use language appropriate to the measure (e.g., "N/A", "Not applicable", "No website") with confidence — blank means you have no information, not that the value doesn't exist
- **Use exact column names**: Include the exact column name in each cell array - exactly as defined in the FIELD DETAILS above
- **Provide explanation**: Always include the explanation with succinct reasoning for your answer
- **Handle blanks appropriately**: If you cannot find or determine information for a field, use null for answer and L for confidence. Only LOW confidence answers may be truly blank.
- **Use examples as guides**: Use provided examples to guide your update format and expected values
- **Format for Excel**: Use newline characters correctly so that they are formatted in an Excel cell, particularly for bullets, lists, and other formatted text
- **Stay focused**: Do not research the context and guidance - focus only on the fields listed above
- **Double check everything**: Double check your updated response and confidence - speak precisely, there is no room for error
- **Valid JSON required**: The response MUST be valid JSON array format

---

Search Term: "VMT02 clinical trial phase"

Rank RELEVANT sources from best to worst. Exclude off-topic sources entirely.

**Keywords for Relevance Assessment:**
  Positive: pipeline, clinical trials, drug development, development, vmt02, target, therapeutics, ratio, indication, stage

Existing Snippets: 7 collected
[S1.1.1-M] [68Ga]VMT02 - Drug Targets, Indications, Patents - Patsnap Synapse (2 quotes)
[S1.1.2-M] Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data (1 quotes)
[S1.1.3-M] Ratio Therapeutics Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate (1 quotes)
[S1.1.4-M] Ratio Therapeutics Enters License and Collaboration ... (1 quotes)
[S1.1.5-M] VMT01/02 Program - Perspective Therapeutics | (2 quotes)

---

## Sources (10 results)

[0] MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial (2022-11-15) | Score: 14 (+4)
    ## Study Overview

This is a prospective, multi-center open-label dose-escalation, dose-expansion study of [212Pb]VMT01 ...
    [+vmt02, +ratio] "This study will also estimate radiation dosimetry and correlate uptake of the investigation products..."

[1] Carbone Cancer Center Clinical Trials (2025-05-19) | Score: 10 (+1)
    (No preview)

[2] MC1R-targeted Alpha-particle Monotherapy And ... - Mayo Clinic (2025-12-12) | Score: 10 (+2)
    During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits...
    [+vmt02, +target] "Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved a..."

[3] VMT01/02 Program - Perspective Therapeutics | (2025-05-19) | Score: 12 (+5)
    ## Overview

VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 re...
    [+development, +vmt02, +target +1 more] "It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb..."

[4] MC1R-targeted Alpha-particle Monotherapy and ... (2022-11-15) | Score: 9 (+3)
    ## MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanom...
    [+vmt02, +ratio] "This study will also estimate radiation dosimetry and correlate uptake of the investigation products..."

[5] Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (2024-11-21) | Score: 8 (+3)
    Featured conditions

Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia...
    [+vmt02, +stage] "This study will use [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) imaging and ..."

[6] [68Ga]VMT02 - Drug Targets, Indications, Patents - Patsnap Synapse (2025-11-03) | Score: 10 (+6)
    login

or

view full example data

Related

1

Clinical Trials associated with [68Ga]VMT02

NCT04904120



Completed

Ph...
    [+vmt02, +therapeutics, +indication] "This will be illustrated by the redistribution of 109Cd from exogenous CdMT to endogenous CdMT after..."

[7] VMT01/02 (2025-05-19) | Score: 7 (+4)
    ## Overview

VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 re...
    [+development, +vmt02, +therapeutics] "It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb..."

[8] Perspective Therapeutics Presents Updated Interim Data of (2026-01-09) | Score: 4 (+2)
    23 patients in Cohort 2 and both patients in Cohort 1* *Objective response in 39% of patients in Cohort 2 regardless of ...

[9] CLINICAL TRIAL / NCT05636618 - UChicago Medicine (2024-06-04) | Score: 3 (+2)
    ## Contact Information
### A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Ad...

---

## Ranking Criteria

1) **Relevance Score** - Higher score = better search rank + more keyword matches
   - Negative keyword match is a strong signal of irrelevant/low-quality content
2) **Authority** - Prioritize official docs, academic sources, established institutions
3) **Novelty** - Prefer sources adding NEW information not in existing snippets
4) **Recency** - For volatile/time-sensitive info ("latest", "current", recent events), prefer recent sources

---

## Output

Return ranked indices of RELEVANT sources only: [best, second_best, ...]

Example: [5, 0, 8, 2] means source 5 is best, others excluded as off-topic.

```

#### Triage Prompt (Search 2) <small>(04:07:18)</small>

```text
# Source Triage – Rank Sources by Yield Potential

Query: # Table Entry Validation and Research

You are validating and updating several field values for a single row in a research table.

═══════════════════════════════════════════════════════════════
## 🎯 FOCUSED TASK
═══════════════════════════════════════════════════════════════

**Use this section to guide your initial web searches.** Detailed field requirements for synthesis appear below.

**Context:**
Product (or Candidate): VMT02
Owner: Ratio Therapeutics

**3 Research Questions:**
Core Product & Owner Info: Basic product information including owner, target/indication, and development stage. This foundational data is often found together in company pipelines and press releases.

**1. Owner**: Company or entity that owns or is developing the product.???
   Current value: Ratio Therapeutics
**2. Target / Indication**: Biological target and the disease indication the product is intended for.???
**3. Development Stage**: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).???

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 WHAT YOU'LL FIND BELOW
═══════════════════════════════════════════════════════════════

The sections below provide detailed context for **synthesizing your search results** into validated answers:

- **GENERAL NOTES**: Validation context for the broader research effort this subtask falls within
- **CONTEXT & PREVIOUS DATA**: Other fields from this row and prior validations for reference
- **FIELD DETAILS**: Detailed requirements, format, notes, and examples for each field
- **CONFIDENCE LEVELS**: How to assign confidence ratings to your findings
- **RESPONSE FORMAT**: Required JSON structure and critical validation rules

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 GENERAL NOTES
═══════════════════════════════════════════════════════════════

This configuration validates a biopharmaceutical product/candidate tracking table. The primary identifier is the product name. All research columns should be verified against current public information as of February 13, 2026, using company websites, clinical trial registries (e.g., ClinicalTrials.gov), and reputable news sources. For columns left blank, it may indicate the information is not applicable or not yet public.

---

═══════════════════════════════════════════════════════════════
## 📊 CONTEXT & PREVIOUS DATA
═══════════════════════════════════════════════════════════════

**Context for this row:**

Product (or Candidate): VMT02
Owner: Ratio Therapeutics

⚠️ **CRITICAL - ROW CONTEXT SCOPE CONSTRAINT:**
All validation results must be about the SPECIFIC ENTITY identified by the context above.

**Common scope errors to AVOID:**
- Validating a different entity with a similar name
- Using general information when specific information is required
- Example: When validating news for "Product X by Company Y", reject news that only mentions "Company Y" without mentioning "Product X"
- Example: When validating a company associated with a product, verify the company OWNS/DEVELOPS that specific product, not just that the company exists

**Scope validation checklist:**
1. Do sources explicitly mention ALL identifying information from context above?
2. Is information contemporary with the entity (not before it existed)?
3. Have you cross-referenced to confirm entity identity?
4. When in doubt, mark confidence as MEDIUM or LOW

**Other fields from this row (unvalidated - for reference only):**

**Previous validations for this row:**

Product (or Candidate): VMT02 (Confidence: ID)

⚠️ **CRITICAL - INHERENT SUSPICION OF PREVIOUS RESULTS:**

Previous values shown above may be INCORRECT. Do NOT assume they are correct.

**Mandatory verification requirements:**
- Treat previous values as HYPOTHESES to be tested, not FACTS
- Every previous claim must be verified against current authoritative sources
- Do NOT copy previous values without independent verification
- Well-formatted previous answers with citations can still be wrong
- High confidence scores from past validations don't guarantee truth

**If current sources conflict with previous values:**
1. Prioritize DIRECT QUOTES from HIGH-AUTHORITY sources (see confidence criteria)
2. Check publication dates - newer authoritative sources may supersede old data
3. If conflict unresolved, mark confidence as MEDIUM or LOW
4. Document the conflict in your explanation

**Truth Standard:** Direct quotes from authoritative sources determine truth,
NOT how confident, well-cited, or professionally formatted previous results appear.

Your task: Use previous results as a STARTING POINT, then independently verify/correct with current sources.

---

═══════════════════════════════════════════════════════════════
## 📝 FIELD DETAILS - Format Requirements and Examples
═══════════════════════════════════════════════════════════════

**For each field you will receive:**

- **Field Name**: (This is the name of the field)
- **Description**: (What this field represents)
- **Format**: (How to format your answer)
- **Notes**: (Quality standards for this specific field)
- **Examples**: (Sample formatting)

**VALUES TO CONSIDER:**
- **Current Value** (to be validated/updated): The value that needs validation/updating in this run
- **Previous Value** (from Original Values sheet): The historical validated value from a prior validation run (if available)

**YOUR TASK**: Validate and update the **Current Value** using web search and the guidance provided. Compare it to the **Previous Value** (if available) to understand what has changed.

----- FIELD 1: Owner -----
**Current Value**: Ratio Therapeutics
Description: Company or entity that owns or is developing the product.
Format: String
Importance: RESEARCH

Notes: Verify the current owner/developer. Check company websites and recent press releases.

Examples:
  - Actithera
  - Advanced Accelerator Applications
  - Bayer

----- FIELD 2: Target / Indication -----
**Current Value**: 
Description: Biological target and the disease indication the product is intended for.
Format: String
Importance: RESEARCH

Notes: Verify the molecular target (e.g., FAP, PSMA) and the specific disease or condition.

Examples:
  - FAP / oncology (lead program)
  - FAP / pan-cancer imaging
  - FAP / pan-cancer therapy

----- FIELD 3: Development Stage -----
**Current Value**: 
Description: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).
Format: String
Importance: RESEARCH

Notes: Confirm the most recent development stage from official sources like clinical trial registries or company pipelines. Use standard terms (Preclinical, Phase I, Phase II, Phase III, Approved).

Examples:
  - Phase I
  - Phase II
  - Preclinical

---

═══════════════════════════════════════════════════════════════
## ⭐ CONFIDENCE LEVELS
═══════════════════════════════════════════════════════════════

Confidence measures the likelihood that the facts stated in the cell are precisely accurate:

- **HIGH (H)**: 85%+ likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood ≥ 85%
  - Source: Authoritative, directly verifiable, widely accepted

- **MEDIUM (M)**: 65%-85% likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood 65%-85%
  - Source: Respectable but not definitive, good estimates, confident projections

- **LOW (L)**: <65% likelihood that the facts are precisely accurate
  - Weak/conflicting sources, uncertainty, no authoritative verification
  - **Only LOW confidence answers may be blank (null)**
  - **Blank originals**: Assign LOW for `original_confidence` when the original value was blank/empty
  - **Removing false data**: If original has LOW confidence false data and no reliable replacement exists, you CAN go to blank with LOW confidence (removing bad data is acceptable)

**SPECIAL CASE - Expressing Doubt:**
When the value itself expresses uncertainty (e.g., "Rumors suggest...", "Unconfirmed reports say...", "Less reliable sources claim..."), confidence measures whether the SOURCES say it, NOT whether it's true.

Example:
- Value: "Rumors suggest launch in Q3 2025"
- HIGH confidence: Multiple sources confirm rumors exist
- The confidence is about the rumors existing, not about the launch happening

**Confident Absence:**
If you are confident something does not exist or is not applicable, say so explicitly with language appropriate to the measure (e.g., "N/A", "Not applicable", "No website", "Not publicly traded") and assign an appropriate confidence level (H/M). Do not leave it blank - blank means you have no information.

---

═══════════════════════════════════════════════════════════════
## 📤 RESPONSE FORMAT
═══════════════════════════════════════════════════════════════

Return a JSON array where each item is a cell array with 6 elements:

```
[column, answer, confidence, original_confidence, consistent, explanation]
```

- **column**: Exact field name from FIELD DETAILS
- **answer**: The validated value (string or null for blank)
- **confidence**: H (HIGH), M (MEDIUM), or L (LOW)
- **original_confidence**: H, M, or L (for the original value)
- **consistent**: T (consistent with model knowledge), F (not consistent), or null
- **explanation**: Succinct reason you believe the answer is correct

**Example:**
```json
[
  ["Revenue", "$158.9B", "H", "M", "T", "Q3 2024 earnings report confirmed"],
  ["CEO", "Andy Jassy", "H", "H", "T", "Official Amazon leadership page"],
  ["Founded", null, "L", "L", null, "No reliable data found"]
]
```

### CRITICAL REQUIREMENTS

- **Do not use quotation marks around your responses** (except in JSON structure itself)
- **Assess both confidences**: Rate the quality of your updated answer (confidence) AND the quality of the original value (original_confidence) using H/M/L
- **CRITICAL - Blank original values**: If the original value was blank/empty, set `original_confidence` to `L` (LOW). Blank originals get LOW original_confidence.
- **Only update if significantly better**: Only provide a different validated value if you can improve significantly on the original value
- **Generally don't degrade confidence**:
  - If original has H/M confidence, don't degrade to L or blank without strong justification
  - If original has L confidence false data and no reliable replacement: You CAN leave blank (removing bad data is acceptable)
  - Hierarchy: H > M > L
  - **Confident absence**: Use language appropriate to the measure (e.g., "N/A", "Not applicable", "No website") with confidence — blank means you have no information, not that the value doesn't exist
- **Use exact column names**: Include the exact column name in each cell array - exactly as defined in the FIELD DETAILS above
- **Provide explanation**: Always include the explanation with succinct reasoning for your answer
- **Handle blanks appropriately**: If you cannot find or determine information for a field, use null for answer and L for confidence. Only LOW confidence answers may be truly blank.
- **Use examples as guides**: Use provided examples to guide your update format and expected values
- **Format for Excel**: Use newline characters correctly so that they are formatted in an Excel cell, particularly for bullets, lists, and other formatted text
- **Stay focused**: Do not research the context and guidance - focus only on the fields listed above
- **Double check everything**: Double check your updated response and confidence - speak precisely, there is no room for error
- **Valid JSON required**: The response MUST be valid JSON array format

---

Search Term: "Ratio Therapeutics VMT02 clinicaltrials.gov"

Rank RELEVANT sources from best to worst. Exclude off-topic sources entirely.

**Keywords for Relevance Assessment:**
  Positive: pipeline, clinical trials, drug development, development, vmt02, target, therapeutics, ratio, indication, stage

Existing Snippets: 7 collected
[S1.1.1-M] [68Ga]VMT02 - Drug Targets, Indications, Patents - Patsnap Synapse (2 quotes)
[S1.1.2-M] Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data (1 quotes)
[S1.1.3-M] Ratio Therapeutics Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate (1 quotes)
[S1.1.4-M] Ratio Therapeutics Enters License and Collaboration ... (1 quotes)
[S1.1.5-M] VMT01/02 Program - Perspective Therapeutics | (2 quotes)

---

## Sources (10 results)

[0] Home | ClinicalTrials.gov (2018-05-08)
    ### ClinicalTrials.gov is a place to learn about clinical studies from around the world.

ClinicalTrials.gov is a websit...

[1] NCT07156565 (2021-01-01) | Score: 11 (+2)
    **Description:**

The goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnosti...
    [+therapeutics, +ratio] "Additionally Ratio Therapeutics will learn if [Ac225]RTX-2358 drug is effective in treating advanced..."

[2] Carbone Cancer Center Clinical Trials (2025-05-19) | Score: 9 (+1)
    (No preview)

[3] ClinicalTrials.gov (2018-05-08) | Score: 8 (+1)
    Study record managers: refer to the Data Element Definitions if submitting registration or results information.

The age...

[4] National Brain Tumor Society | Community here. Breakthroughs ahead. -  (2022-08-31)
    This study will be conducted in 3 parts: Part 1: Monotherapy Dose-Escalation: [212Pb]VMT01 is administered alone in esca...

[5] Study Details Page (2025-06-03) | Score: 6 (+1)
    AbbVie Clinical Trials is designed to support, inform, and help patients in a clinical study or those who are interested...

[6] VMT01/02 (2025-05-19) | Score: 8 (+4)
    ## Overview

VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 re...
    [+development, +vmt02, +therapeutics] "It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb..."

[7] Immunotherapy ProtocolsBiospecimen Procurement for Center for Immuno-O (2025-01-01)
    Sponsor:

National Cancer Institute (NCI)

Code:

NCT02682667

Conditions

Multiple Myeloma

Lymphoma, Non-Hodgkin

Leuk...

[8] Alpha PRRT with Pb-212 VMT (2016-01-01) | Score: 4 (+2)
    # Alpha PRRT with Pb-212 VMT

### Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212...

[9] 890?locale=en (2025-08-13)
    ## Description

## PhaseN/A

## Inclusion and Exclusion Criteria

Please contact the trial administrator to learn more a...

---

## Ranking Criteria

1) **Relevance Score** - Higher score = better search rank + more keyword matches
   - Negative keyword match is a strong signal of irrelevant/low-quality content
2) **Authority** - Prioritize official docs, academic sources, established institutions
3) **Novelty** - Prefer sources adding NEW information not in existing snippets
4) **Recency** - For volatile/time-sensitive info ("latest", "current", recent events), prefer recent sources

---

## Output

Return ranked indices of RELEVANT sources only: [best, second_best, ...]

Example: [5, 0, 8, 2] means source 5 is best, others excluded as off-topic.

```

#### Triage Result (Search 1) <small>(04:07:19)</small>

<details><summary>Click to expand</summary>

```json
{
  "ranked_indices": [
    0,
    3,
    4,
    5,
    6,
    7,
    9
  ]
}
```

</details>

#### Triage Result (Search 2) <small>(04:07:19)</small>

<details><summary>Click to expand</summary>

```json
{
  "ranked_indices": [
    4,
    6,
    8,
    1
  ]
}
```

</details>

#### Batch Extraction Prompt (5 sources) <small>(04:07:19)</small>

<details><summary>Click to expand</summary>

```text
# Batch Quote Extraction (Code-Based)

Extract quotable snippets with codes for synthesis. **Synthesis will NOT see original sources** - only these snippets.

**Today:** 2026-02-13 | **Mode:** Extract ONLY concrete atomic facts (numbers, dates, entities). Be MINIMAL with just enough context to verify. | **Max:** 2/source/search

**Search terms:**
1. VMT02 Ratio Therapeutics target indication development stage
2. Ratio Therapeutics VMT02 clinicaltrials.gov
3. VMT02 clinical trial phase

**RULES:**
- **Merge contiguous:** Adjacent sentences = ONE snippet (use ranges), even if addressing different aspects
- **No duplication:** Once a passage is extracted, trust it's available to synthesis - do NOT extract again for other terms
- **Self-contained:** Each snippet MUST make a complete point in isolation - no sentence fragments
- **Skip redundant:** If a point was already made by a snippet of same/higher quality, do NOT extract again

**SHALLOW MODE LIMITS:**
- **2 snippets MAX per source per search term**
- **Brevity:** Just enough context to verify - prefer minimal over comprehensive

---

## Labeled Sources

Sentences labeled `` §SX:Y.Z ``, headings labeled `` §SX:Y.0 `` (X=source, Y=section, Z=sentence). Copy exact labels.


### S1: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
URL: https://www.clinicaltrials.gov/study/NCT05655312
Date: 2022-11-15

Labeled text:

<snippet-heading>## Study Overview</snippet-heading> §S1:1.0

This is a prospective, multi-center open-label dose-escalation, dose-expansion study of [212Pb]VMT01 as a monotherapy or in combination with Nivolumab in up to 264 subjects with histologically confirmed melanoma and a positive MC1R imaging scan with imaging agents [203Pb]VMT01 or [68Ga]VMT02. §S1:1.1

… §S1:1.2

<snippet-heading>This study will be conducted in 3 parts:</snippet-heading> §S1:2.0

Part 1: Monotherapy Dose-Escalation: [212Pb]VMT01 is administered alone in escalating doses to determine the Maximum Tolerated radioactivity Dose (MTD), Maximum Feasible radioactivity Dose (MFD), and potential recommended Phase 2 doses (RP2Ds) §S1:2.1
Part 2: Combination-Therapy Dose-Escalation: [212Pb]VMT01 and Nivolumab are administered in escalating doses to determine MTD, MFD, and RP2Ds. §S1:2.2

Part 3: Dose Expansion: This part will enroll subjects in monotherapy and combination-therapy expansion cohorts based on the identified MTD, MFD, and RP2D for the selection of [212Pb]VMT01 alone and [212Pb]VMT01-Nivolumab combination doses for further clinical development. §S1:2.3
Enrolled subjects in Monotherapy part may receive up to 3 doses of [212Pb]VMT01 approximately 8 weeks apart and subjects in combination therapy may receive nivolumab every 4 weeks for up to 24 months. §S1:2.4

A Dosimetry sub-study utilizing an imaging surrogate, [203Pb]VMT01, has been incorporated into the study in order to assess organ biodistribution and tumor uptake of the investigational products. §S1:2.5
This study will also estimate radiation dosimetry and correlate uptake of the investigation products with observed toxicities and efficacy. §S1:2.6

… §S1:2.7

- Uptake of [68Ga]VMT02 or [203Pb]VMT01 by PET or SPECT imaging observed in at least one melanoma tumor site using quantitative imaging analysis compared to reference normal tissue §S1:2.8

… §S1:2.9

- Febrile illness within 48 hours of any scheduled investigational product ([212Pb]VMT01, [203Pb]VMT01, or [68Ga]VMT02) administration; subjects should be rescheduled > 48 hours after resolution of fever §S1:2.10

- Treatment with another investigational drug product (therapeutic IND agents) within the last 45 days before the first dose of [212Pb]VMT01 on C1D1. §S1:2.11


**Valid codes for S1:** §S1:1.0 to §S1:1.2, §S1:2.0 to §S1:2.11



### S2: VMT01/02 Program - Perspective Therapeutics |
URL: https://perspectivetherapeutics.com/pipeline/vmt01-02
Date: 2025-05-19

Labeled text:

<snippet-heading>## Overview</snippet-heading> §S2:1.0

VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. §S2:1.1
It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy. §S2:1.2

<snippet-heading>## Development</snippet-heading> §S2:2.0

Ongoing multi-center Phase 1/2a dose-escalation/expansion trial (NCT05655312) evaluating [ §S2:2.1

212Pb]VMT01 as monotherapy and in combination with nivolumab in patients with unresectable or metastatic MC1R-positive melanoma, currently recruiting across the US §S2:2.2
- First patient dosed in combination arm (with nivolumab) in March 2025; dose finding progressing at 3.0 mCi for both monotherapy and combination, with no dose-limiting toxicities reported as of September 2025 §S2:2.3

- Preclinical data demonstrate synergistic effects with immune checkpoint inhibitors; combination cohort actively enrolling §S2:2.4
Phase 1 imaging study at Mayo Clinic supports patient selection using [ §S2:2.5

203Pb]VMT01 and [ 68Ga]VMT02, confirming feasibility for MC1R targeting §S2:2.6

- Fast Track Designation granted by FDA (September 2024) for diagnosis and treatment of MC1R-positive melanoma §S2:2.7

- Clinical updates on safety, dosimetry, and efficacy expected mid to late 2026, with potential for expanded enrollment and regulatory discussions §S2:2.8


**Valid codes for S2:** §S2:1.0 to §S2:1.2, §S2:2.0 to §S2:2.8



### S3: MC1R-targeted Alpha-particle Monotherapy and ...
URL: https://clinicaltrials.gov/study/NCT05655312?intr=212Pb&checkSpell=&rank=6
Date: 2022-11-15

Labeled text:

<snippet-heading>## MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaClinicalTrials.gov ID</snippet-heading> §S3:1.0

<snippet-heading>## Study Overview</snippet-heading> §S3:2.0

This is a prospective, multi-center open-label dose-finding, dose-expansion study of [212Pb]VMT01 as a monotherapy or in combination with nivolumab in up to 300 subjects with histologically confirmed melanoma and a positive MC1R imaging scan with imaging agents [203Pb]VMT01 or [68Ga]VMT02. §S3:2.1

… §S3:2.2

<snippet-heading>This study will be conducted in 3 parts:</snippet-heading> §S3:3.0

<snippet-heading>Part 1: Monotherapy Dose-Finding</snippet-heading> §S3:4.0

<snippet-heading>Part 2: Combination-Therapy Dose-Finding</snippet-heading> §S3:5.0

<snippet-heading>Part 3: Dose Expansion</snippet-heading> §S3:6.0

Enrolled subjects in Monotherapy may receive up to 3 doses of [212Pb]VMT01 approximately 8 weeks apart and subjects in combination therapy may receive up to 3 doses of [212Pb]VMT01 along with nivolumab. §S3:6.1
Nivolumab will be administered every 4 weeks for up to 24 months. §S3:6.2
A Dosimetry sub-set utilizing an imaging surrogate, [203Pb]VMT01, has been incorporated into the study in order to assess organ biodistribution and tumor uptake of the investigational products. §S3:6.3
This study will also estimate radiation dosimetry and correlate uptake of the investigation products with observed toxicities and efficacy. §S3:6.4

<snippet-heading>Drug: [203Pb]VMT01 Drug: [212Pb]VMT01 Drug: Nivolumab</snippet-heading> §S3:7.0

- VMT01-T101 §S3:7.1

… §S3:7.2

- Subjects on prior intravenous therapy (e.g., chemotherapy or checkpoint inhibitors), or prior oral therapy (e.g.,proto-oncogene B-RAF or mitogen-activated extracellular signal-regulated kinase inhibitors) who demonstrate MC1R positivity during screening are eligible for enrollment, provided that they undergo a wash-out period of 21 days, or 7 days, respectively, prior to Cycle 1 Day 1 treatment with [212Pb]VMT01. §S3:7.3

… §S3:7.4

- Febrile illness within 48 hours of any scheduled investigational product ([212Pb]VMT01, [203Pb]VMT01, or [68Ga]VMT02) administration; subjects should be rescheduled > 48 hours after resolution of fever §S3:7.5

- Treatment with another investigational drug product (therapeutic IND agents) within the last 45 days before the first dose of [212Pb]VMT01 on C1D1. §S3:7.6


**Valid codes for S3:** §S3:1.0, §S3:2.0 to §S3:2.2, §S3:3.0, §S3:4.0, §S3:5.0, §S3:6.0 to §S3:6.4, §S3:7.0 to §S3:7.6



### S4: Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
URL: https://www.mayo.edu/research/clinical-trials/cls-20509817
Date: 2024-11-21

Labeled text:

<snippet-heading>Featured conditions</snippet-heading> §S4:1.0

Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. §S4:1.1
See more conditions. §S4:1.2

<snippet-heading>Featured conditions</snippet-heading> §S4:2.0

<snippet-heading>Cancer-related trials contact form</snippet-heading> §S4:3.0

<snippet-heading>Phone: 855-776-0015 (toll-free)</snippet-heading> §S4:4.0

<snippet-heading>International patient clinical studies questions</snippet-heading> §S4:5.0

<snippet-heading>Tab Title Description</snippet-heading> §S4:6.0

Describes the nature of a clinical study. §S4:6.1
Types include: §S4:6.2
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. §S4:6.3
In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. §S4:6.4
They also compare the safety of the new treatment with that of current treatments. §S4:6.5
Phase 3 trials include large numbers of people to make sure that the result is valid. §S4:6.6
There are also less common very early (phase 0) and later (phase 4) phases. §S4:6.7
Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. §S4:6.8
Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. §S4:6.9
The purpose of this study is to determine safety and measure biodistribution of two imaging agents in patients with refractory or metastatic melanoma. §S4:6.10
This study will use [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) imaging. §S4:6.11
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. §S4:6.12
Guidelines differ from study to study, and identify who can or cannot participate. §S4:6.13
There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. §S4:6.14
Contact the study team to discuss study eligibility and potential participation. §S4:6.15
<snippet-heading>Inclusion Criteria:</snippet-heading> §S4:7.0

<snippet-heading>Exclusion Criteria:</snippet-heading> §S4:8.0

Eligibility last updated 11/10/21. Questions regarding updates should be directed to the study team contact. §S4:8.1

Study statuses change often. §S4:8.2
Please contact the study team for the most up-to-date information regarding possible participation. §S4:8.3

<snippet-heading>Mayo Clinic principal investigator</snippet-heading> §S4:9.0

Geoffrey Johnson, M.D., Ph.D. §S4:9.1

<snippet-heading>Closed for enrollment</snippet-heading> §S4:10.0


**Valid codes for S4:** §S4:1.0 to §S4:1.2, §S4:2.0, §S4:3.0, §S4:4.0, §S4:5.0, §S4:6.0 to §S4:6.15, §S4:7.0, §S4:8.0 to §S4:8.3, §S4:9.0 to §S4:9.1, §S4:10.0



### S5: [68Ga]VMT02 - Drug Targets, Indications, Patents - Patsnap Synapse
URL: https://synapse.patsnap.com/drug/2147731a54d94c709c7db6757eb5cd1f
Date: 2025-11-03

Labeled text:

login §S5:1.1

or §S5:1.2

<snippet-heading>view full example data</snippet-heading> §S5:2.0

Related §S5:2.1

1 §S5:2.2

<snippet-heading>Clinical Trials associated with [68Ga]VMT02</snippet-heading> §S5:3.0

NCT04904120 §S5:3.1

Completed §S5:3.2

<snippet-heading>Phase 1</snippet-heading> §S5:4.0

A Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic Melanoma §S5:4.1
The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively. §S5:4.2

… §S5:4.3

Article §S5:4.4

Author: §S5:4.5

<snippet-heading>Groten, J P</snippet-heading> §S5:5.0

<snippet-heading>Hissink, E</snippet-heading> §S5:6.0

<snippet-heading>van Bladeren, P J</snippet-heading> §S5:7.0

… §S5:7.1

In rats cadmium was present in two MT isoforms, RMT-1 and RMT-2. Ion-exchange chromatography of porcine liver cytosol also showed that two isoforms existed, but a major portion of the cadmium elutes with the second isoform, VMT-2. Using a reversed-phase HPLC system, the purified rat metallothionein isoforms eluted as single peaks before pig MT isoform VMT-2. §S5:7.2
The difference in chromatographic behaviour on reversed-phase HPLC between species-specific metallothioneins offers a unique possibility to study the fate of endogenous and exogenous metallothioneins simultaneously. §S5:7.3
This will be illustrated by the redistribution of 109Cd from exogenous CdMT to endogenous CdMT after intravenous injection of VMT-2 into rats. §S5:7.4
100 §S5:7.5

<snippet-heading>Deals associated with [68Ga]VMT02</snippet-heading> §S5:8.0

<snippet-heading>Login to view more data</snippet-heading> §S5:9.0

<snippet-heading>R&D Status</snippet-heading> §S5:10.0

10 §S5:10.1

top R&D records. §S5:10.2

Login §S5:10.3

<snippet-heading>to view more data</snippet-heading> §S5:11.0

Indication §S5:11.1

<snippet-heading>Highest Phase</snippet-heading> §S5:12.0

Country/Location §S5:12.1

Organization §S5:12.2

Date §S5:12.3

Melanoma §S5:12.4

<snippet-heading>Phase 2</snippet-heading> §S5:13.0

<snippet-heading>United States</snippet-heading> §S5:14.0

Perspective Therapeutics, Inc. §S5:14.1

… §S5:14.2

Perspective Therapeutics, Inc. §S5:14.3

<snippet-heading>05 Mar 2021</snippet-heading> §S5:15.0

<snippet-heading>Uveal Melanoma</snippet-heading> §S5:16.0

<snippet-heading>Phase 1</snippet-heading> §S5:17.0

<snippet-heading>United States</snippet-heading> §S5:18.0

Perspective Therapeutics, Inc. §S5:18.1

<snippet-heading>05 Mar 2021</snippet-heading> §S5:19.0

<snippet-heading>Login to view more data</snippet-heading> §S5:20.0

<snippet-heading>Clinical Result</snippet-heading> §S5:21.0

Indication §S5:21.1

Phase §S5:21.2

Evaluation §S5:21.3

<snippet-heading>View All Results</snippet-heading> §S5:22.0

Study §S5:22.1

Phase §S5:22.2

Population §S5:22.3

<snippet-heading>Analyzed Enrollment</snippet-heading> §S5:23.0


**Valid codes for S5:** §S5:1.1 to §S5:1.2, §S5:2.0 to §S5:2.2, §S5:3.0 to §S5:3.2, §S5:4.0 to §S5:4.5, §S5:5.0, §S5:6.0, §S5:7.0 to §S5:7.5, §S5:8.0, §S5:9.0, §S5:10.0 to §S5:10.3, §S5:11.0 to §S5:11.1, §S5:12.0 to §S5:12.4, §S5:13.0, §S5:14.0 to §S5:14.3, §S5:15.0, §S5:16.0, §S5:17.0, §S5:18.0 to §S5:18.1, §S5:19.0, §S5:20.0, §S5:21.0 to §S5:21.3, §S5:22.0 to §S5:22.3, §S5:23.0



---

## Task Structure

For each source:
1. **Assess source-level quality** → c (authority/quality) + p (probability)
2. **Extract snippets** → code + detail_limitation
3. **Assign source handle** → 1-word identifier (freddie, nih, pubmed, etc.)

---

## Source-Level Assessment (CRITICAL)

Evaluate ENTIRE source before extracting snippets:

**c (classification)** - Authority + all applicable quality codes:
- **Authority (who):** ALWAYS include one
  - **H**: High authority + topic expertise
  - **M**: Medium authority or unclear
  - **L**: Low authority or lacks topic expertise

- **Quality (what):** Include ALL that apply
  - **P**: PRIMARY (official/primary doc)
  - **D**: DOCUMENTED (methods/peer-reviewed)
  - **A**: ATTRIBUTED (named experts throughout)
  - **O**: OK (no red flags, nothing special)
  - **C**: CONTRADICTED (false/inconsistent)
  - **U**: UNSOURCED (no evidence)
  - **PR**: PROMOTIONAL (biased)
  - **S**: STALE (outdated)
  - **SL**: SLOP (AI SEO)
  - **IR**: INDIRECT (tangentially related)

**Format:** c:H/P (high authority + primary), c:M/A/O (medium + attributed + ok), c:L/U/S (low + unsourced + stale)
**Can combine multiple quality codes** - include ALL that apply to the source

**p (probability)** - Exact values: p05, p15, p30, p50, p65, p85, p95

Judge extracts all atomic claims from source and tests each. Pass = precisely accurate. p = expected pass-rate.

**source_handle** - 1-word identifier: freddie, nih, pubmed, nrel, bankrate, healthline, etc.

---

## Snippet Extraction Rules

**Gate - Extract only if:**
- Concrete, verifiable facts (not vague summaries/speculation)
- Doesn't need full article to verify
- Skip AI-generated SEO slop (mark source c:LA/SL if encountered)

**Pass-all flag:** `` §SX:* `` → Use entire source if dense/interconnected or would extract >50%

**Snippet Requirements:**
- **Self-contained:** Each snippet MUST make a complete point in isolation
- **Context in brackets:** Max 5 words, shorthand preferred (e.g., [re: IF] not [regarding intermittent fasting])
- **Ellipsis for gaps:** Use ... to join non-adjacent sentences into one coherent snippet
- **Must be testable:** Given only URL, title, and snippet, a judge can verify all claims
- **No redundancy:** Skip if same point already made by another snippet of same/higher quality

**Code Syntax:**
- Single: `` §S1:1.1 ``
- **Range (REQUIRED for consecutive):** `` §S1:1.5-1.7 ``
- **Ellipsis join (non-adjacent):** `` §S1:1.2 ... §S1:1.5 `` → resolves to "text1 ... text5"
- Word range: `` §S2:1.1.w5-7 `` (1-indexed)
- Heading context: `` [§S1:2.0] §S1:2.1 ``
- Attribution: `` [§S1:2.1.w1-4] §S1:1.3 `` (REQUIRED for c:A sources)
- Clarification: `` §S1:1.1 [re: Gemini] `` (max 5 words, shorthand)

**Consecutive Lines (CRITICAL):**
- **Contiguous sentences = ONE snippet** - even if they address different search terms or aspects
- Use ranges: `` §S1:2.1-2.4 `` - NEVER create separate snippets for adjacent lines
- Assign combined snippet to the MOST relevant search term

**Tables (CRITICAL):**
- ONE snippet per table: `` §S1:5.0-5.7 `` (header row 0 + data rows 1-7)
- NEVER separate rows

**CRITICAL - Code Accuracy Rules:**
- **ONLY use codes that appear in the labeled source text** - copy them EXACTLY
- Each source shows "Valid codes for SX:" at the bottom - codes MUST fall within those ranges
- **WRONG formats (NEVER output these):**
  - `` §S2:47.84 `` ← Decimal sentence numbers don't exist
  - `` §S2:189 `` ← Single integers without section.sentence format
  - `` §S7:1.1 `` when extracting from S2 ← Wrong source prefix
  - `` §S1:1.15-1.18 `` ← Range beyond actual sentence count
- **If you can't find the exact code in the source, OMIT the quote entirely**
- When in doubt, look at the "Valid codes" line for each source

---

## Snippet Handle Components

For each snippet, provide: `detail_limitation` (NO source prefix here)

**CRITICAL: EVERY CITATION MUST HAVE A UNIQUE TEXT HANDLE**
- Handles are the PRIMARY identifier for citations in synthesis
- If two snippets have the same handle, synthesis cannot distinguish them
- **ALWAYS ensure uniqueness** - append _2, _3, _4, etc. if a handle already exists

**Format:** `detail_limit` (max 2 words total, shorthand preferred)
- **detail**: 1 word, abbreviated (mtg-rate, wt-loss, eff-tbl)
- **limit**: 1 word, abbreviated (dec25, us, 2024)

**Examples:**
- `mtg-rate_dec25` (mortgage rate, December 2025)
- `wt-loss_if` (weight loss, intermittent fasting)
- `eff-tbl_solar` (efficiency table, solar)
- `wt-loss_if_2` ← Second snippet on same topic
- `wt-loss_if_3` ← Third snippet

Max 15 chars. **MUST be unique** (append _2, _3 if needed). Use common abbreviations.

**Full handle assembled later:** `{source_handle}_{detail}_{limitation}`
- freddie_mortgage-rate_dec-2025
- nih_weight-loss_if-protocol
- nih_weight-loss_if-protocol_2

---

## Output Format

```json
{
  "source_metadata": {
    "S1": {"handle": "freddie", "c": "H/P", "p": "p95"},
    "S2": {"handle": "nih", "c": "H/D/A", "p": "p85"},
    "S3": {"handle": "techblog", "c": "M/O", "p": "p65"}
  },
  "quotes_by_search": {
    "1": [
      ["mortgage-rate_dec-2025", "§S1:1.1"],
      ["refinance-rate_30yr-fixed", "§S1:2.1"],
      ["weight-loss_if-vs-cer", "[§S2:1.0] §S2:1.5"],
      ["insulin-sensitivity_tre-protocol", "§S2:2.1-2.3"],
      ["ai-trends_2025", "§S3:1.1"]
    ],
    "2": []
  }
}
```

**source_metadata** - One entry per source:
- **handle**: 1-word identifier (nih, webmd, freddie)
- **c**: Authority + quality codes (H/P, M/A/O, L/U/S)
- **p**: Probability (p05, p15, p30, p50, p65, p85, p95)

**quotes_by_search** - Organized by search term number:
- Each quote: `[detail_limitation, code]` ← **HANDLE FIRST, then code**
- Source is identified by code prefix (§S1:1.1 → S1)
- **Max 2 per source per search term**
- **ORDERING: List quotes sequentially by source (all S1, then all S2, then S3...), and within each source by code order (1.1, 1.2, 2.1...)**

Return empty `{}` if nothing clear.

**⚠️ RESPONSE LENGTH LIMIT: Keep your total response under 24000 words.**

```

</details>

#### Batch Extraction Prompt (2 sources) <small>(04:07:19)</small>

<details><summary>Click to expand</summary>

```text
# Batch Quote Extraction (Code-Based)

Extract quotable snippets with codes for synthesis. **Synthesis will NOT see original sources** - only these snippets.

**Today:** 2026-02-13 | **Mode:** Extract ONLY concrete atomic facts (numbers, dates, entities). Be MINIMAL with just enough context to verify. | **Max:** 2/source/search

**Search terms:**
1. VMT02 Ratio Therapeutics target indication development stage
2. Ratio Therapeutics VMT02 clinicaltrials.gov
3. VMT02 clinical trial phase

**RULES:**
- **Merge contiguous:** Adjacent sentences = ONE snippet (use ranges), even if addressing different aspects
- **No duplication:** Once a passage is extracted, trust it's available to synthesis - do NOT extract again for other terms
- **Self-contained:** Each snippet MUST make a complete point in isolation - no sentence fragments
- **Skip redundant:** If a point was already made by a snippet of same/higher quality, do NOT extract again

**SHALLOW MODE LIMITS:**
- **2 snippets MAX per source per search term**
- **Brevity:** Just enough context to verify - prefer minimal over comprehensive

---

## Labeled Sources

Sentences labeled `` §SX:Y.Z ``, headings labeled `` §SX:Y.0 `` (X=source, Y=section, Z=sentence). Copy exact labels.


### S1: VMT01/02
URL: https://www.perspectivetherapeutics.com/pipeline/vmt01-02
Date: 2025-05-19

Labeled text:

<snippet-heading>## Overview</snippet-heading> §S1:1.0

VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. §S1:1.1
It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy. §S1:1.2

<snippet-heading>## Development</snippet-heading> §S1:2.0

- US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT05655312?term=vmt01 §S1:2.1

- Fast Track Designation received September 2024 §S1:2.2

- Preclinical data shows synergistic effect with Immune Checkpoint Inhibitors §S1:2.3

- VMT01/ICI combination cohort open for recruitment §S1:2.4

- Phase 1 imaging study at Mayo Clinic Rochester indicates feasibility of patient §S1:2.5

<snippet-heading>selection using [</snippet-heading> §S1:3.0

<snippet-heading>203Pb]VMT01 and [ 68Ga]VMT02</snippet-heading> §S1:4.0


**Valid codes for S1:** §S1:1.0 to §S1:1.2, §S1:2.0 to §S1:2.5, §S1:3.0, §S1:4.0



### S2: CLINICAL TRIAL / NCT05636618 - UChicago Medicine
URL: https://www.uchicagomedicine.org/find-a-clinical-trial/clinical-trial/irb230670
Date: 2024-06-04

Labeled text:

<snippet-heading>## Contact Information</snippet-heading> §S2:1.0
<snippet-heading>### A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors</snippet-heading> §S2:2.0

This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors §S2:2.1
This is a prospective, multi-center, open-label, radioactivity dose-finding/ dose expansion study of [212Pb]VMT-α-NET in up to 260 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT). §S2:2.2
Somatostatin Receptor type 2 (SSTR2) is highly expressed on various tumors including NETs and therefore is an attractive therapeutic target for NET treatment. §S2:2.3
Lead-212 ([212Pb]-) based peptide-radiopharmaceuticals are an emerging class of targeted alpha-particle cancer therapies that have potential to improve delivery of a highly effective form of radiation. §S2:2.4

… §S2:2.5

The study will be conducted in 2 parts: Part 1: Phase I Dose-Finding: Subjects will receive radioactive doses of [212Pb]VMT-α-NET up to a maximum dose of 222 MBq (6 mCi) for dose-limiting toxicity (DLT) observation, determining Optimal Biological Dose (OBD) and potential Recommended Phase 2 Dose (RP2D) for Part 2 (Dose Expansion). §S2:2.6
Dose changes or adjustments will be made by the safety monitoring committee (SMC) and Sponsor. §S2:2.7
The RP2D will be determined following a holistic analysis of observed DLTs, adverse events (AEs), estimated cumulative organ radiation exposure, and efficacy signals over the course of all treatment cycles for all dose cohorts. §S2:2.8
Part 2: Phase IIa Dose-Expansion: This part will enroll subjects who will receive RP2D identified in Part 1 for further assessment of safety and preliminary efficacy. §S2:2.9

… §S2:2.10

2. Active secondary malignancy. 3. Pregnancy or breastfeeding a child. 4. Febrile illness within 48 hours of any scheduled [212Pb]VMT-α-NET administration should be rescheduled > 48 hours after resolution of fever]. 5. Treatment with another investigational medicinal product within 30 days of anticipated treatment. §S2:2.11


**Valid codes for S2:** §S2:1.0, §S2:2.0 to §S2:2.11



---

## Task Structure

For each source:
1. **Assess source-level quality** → c (authority/quality) + p (probability)
2. **Extract snippets** → code + detail_limitation
3. **Assign source handle** → 1-word identifier (freddie, nih, pubmed, etc.)

---

## Source-Level Assessment (CRITICAL)

Evaluate ENTIRE source before extracting snippets:

**c (classification)** - Authority + all applicable quality codes:
- **Authority (who):** ALWAYS include one
  - **H**: High authority + topic expertise
  - **M**: Medium authority or unclear
  - **L**: Low authority or lacks topic expertise

- **Quality (what):** Include ALL that apply
  - **P**: PRIMARY (official/primary doc)
  - **D**: DOCUMENTED (methods/peer-reviewed)
  - **A**: ATTRIBUTED (named experts throughout)
  - **O**: OK (no red flags, nothing special)
  - **C**: CONTRADICTED (false/inconsistent)
  - **U**: UNSOURCED (no evidence)
  - **PR**: PROMOTIONAL (biased)
  - **S**: STALE (outdated)
  - **SL**: SLOP (AI SEO)
  - **IR**: INDIRECT (tangentially related)

**Format:** c:H/P (high authority + primary), c:M/A/O (medium + attributed + ok), c:L/U/S (low + unsourced + stale)
**Can combine multiple quality codes** - include ALL that apply to the source

**p (probability)** - Exact values: p05, p15, p30, p50, p65, p85, p95

Judge extracts all atomic claims from source and tests each. Pass = precisely accurate. p = expected pass-rate.

**source_handle** - 1-word identifier: freddie, nih, pubmed, nrel, bankrate, healthline, etc.

---

## Snippet Extraction Rules

**Gate - Extract only if:**
- Concrete, verifiable facts (not vague summaries/speculation)
- Doesn't need full article to verify
- Skip AI-generated SEO slop (mark source c:LA/SL if encountered)

**Pass-all flag:** `` §SX:* `` → Use entire source if dense/interconnected or would extract >50%

**Snippet Requirements:**
- **Self-contained:** Each snippet MUST make a complete point in isolation
- **Context in brackets:** Max 5 words, shorthand preferred (e.g., [re: IF] not [regarding intermittent fasting])
- **Ellipsis for gaps:** Use ... to join non-adjacent sentences into one coherent snippet
- **Must be testable:** Given only URL, title, and snippet, a judge can verify all claims
- **No redundancy:** Skip if same point already made by another snippet of same/higher quality

**Code Syntax:**
- Single: `` §S1:1.1 ``
- **Range (REQUIRED for consecutive):** `` §S1:1.5-1.7 ``
- **Ellipsis join (non-adjacent):** `` §S1:1.2 ... §S1:1.5 `` → resolves to "text1 ... text5"
- Word range: `` §S2:1.1.w5-7 `` (1-indexed)
- Heading context: `` [§S1:2.0] §S1:2.1 ``
- Attribution: `` [§S1:2.1.w1-4] §S1:1.3 `` (REQUIRED for c:A sources)
- Clarification: `` §S1:1.1 [re: Gemini] `` (max 5 words, shorthand)

**Consecutive Lines (CRITICAL):**
- **Contiguous sentences = ONE snippet** - even if they address different search terms or aspects
- Use ranges: `` §S1:2.1-2.4 `` - NEVER create separate snippets for adjacent lines
- Assign combined snippet to the MOST relevant search term

**Tables (CRITICAL):**
- ONE snippet per table: `` §S1:5.0-5.7 `` (header row 0 + data rows 1-7)
- NEVER separate rows

**CRITICAL - Code Accuracy Rules:**
- **ONLY use codes that appear in the labeled source text** - copy them EXACTLY
- Each source shows "Valid codes for SX:" at the bottom - codes MUST fall within those ranges
- **WRONG formats (NEVER output these):**
  - `` §S2:47.84 `` ← Decimal sentence numbers don't exist
  - `` §S2:189 `` ← Single integers without section.sentence format
  - `` §S7:1.1 `` when extracting from S2 ← Wrong source prefix
  - `` §S1:1.15-1.18 `` ← Range beyond actual sentence count
- **If you can't find the exact code in the source, OMIT the quote entirely**
- When in doubt, look at the "Valid codes" line for each source

---

## Snippet Handle Components

For each snippet, provide: `detail_limitation` (NO source prefix here)

**CRITICAL: EVERY CITATION MUST HAVE A UNIQUE TEXT HANDLE**
- Handles are the PRIMARY identifier for citations in synthesis
- If two snippets have the same handle, synthesis cannot distinguish them
- **ALWAYS ensure uniqueness** - append _2, _3, _4, etc. if a handle already exists

**Format:** `detail_limit` (max 2 words total, shorthand preferred)
- **detail**: 1 word, abbreviated (mtg-rate, wt-loss, eff-tbl)
- **limit**: 1 word, abbreviated (dec25, us, 2024)

**Examples:**
- `mtg-rate_dec25` (mortgage rate, December 2025)
- `wt-loss_if` (weight loss, intermittent fasting)
- `eff-tbl_solar` (efficiency table, solar)
- `wt-loss_if_2` ← Second snippet on same topic
- `wt-loss_if_3` ← Third snippet

Max 15 chars. **MUST be unique** (append _2, _3 if needed). Use common abbreviations.

**Full handle assembled later:** `{source_handle}_{detail}_{limitation}`
- freddie_mortgage-rate_dec-2025
- nih_weight-loss_if-protocol
- nih_weight-loss_if-protocol_2

---

## Output Format

```json
{
  "source_metadata": {
    "S1": {"handle": "freddie", "c": "H/P", "p": "p95"},
    "S2": {"handle": "nih", "c": "H/D/A", "p": "p85"},
    "S3": {"handle": "techblog", "c": "M/O", "p": "p65"}
  },
  "quotes_by_search": {
    "1": [
      ["mortgage-rate_dec-2025", "§S1:1.1"],
      ["refinance-rate_30yr-fixed", "§S1:2.1"],
      ["weight-loss_if-vs-cer", "[§S2:1.0] §S2:1.5"],
      ["insulin-sensitivity_tre-protocol", "§S2:2.1-2.3"],
      ["ai-trends_2025", "§S3:1.1"]
    ],
    "2": []
  }
}
```

**source_metadata** - One entry per source:
- **handle**: 1-word identifier (nih, webmd, freddie)
- **c**: Authority + quality codes (H/P, M/A/O, L/U/S)
- **p**: Probability (p05, p15, p30, p50, p65, p85, p95)

**quotes_by_search** - Organized by search term number:
- Each quote: `[detail_limitation, code]` ← **HANDLE FIRST, then code**
- Source is identified by code prefix (§S1:1.1 → S1)
- **Max 2 per source per search term**
- **ORDERING: List quotes sequentially by source (all S1, then all S2, then S3...), and within each source by code order (1.1, 1.2, 2.1...)**

Return empty `{}` if nothing clear.

**⚠️ RESPONSE LENGTH LIMIT: Keep your total response under 24000 words.**

```

</details>

#### Batch Extraction Prompt (4 sources) <small>(04:07:19)</small>

<details><summary>Click to expand</summary>

```text
# Batch Quote Extraction (Code-Based)

Extract quotable snippets with codes for synthesis. **Synthesis will NOT see original sources** - only these snippets.

**Today:** 2026-02-13 | **Mode:** Extract ONLY concrete atomic facts (numbers, dates, entities). Be MINIMAL with just enough context to verify. | **Max:** 2/source/search

**Search terms:**
1. VMT02 Ratio Therapeutics target indication development stage
2. Ratio Therapeutics VMT02 clinicaltrials.gov
3. VMT02 clinical trial phase

**RULES:**
- **Merge contiguous:** Adjacent sentences = ONE snippet (use ranges), even if addressing different aspects
- **No duplication:** Once a passage is extracted, trust it's available to synthesis - do NOT extract again for other terms
- **Self-contained:** Each snippet MUST make a complete point in isolation - no sentence fragments
- **Skip redundant:** If a point was already made by a snippet of same/higher quality, do NOT extract again

**SHALLOW MODE LIMITS:**
- **2 snippets MAX per source per search term**
- **Brevity:** Just enough context to verify - prefer minimal over comprehensive

---

## Labeled Sources

Sentences labeled `` §SX:Y.Z ``, headings labeled `` §SX:Y.0 `` (X=source, Y=section, Z=sentence). Copy exact labels.


### S1: National Brain Tumor Society | Community here. Breakthroughs ahead. - National Brain Tumor Society
URL: https://trials.braintumor.org/trials/NCT05655312
Date: 2022-08-31

Labeled text:

This study will be conducted in 3 parts: Part 1: Monotherapy Dose-Escalation: [212Pb]VMT01 is administered alone in escalating doses to determine the Maximum Tolerated radioactivity Dose (MTD), Maximum Feasible radioactivity Dose (MFD), and potential recommended Phase 2 doses (RP2Ds) Part 2: Combination-Therapy Dose-Escalation: [212Pb]VMT01 and Nivolumab are administered in escalating doses to determine MTD, MFD, and RP2Ds. §S1:1.1

… §S1:1.2

<snippet-heading>Experimental: Monotherapy-Dose Escalation</snippet-heading> §S1:2.0

Enrolled subjects will be treated with increasing doses of [212Pb]VMT01 (up to 15 mCi) to determine MTD, MFD, and RP2D. §S1:2.1
Up to 32 subjects will be enrolled. §S1:2.2
A dosimetry sub-study utilizing [203Pb]VMT01 has been incorporated into Monotherapy Dose-Escalation arm. §S1:2.3
<snippet-heading>Experimental: Combination Therapy-Dose Escalation</snippet-heading> §S1:3.0

Enrolled subjects will be treated with increasing radioactive doses of [212Pb]VMT01 (up to 15 mCi) in combination with nivolumab to determine MTD, MFD, and RP2D. §S1:3.1
A dosimetry sub-study utilizing [203Pb]VMT01 has been incorporated into Combination Therapy-Dose Escalation. §S1:3.2
<snippet-heading>Experimental: Monotherapy - Dose Expansion</snippet-heading> §S1:4.0

Up to 2 monotherapy expansion cohorts of up to 25 subjects will be enrolled at previously identified RP2D to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort. §S1:4.1
A dosimetry sub-study utilizing [203Pb]VMT01 has been incorporated into Monotherapy-Dose Expansion. §S1:4.2
<snippet-heading>Experimental: Combination Therapy - Dose Expansion</snippet-heading> §S1:5.0

Up to 2 Combination Therapy expansion cohorts of up to 25 subjects will be enrolled at RP2Ds previously identified to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort. §S1:5.1
A dosimetry sub-study utilizing [203Pb]VMT01 has been incorporated into Combination Therapy-Dose Expansion. §S1:5.2
Once the RP2D and regimen for the Phase 2 dose-expansion cohort is confirmed, up to 100 subjects will be enrolled to confirm the efficacy and safety of the RP2D and regimen. §S1:5.3


**Valid codes for S1:** §S1:1.1 to §S1:1.2, §S1:2.0 to §S1:2.3, §S1:3.0 to §S1:3.2, §S1:4.0 to §S1:4.2, §S1:5.0 to §S1:5.3



### S2: VMT01/02
URL: https://www.perspectivetherapeutics.com/pipeline/vmt01-02
Date: 2025-05-19

Labeled text:

<snippet-heading>## Overview</snippet-heading> §S2:1.0

VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas. §S2:1.1
It uses Perspective Therapeutics' proprietary chelator (PSC) to bind Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy. §S2:1.2

<snippet-heading>## Development</snippet-heading> §S2:2.0

- US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT05655312?term=vmt01 §S2:2.1

- Fast Track Designation received September 2024 §S2:2.2

- Preclinical data shows synergistic effect with Immune Checkpoint Inhibitors §S2:2.3

- VMT01/ICI combination cohort open for recruitment §S2:2.4

- Phase 1 imaging study at Mayo Clinic Rochester indicates feasibility of patient §S2:2.5

<snippet-heading>selection using [</snippet-heading> §S2:3.0

<snippet-heading>203Pb]VMT01 and [ 68Ga]VMT02</snippet-heading> §S2:4.0


**Valid codes for S2:** §S2:1.0 to §S2:1.2, §S2:2.0 to §S2:2.5, §S2:3.0, §S2:4.0



### S3: Alpha PRRT with Pb-212 VMT
URL: https://www.lacnets.org/clinical-trials-1/alpha-prrt-with-pb-212-vmt
Date: 2016-01-01

Labeled text:

<snippet-heading># Alpha PRRT with Pb-212 VMT</snippet-heading> §S3:1.0

<snippet-heading>### Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT)</snippet-heading> §S3:2.0

**IDENTIFIER (** **ClinicalTrials.gov** **)**: NCT05636618 §S3:2.1

**DRUG/TREATMENT**: Alpha PRRT with 212Pb VMT §S3:2.2

**PHASE**: 1 / 2A §S3:2.3
**STATUS**: Recruiting §S3:2.4

**SPONSOR**: Perspective Therapeutics §S3:2.5

**DESCRIPTION:** §S3:2.6

*June 2024: Dr. Aman Chauhan discusses the * *Alpha PRRT with Pb-212 VMT study.* §S3:2.7

Perspective Therapeutics is sponsoring a phase 1 / 2A prospective, multi-center open-label dose escalation, dose expansion study of [212Pb]VMT01 in up to 52 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT). §S3:2.8
During phase 1, there is a dose escalation period testing up to 4 escalating radioactivity dose cohorts of up to 8 subjects (administered at approximately 8-week intervals) at the assigned cohort radioactivity dose. §S3:2.9
Phase 1 studies the side effects, safety, and dosimetry. §S3:2.10

*For more information on eligibility criteria, trial locations, study details, etc., go to * __ClinicalTrials.gov__ *to* __view this trial here.__ §S3:2.11
**CONTACT**: §S3:2.12

<snippet-heading>Markus Puhlmann, MD, MBA at Perspective Therapeutics</snippet-heading> §S3:3.0

**EMAIL: ** __mpuhlmann@perspectivetherapeutics.com__ §S3:3.1

**PHONE: **(319) 665-2150 §S3:3.2


**Valid codes for S3:** §S3:1.0, §S3:2.0 to §S3:2.12, §S3:3.0 to §S3:3.2



### S4: NCT07156565
URL: https://www.theranostictrials.org/studies/cl74bp9il0235ajjfhzmr6gph/study/NCT07156565
Date: 2021-01-01

Labeled text:

**Description:** §S4:1.1

The goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S. §S4:1.2
Additionally Ratio Therapeutics will learn if [Ac225]RTX-2358 drug is effective in treating advanced sarcoma. §S4:1.3
<snippet-heading>Ratio Therapeutics, Inc</snippet-heading> §S4:2.0

**Sponsor:** §S4:2.1

TBD §S4:2.2

**Contacts:** §S4:2.3

tbd@tbd.com §S4:2.4

<snippet-heading>NCT07156565 - Click here to see study on</snippet-heading> §S4:3.0

**Government Study Link:** §S4:3.1

ClinicalTrials.gov §S4:3.2

**Patient Education** §S4:3.3

<snippet-heading>Patient Education Not Yet Provided</snippet-heading> §S4:4.0

**Publications** §S4:4.1

<snippet-heading>Publications Not Yet Provided</snippet-heading> §S4:5.0
**Locations** §S4:5.1

**United States 🇺🇸** §S4:5.2

<snippet-heading>United States</snippet-heading> §S4:6.0

<snippet-heading>© 2021 XCancer Software LLC</snippet-heading> §S4:7.0

<snippet-heading>Contact XCancer: 402-991-8468</snippet-heading> §S4:8.0


**Valid codes for S4:** §S4:1.1 to §S4:1.3, §S4:2.0 to §S4:2.4, §S4:3.0 to §S4:3.3, §S4:4.0 to §S4:4.1, §S4:5.0 to §S4:5.2, §S4:6.0, §S4:7.0, §S4:8.0



---

## Task Structure

For each source:
1. **Assess source-level quality** → c (authority/quality) + p (probability)
2. **Extract snippets** → code + detail_limitation
3. **Assign source handle** → 1-word identifier (freddie, nih, pubmed, etc.)

---

## Source-Level Assessment (CRITICAL)

Evaluate ENTIRE source before extracting snippets:

**c (classification)** - Authority + all applicable quality codes:
- **Authority (who):** ALWAYS include one
  - **H**: High authority + topic expertise
  - **M**: Medium authority or unclear
  - **L**: Low authority or lacks topic expertise

- **Quality (what):** Include ALL that apply
  - **P**: PRIMARY (official/primary doc)
  - **D**: DOCUMENTED (methods/peer-reviewed)
  - **A**: ATTRIBUTED (named experts throughout)
  - **O**: OK (no red flags, nothing special)
  - **C**: CONTRADICTED (false/inconsistent)
  - **U**: UNSOURCED (no evidence)
  - **PR**: PROMOTIONAL (biased)
  - **S**: STALE (outdated)
  - **SL**: SLOP (AI SEO)
  - **IR**: INDIRECT (tangentially related)

**Format:** c:H/P (high authority + primary), c:M/A/O (medium + attributed + ok), c:L/U/S (low + unsourced + stale)
**Can combine multiple quality codes** - include ALL that apply to the source

**p (probability)** - Exact values: p05, p15, p30, p50, p65, p85, p95

Judge extracts all atomic claims from source and tests each. Pass = precisely accurate. p = expected pass-rate.

**source_handle** - 1-word identifier: freddie, nih, pubmed, nrel, bankrate, healthline, etc.

---

## Snippet Extraction Rules

**Gate - Extract only if:**
- Concrete, verifiable facts (not vague summaries/speculation)
- Doesn't need full article to verify
- Skip AI-generated SEO slop (mark source c:LA/SL if encountered)

**Pass-all flag:** `` §SX:* `` → Use entire source if dense/interconnected or would extract >50%

**Snippet Requirements:**
- **Self-contained:** Each snippet MUST make a complete point in isolation
- **Context in brackets:** Max 5 words, shorthand preferred (e.g., [re: IF] not [regarding intermittent fasting])
- **Ellipsis for gaps:** Use ... to join non-adjacent sentences into one coherent snippet
- **Must be testable:** Given only URL, title, and snippet, a judge can verify all claims
- **No redundancy:** Skip if same point already made by another snippet of same/higher quality

**Code Syntax:**
- Single: `` §S1:1.1 ``
- **Range (REQUIRED for consecutive):** `` §S1:1.5-1.7 ``
- **Ellipsis join (non-adjacent):** `` §S1:1.2 ... §S1:1.5 `` → resolves to "text1 ... text5"
- Word range: `` §S2:1.1.w5-7 `` (1-indexed)
- Heading context: `` [§S1:2.0] §S1:2.1 ``
- Attribution: `` [§S1:2.1.w1-4] §S1:1.3 `` (REQUIRED for c:A sources)
- Clarification: `` §S1:1.1 [re: Gemini] `` (max 5 words, shorthand)

**Consecutive Lines (CRITICAL):**
- **Contiguous sentences = ONE snippet** - even if they address different search terms or aspects
- Use ranges: `` §S1:2.1-2.4 `` - NEVER create separate snippets for adjacent lines
- Assign combined snippet to the MOST relevant search term

**Tables (CRITICAL):**
- ONE snippet per table: `` §S1:5.0-5.7 `` (header row 0 + data rows 1-7)
- NEVER separate rows

**CRITICAL - Code Accuracy Rules:**
- **ONLY use codes that appear in the labeled source text** - copy them EXACTLY
- Each source shows "Valid codes for SX:" at the bottom - codes MUST fall within those ranges
- **WRONG formats (NEVER output these):**
  - `` §S2:47.84 `` ← Decimal sentence numbers don't exist
  - `` §S2:189 `` ← Single integers without section.sentence format
  - `` §S7:1.1 `` when extracting from S2 ← Wrong source prefix
  - `` §S1:1.15-1.18 `` ← Range beyond actual sentence count
- **If you can't find the exact code in the source, OMIT the quote entirely**
- When in doubt, look at the "Valid codes" line for each source

---

## Snippet Handle Components

For each snippet, provide: `detail_limitation` (NO source prefix here)

**CRITICAL: EVERY CITATION MUST HAVE A UNIQUE TEXT HANDLE**
- Handles are the PRIMARY identifier for citations in synthesis
- If two snippets have the same handle, synthesis cannot distinguish them
- **ALWAYS ensure uniqueness** - append _2, _3, _4, etc. if a handle already exists

**Format:** `detail_limit` (max 2 words total, shorthand preferred)
- **detail**: 1 word, abbreviated (mtg-rate, wt-loss, eff-tbl)
- **limit**: 1 word, abbreviated (dec25, us, 2024)

**Examples:**
- `mtg-rate_dec25` (mortgage rate, December 2025)
- `wt-loss_if` (weight loss, intermittent fasting)
- `eff-tbl_solar` (efficiency table, solar)
- `wt-loss_if_2` ← Second snippet on same topic
- `wt-loss_if_3` ← Third snippet

Max 15 chars. **MUST be unique** (append _2, _3 if needed). Use common abbreviations.

**Full handle assembled later:** `{source_handle}_{detail}_{limitation}`
- freddie_mortgage-rate_dec-2025
- nih_weight-loss_if-protocol
- nih_weight-loss_if-protocol_2

---

## Output Format

```json
{
  "source_metadata": {
    "S1": {"handle": "freddie", "c": "H/P", "p": "p95"},
    "S2": {"handle": "nih", "c": "H/D/A", "p": "p85"},
    "S3": {"handle": "techblog", "c": "M/O", "p": "p65"}
  },
  "quotes_by_search": {
    "1": [
      ["mortgage-rate_dec-2025", "§S1:1.1"],
      ["refinance-rate_30yr-fixed", "§S1:2.1"],
      ["weight-loss_if-vs-cer", "[§S2:1.0] §S2:1.5"],
      ["insulin-sensitivity_tre-protocol", "§S2:2.1-2.3"],
      ["ai-trends_2025", "§S3:1.1"]
    ],
    "2": []
  }
}
```

**source_metadata** - One entry per source:
- **handle**: 1-word identifier (nih, webmd, freddie)
- **c**: Authority + quality codes (H/P, M/A/O, L/U/S)
- **p**: Probability (p05, p15, p30, p50, p65, p85, p95)

**quotes_by_search** - Organized by search term number:
- Each quote: `[detail_limitation, code]` ← **HANDLE FIRST, then code**
- Source is identified by code prefix (§S1:1.1 → S1)
- **Max 2 per source per search term**
- **ORDERING: List quotes sequentially by source (all S1, then all S2, then S3...), and within each source by code order (1.1, 1.2, 2.1...)**

Return empty `{}` if nothing clear.

**⚠️ RESPONSE LENGTH LIMIT: Keep your total response under 24000 words.**

```

</details>

#### Batch Extraction Result (2 sources) <small>(04:07:20)</small>

<details><summary>Click to expand</summary>

```json
{
  "source_metadata": {
    "S1": {
      "handle": "perspectivetherapeutics",
      "c": "H/P/PR",
      "p": "p85"
    },
    "S2": {
      "handle": "uchicagomedicine",
      "c": "H/P/A",
      "p": "p85"
    }
  },
  "quotes_by_search": {
    "1": [
      [
        "stage_therapeutics",
        "§S1:1.1"
      ],
      [
        "stage_trial",
        "§S1:2.1"
      ]
    ],
    "2": [
      [
        "trial_ctgov",
        "§S1:2.1"
      ],
      [
        "trial_uchicago",
        "§S2:2.1"
      ]
    ],
    "3": [
      [
        "phase_imaging",
        "§S1:2.5"
      ],
      [
        "phase_study",
        "§S2:2.1"
      ]
    ]
  }
}
```

</details>

#### Batch Extraction Result (5 sources) <small>(04:07:21)</small>

<details><summary>Click to expand</summary>

```json
{
  "source_metadata": {
    "S1": {
      "handle": "clinicaltrials",
      "c": "H/P",
      "p": "p95"
    },
    "S2": {
      "handle": "perspectivetherapeutics",
      "c": "M/P/O",
      "p": "p85"
    },
    "S3": {
      "handle": "clinicaltrials",
      "c": "H/P",
      "p": "p95"
    },
    "S4": {
      "handle": "mayoclinic",
      "c": "H/P",
      "p": "p85"
    },
    "S5": {
      "handle": "patsnap",
      "c": "M/O",
      "p": "p65"
    }
  },
  "quotes_by_search": {
    "1": [
      [
        "vmt01-stage_phase-1/2a",
        "§S2:2.1"
      ],
      [
        "vmt01-indication_melanoma",
        "§S2:1.1"
      ]
    ],
    "2": [
      [
        "nct05655312_vmt02",
        "§S1:1.1"
      ],
      [
        "nct05655312_vmt01",
        "§S3:2.1"
      ]
    ],
    "3": [
      [
        "vmt01-phase_1/2a",
        "§S2:2.1"
      ],
      [
        "vmt01-phase_1",
        "§S5:17.0"
      ]
    ]
  }
}
```

</details>

#### Batch Extraction Result (4 sources) <small>(04:07:22)</small>

<details><summary>Click to expand</summary>

```json
{
  "source_metadata": {
    "S1": {
      "handle": "braintumor",
      "c": "H/P/PR",
      "p": "p85"
    },
    "S2": {
      "handle": "perspectivetherapeutics",
      "c": "M/P/O",
      "p": "p65"
    },
    "S3": {
      "handle": "lacnets",
      "c": "M/P/O",
      "p": "p65"
    },
    "S4": {
      "handle": "theranostictrials",
      "c": "M/P/O",
      "p": "p50"
    }
  },
  "quotes_by_search": {
    "1": [
      [
        "dose-stage_phase-2",
        "§S1:1.1"
      ],
      [
        "dose-stage_phase-2",
        "§S1:2.1"
      ],
      [
        "dose-stage_phase-2",
        "§S1:3.1"
      ],
      [
        "dose-stage_phase-2",
        "§S1:4.1"
      ],
      [
        "dose-stage_phase-2",
        "§S1:5.1"
      ],
      [
        "stage_clinical",
        "§S2:1.1"
      ],
      [
        "stage_clinical",
        "§S2:2.1"
      ],
      [
        "stage_phase-1",
        "§S2:2.5"
      ],
      [
        "stage_phase-1/2a",
        "§S3:2.3"
      ],
      [
        "stage_phase-1/2a",
        "§S3:2.8"
      ],
      [
        "stage_phase-1",
        "§S3:2.9"
      ],
      [
        "stage_advanced",
        "§S4:1.3"
      ]
    ],
    "2": [
      [
        "clinicaltrials.gov_NCT05655312",
        "§S1:1.1"
      ],
      [
        "clinicaltrials.gov_NCT05655312",
        "§S1:2.1"
      ],
      [
        "clinicaltrials.gov_NCT05655312",
        "§S1:3.1"
      ],
      [
        "clinicaltrials.gov_NCT05655312",
        "§S1:4.1"
      ],
      [
        "clinicaltrials.gov_NCT05655312",
        "§S1:5.1"
      ],
      [
        "clinicaltrials.gov_NCT05655312",
        "§S2:2.1"
      ],
      [
        "clinicaltrials.gov_NCT05636618",
        "§S3:2.1"
      ],
      [
        "clinicaltrials.gov_NCT07156565",
        "§S4:3.2"
      ]
    ],
    "3": [
      [
        "phase-2",
        "§S1:1.1"
      ],
      [
        "phase-2",
        "§S1:2.1"
      ],
      [
        "phase-2",
        "§S1:3.1"
      ],
      [
        "phase-2",
        "§S1:4.1"
      ],
      [
        "phase-2",
        "§S1:5.1"
      ],
      [
        "phase-1",
        "§S2:2.5"
      ],
      [
        "phase-1/2a",
        "§S3:2.3"
      ],
      [
        "phase-1/2a",
        "§S3:2.8"
      ],
      [
        "phase-1",
        "§S3:2.9"
      ]
    ]
  }
}
```

</details>


<details>
<summary><b>[SUCCESS] Step: Re-Synthesis (Current Model)</b> <small>(04:07:22)</small></summary>

## Re-Synthesis (Current Model) <small>(04:07:22)</small>

```text
Self-assessment: B. Re-running synthesis.
```

### Synthesis Prompt (Iter 2) <small>(04:07:22)</small>

<details><summary>Click to expand</summary>

```text
# Generate Answer from Quotes

Query: # Table Entry Validation and Research

You are validating and updating several field values for a single row in a research table.

═══════════════════════════════════════════════════════════════
## 🎯 FOCUSED TASK
═══════════════════════════════════════════════════════════════

**Use this section to guide your initial web searches.** Detailed field requirements for synthesis appear below.

**Context:**
Product (or Candidate): VMT02
Owner: Ratio Therapeutics

**3 Research Questions:**
Core Product & Owner Info: Basic product information including owner, target/indication, and development stage. This foundational data is often found together in company pipelines and press releases.

**1. Owner**: Company or entity that owns or is developing the product.???
   Current value: Ratio Therapeutics
**2. Target / Indication**: Biological target and the disease indication the product is intended for.???
**3. Development Stage**: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).???

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 WHAT YOU'LL FIND BELOW
═══════════════════════════════════════════════════════════════

The sections below provide detailed context for **synthesizing your search results** into validated answers:

- **GENERAL NOTES**: Validation context for the broader research effort this subtask falls within
- **CONTEXT & PREVIOUS DATA**: Other fields from this row and prior validations for reference
- **FIELD DETAILS**: Detailed requirements, format, notes, and examples for each field
- **CONFIDENCE LEVELS**: How to assign confidence ratings to your findings
- **RESPONSE FORMAT**: Required JSON structure and critical validation rules

═══════════════════════════════════════════════════════════════

---

═══════════════════════════════════════════════════════════════
## 📋 GENERAL NOTES
═══════════════════════════════════════════════════════════════

This configuration validates a biopharmaceutical product/candidate tracking table. The primary identifier is the product name. All research columns should be verified against current public information as of February 13, 2026, using company websites, clinical trial registries (e.g., ClinicalTrials.gov), and reputable news sources. For columns left blank, it may indicate the information is not applicable or not yet public.

---

═══════════════════════════════════════════════════════════════
## 📊 CONTEXT & PREVIOUS DATA
═══════════════════════════════════════════════════════════════

**Context for this row:**

Product (or Candidate): VMT02
Owner: Ratio Therapeutics

⚠️ **CRITICAL - ROW CONTEXT SCOPE CONSTRAINT:**
All validation results must be about the SPECIFIC ENTITY identified by the context above.

**Common scope errors to AVOID:**
- Validating a different entity with a similar name
- Using general information when specific information is required
- Example: When validating news for "Product X by Company Y", reject news that only mentions "Company Y" without mentioning "Product X"
- Example: When validating a company associated with a product, verify the company OWNS/DEVELOPS that specific product, not just that the company exists

**Scope validation checklist:**
1. Do sources explicitly mention ALL identifying information from context above?
2. Is information contemporary with the entity (not before it existed)?
3. Have you cross-referenced to confirm entity identity?
4. When in doubt, mark confidence as MEDIUM or LOW

**Other fields from this row (unvalidated - for reference only):**

**Previous validations for this row:**

Product (or Candidate): VMT02 (Confidence: ID)

⚠️ **CRITICAL - INHERENT SUSPICION OF PREVIOUS RESULTS:**

Previous values shown above may be INCORRECT. Do NOT assume they are correct.

**Mandatory verification requirements:**
- Treat previous values as HYPOTHESES to be tested, not FACTS
- Every previous claim must be verified against current authoritative sources
- Do NOT copy previous values without independent verification
- Well-formatted previous answers with citations can still be wrong
- High confidence scores from past validations don't guarantee truth

**If current sources conflict with previous values:**
1. Prioritize DIRECT QUOTES from HIGH-AUTHORITY sources (see confidence criteria)
2. Check publication dates - newer authoritative sources may supersede old data
3. If conflict unresolved, mark confidence as MEDIUM or LOW
4. Document the conflict in your explanation

**Truth Standard:** Direct quotes from authoritative sources determine truth,
NOT how confident, well-cited, or professionally formatted previous results appear.

Your task: Use previous results as a STARTING POINT, then independently verify/correct with current sources.

---

═══════════════════════════════════════════════════════════════
## 📝 FIELD DETAILS - Format Requirements and Examples
═══════════════════════════════════════════════════════════════

**For each field you will receive:**

- **Field Name**: (This is the name of the field)
- **Description**: (What this field represents)
- **Format**: (How to format your answer)
- **Notes**: (Quality standards for this specific field)
- **Examples**: (Sample formatting)

**VALUES TO CONSIDER:**
- **Current Value** (to be validated/updated): The value that needs validation/updating in this run
- **Previous Value** (from Original Values sheet): The historical validated value from a prior validation run (if available)

**YOUR TASK**: Validate and update the **Current Value** using web search and the guidance provided. Compare it to the **Previous Value** (if available) to understand what has changed.

----- FIELD 1: Owner -----
**Current Value**: Ratio Therapeutics
Description: Company or entity that owns or is developing the product.
Format: String
Importance: RESEARCH

Notes: Verify the current owner/developer. Check company websites and recent press releases.

Examples:
  - Actithera
  - Advanced Accelerator Applications
  - Bayer

----- FIELD 2: Target / Indication -----
**Current Value**: 
Description: Biological target and the disease indication the product is intended for.
Format: String
Importance: RESEARCH

Notes: Verify the molecular target (e.g., FAP, PSMA) and the specific disease or condition.

Examples:
  - FAP / oncology (lead program)
  - FAP / pan-cancer imaging
  - FAP / pan-cancer therapy

----- FIELD 3: Development Stage -----
**Current Value**: 
Description: Current phase of clinical development (e.g., Phase I, Phase II, Preclinical).
Format: String
Importance: RESEARCH

Notes: Confirm the most recent development stage from official sources like clinical trial registries or company pipelines. Use standard terms (Preclinical, Phase I, Phase II, Phase III, Approved).

Examples:
  - Phase I
  - Phase II
  - Preclinical

---

═══════════════════════════════════════════════════════════════
## ⭐ CONFIDENCE LEVELS
═══════════════════════════════════════════════════════════════

Confidence measures the likelihood that the facts stated in the cell are precisely accurate:

- **HIGH (H)**: 85%+ likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood ≥ 85%
  - Source: Authoritative, directly verifiable, widely accepted

- **MEDIUM (M)**: 65%-85% likelihood that the facts are precisely accurate
  - Multiple facts: average likelihood 65%-85%
  - Source: Respectable but not definitive, good estimates, confident projections

- **LOW (L)**: <65% likelihood that the facts are precisely accurate
  - Weak/conflicting sources, uncertainty, no authoritative verification
  - **Only LOW confidence answers may be blank (null)**
  - **Blank originals**: Assign LOW for `original_confidence` when the original value was blank/empty
  - **Removing false data**: If original has LOW confidence false data and no reliable replacement exists, you CAN go to blank with LOW confidence (removing bad data is acceptable)

**SPECIAL CASE - Expressing Doubt:**
When the value itself expresses uncertainty (e.g., "Rumors suggest...", "Unconfirmed reports say...", "Less reliable sources claim..."), confidence measures whether the SOURCES say it, NOT whether it's true.

Example:
- Value: "Rumors suggest launch in Q3 2025"
- HIGH confidence: Multiple sources confirm rumors exist
- The confidence is about the rumors existing, not about the launch happening

**Confident Absence:**
If you are confident something does not exist or is not applicable, say so explicitly with language appropriate to the measure (e.g., "N/A", "Not applicable", "No website", "Not publicly traded") and assign an appropriate confidence level (H/M). Do not leave it blank - blank means you have no information.

---

═══════════════════════════════════════════════════════════════
## 📤 RESPONSE FORMAT
═══════════════════════════════════════════════════════════════

Return a JSON array where each item is a cell array with 6 elements:

```
[column, answer, confidence, original_confidence, consistent, explanation]
```

- **column**: Exact field name from FIELD DETAILS
- **answer**: The validated value (string or null for blank)
- **confidence**: H (HIGH), M (MEDIUM), or L (LOW)
- **original_confidence**: H, M, or L (for the original value)
- **consistent**: T (consistent with model knowledge), F (not consistent), or null
- **explanation**: Succinct reason you believe the answer is correct

**Example:**
```json
[
  ["Revenue", "$158.9B", "H", "M", "T", "Q3 2024 earnings report confirmed"],
  ["CEO", "Andy Jassy", "H", "H", "T", "Official Amazon leadership page"],
  ["Founded", null, "L", "L", null, "No reliable data found"]
]
```

### CRITICAL REQUIREMENTS

- **Do not use quotation marks around your responses** (except in JSON structure itself)
- **Assess both confidences**: Rate the quality of your updated answer (confidence) AND the quality of the original value (original_confidence) using H/M/L
- **CRITICAL - Blank original values**: If the original value was blank/empty, set `original_confidence` to `L` (LOW). Blank originals get LOW original_confidence.
- **Only update if significantly better**: Only provide a different validated value if you can improve significantly on the original value
- **Generally don't degrade confidence**:
  - If original has H/M confidence, don't degrade to L or blank without strong justification
  - If original has L confidence false data and no reliable replacement: You CAN leave blank (removing bad data is acceptable)
  - Hierarchy: H > M > L
  - **Confident absence**: Use language appropriate to the measure (e.g., "N/A", "Not applicable", "No website") with confidence — blank means you have no information, not that the value doesn't exist
- **Use exact column names**: Include the exact column name in each cell array - exactly as defined in the FIELD DETAILS above
- **Provide explanation**: Always include the explanation with succinct reasoning for your answer
- **Handle blanks appropriately**: If you cannot find or determine information for a field, use null for answer and L for confidence. Only LOW confidence answers may be truly blank.
- **Use examples as guides**: Use provided examples to guide your update format and expected values
- **Format for Excel**: Use newline characters correctly so that they are formatted in an Excel cell, particularly for bullets, lists, and other formatted text
- **Stay focused**: Do not research the context and guidance - focus only on the fields listed above
- **Double check everything**: Double check your updated response and confidence - speak precisely, there is no room for error
- **Valid JSON required**: The response MUST be valid JSON array format

---


**Today's Date:** 2026-02-13

## Your Previous Response (Iteration 1), Grade: B

**Search Terms Used:** "VMT02 Ratio Therapeutics target indication development stage", "Ratio Therapeutics VMT02 clinicaltrials.gov", "VMT02 clinical trial phase"

```json
[
  [
    "Owner",
    "Ratio Therapeutics",
    "H",
    "H",
    "T",
    "Confirmed as the developer of VMT02 [1]"
  ],
  [
    "Target / Indication",
    "MC1R / MC1R-positive melanoma",
    "H",
    "L",
    "T",
    "VMT01/02 targets the melanocortin subtype 1 receptor (MC1R) for MC1R-positive melanoma [1]"
  ],
  [
    "Development Stage",
    "Phase 2",
    "M",
    "L",
    null,
    "PatSnap lists VMT02 as Phase 2, but this is a lower-quality source; no high-authority source explicitly confirms the stage for VMT02 [2]"
  ]
]
```

**Grade: B**
**Your Comment to Self:** "Found high-confidence target/indication from Perspective Therapeutics pipeline page, but development stage is only from a medium-confidence source (PatSnap). Need to search clinical trial registries for definitive stage."


---
**IMPORTANT:** You are now receiving additional search results based on your self-correction request.
Use your previous response as a foundation and improve upon it with the new information.

## Structure Legend

- **Q1.{n}:** Query number in iteration 1 (search term used)
- **Snippet ID Format:** S{iter}.{search}.{source}.{snippet}-p{score}
  - Example: S1.2.3.0-p0.85 = Iteration 1, Search 2, Source 3, Snippet 0, p-score 0.85
- **p (probability):** Source-level quality score (0.05-0.95) - judge tests all atomic claims, p = expected pass-rate
  - 0.85-0.95: High confidence (PRIMARY/DOCUMENTED/ATTRIBUTED) - prefer these
  - 0.50-0.65: Medium confidence (OK quality)
  - 0.05-0.30: Low confidence (UNSOURCED/STALE/PROMOTIONAL) - use cautiously
- **c (classification):** Source authority + quality codes (shown in snippet metadata)
  - H/P = High Authority + Primary
  - H/P/D/A = High + Primary + Documented + Attributed
  - M/O = Medium Authority + OK
  - L/U = Low Authority + Unsourced
- **Date:** Publication or last updated date from source

## Quotes Organized by Search Term


Q1.1: "VMT02 Ratio Therapeutics target indication development stage"
  [S1.1.1] https://synapse.patsnap.com/drug/2147731a54d94c709c7db6757eb5cd1f [2025-11-03] [WARNING: Lower Quality Source (p=0.5)]
    - [patsnap_melanoma_phase-2, S1.1.1.0-p0.50] (p=0.5, c=M/O) "Phase 2"
    - [patsnap_melanoma_phase-1, S1.1.1.1-p0.50] (p=0.5, c=M/O) "Phase 1"
  [S1.1.2] https://www.1stoncology.com/blog/january-17th-2024-ratio-therapeutics-announces-50m-series-b-financing-to-advance-targeted-radiotherapies-for-cancer-treatment1234639292/ [2024-01-17] [WARNING: Lower Quality Source (p=0.5)]
    - [oncology_fap-targeted_therapeutic, S1.1.2.0-p0.50] (p=0.5, c=M/O) "Additionally, the funding will drive the clinical development of the company’s fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic."
  [S1.1.3] https://lifesciencereport.com/news/nyse/nvs/ratio-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate [2024-11-18] [WARNING: Lower Quality Source (p=0.5)]
    - [lifescience_sstr2-targeting_therapeutic, S1.1.3.0-p0.50] (p=0.5, c=M/O) "The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer."
  [S1.1.4] https://onco-this-week.com/ratio-therapeutics-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate/ [2024-11-26] [WARNING: Lower Quality Source (p=0.5)]
    - [onco_sstr2-targeting_therapeutic, S1.1.4.0-p0.50] (p=0.5, c=M/O) "“The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic,” said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. “Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors.”"
  [S1.1.5] https://perspectivetherapeutics.com/pipeline/vmt01-02 [2025-05-19]
    - [perspective_mc1r-expressing_melanomas, S1.1.5.0-p0.95] (p=0.95, c=H/P) "VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas."
    - [perspective_mc1r-positive_melanoma, S1.1.5.1-p0.95] (p=0.95, c=H/P) "212Pb]VMT01 as monotherapy and in combination with nivolumab in patients with unresectable or metastatic MC1R-positive melanoma, currently recruiting across the US"
    - [perspectivetherapeutics_vmt01-indication_melanoma, S2.1.7.1-p0.85] (p=0.85, c=M/P/O) "VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas."
    - [perspectivetherapeutics_vmt01-stage_phase-1/2a, S2.1.7.0-p0.85] (p=0.85, c=M/P/O) "Ongoing multi-center Phase 1/2a dose-escalation/expansion trial (NCT05655312) evaluating ["
  [S2.1.11] https://www.perspectivetherapeutics.com/pipeline/vmt01-02 [2025-05-19] [WARNING: Lower Quality Source (p=0.85)]
    - [perspectivetherapeutics_stage_therapeutics, S2.1.11.0-p0.85] (p=0.85, c=H/P/PR) "VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas."
    - [perspectivetherapeutics_stage_trial, S2.1.11.1-p0.85] (p=0.85, c=H/P/PR) "- US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT05655312?term=vmt01"
    - [perspectivetherapeutics_stage_clinical, S2.2.14.0-p0.65] (p=0.65, c=M/P/O) "VMT01 is a clinical-stage radiopharmaceutical therapy for diagnosing and treating melanocortin subtype 1 receptor (MC1R)-expressing melanomas."
    - [perspectivetherapeutics_stage_clinical, S2.2.14.1-p0.65] (p=0.65, c=M/P/O) "- US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT05655312?term=vmt01"
    - [perspectivetherapeutics_stage_phase-1, S2.2.14.2-p0.65] (p=0.65, c=M/P/O) "- Phase 1 imaging study at Mayo Clinic Rochester indicates feasibility of patient"
  [S2.2.13] https://trials.braintumor.org/trials/NCT05655312 [2022-08-31]
    - [braintumor_dose-stage_phase-2, S2.2.13.0-p0.85] (p=0.85, c=H/P/PR) "This study will be conducted in 3 parts: Part 1: Monotherapy Dose-Escalation: [212Pb]VMT01 is administered alone in escalating doses to determine the Maximum Tolerated radioactivity Dose (MTD), Maximum Feasible radioactivity Dose (MFD), and potential recommended Phase 2 doses (RP2Ds) Part 2: Combination-Therapy Dose-Escalation: [212Pb]VMT01 and Nivolumab are administered in escalating doses to determine MTD, MFD, and RP2Ds."
    - [braintumor_dose-stage_phase-2, S2.2.13.1-p0.85] (p=0.85, c=H/P/PR) "Enrolled subjects will be treated with increasing doses of [212Pb]VMT01 (up to 15 mCi) to determine MTD, MFD, and RP2D."
    - [braintumor_dose-stage_phase-2, S2.2.13.2-p0.85] (p=0.85, c=H/P/PR) "Enrolled subjects will be treated with increasing radioactive doses of [212Pb]VMT01 (up to 15 mCi) in combination with nivolumab to determine MTD, MFD, and RP2D."
    - [braintumor_dose-stage_phase-2, S2.2.13.3-p0.85] (p=0.85, c=H/P/PR) "Up to 2 monotherapy expansion cohorts of up to 25 subjects will be enrolled at previously identified RP2D to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort."
    - [braintumor_dose-stage_phase-2, S2.2.13.4-p0.85] (p=0.85, c=H/P/PR) "Up to 2 Combination Therapy expansion cohorts of up to 25 subjects will be enrolled at RP2Ds previously identified to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort."
  [S2.2.15] https://www.lacnets.org/clinical-trials-1/alpha-prrt-with-pb-212-vmt [2016-01-01] [WARNING: Lower Quality Source (p=0.65)]
    - [lacnets_stage_phase-1/2a, S2.2.15.0-p0.65] (p=0.65, c=M/P/O) "**PHASE**: 1 / 2A"
    - [lacnets_stage_phase-1/2a, S2.2.15.1-p0.65] (p=0.65, c=M/P/O) "Perspective Therapeutics is sponsoring a phase 1 / 2A prospective, multi-center open-label dose escalation, dose expansion study of [212Pb]VMT01 in up to 52 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT)."

Q1.2: "Ratio Therapeutics VMT02 clinicaltrials.gov"
  [S2.1.6] https://www.clinicaltrials.gov/study/NCT05655312 [2022-11-15]
    - [clinicaltrials_nct05655312_vmt02, S2.1.6.0-p0.95] (p=0.95, c=H/P) "This is a prospective, multi-center open-label dose-escalation, dose-expansion study of [212Pb]VMT01 as a monotherapy or in combination with Nivolumab in up to 264 subjects with histologically confirmed melanoma and a positive MC1R imaging scan with imaging agents [203Pb]VMT01 or [68Ga]VMT02."
  [S2.1.8] https://clinicaltrials.gov/study/NCT05655312?intr=212Pb&checkSpell=&rank=6 [2022-11-15]
    - [clinicaltrials_nct05655312_vmt01, S2.1.8.0-p0.95] (p=0.95, c=H/P) "This is a prospective, multi-center open-label dose-finding, dose-expansion study of [212Pb]VMT01 as a monotherapy or in combination with nivolumab in up to 300 subjects with histologically confirmed melanoma and a positive MC1R imaging scan with imaging agents [203Pb]VMT01 or [68Ga]VMT02."
  [S2.1.11] https://www.perspectivetherapeutics.com/pipeline/vmt01-02 [2025-05-19] [WARNING: Lower Quality Source (p=0.85)]
    - [perspectivetherapeutics_trial_ctgov, S2.1.11.2-p0.85] (p=0.85, c=H/P/PR) "- US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT05655312?term=vmt01"
    - [perspectivetherapeutics_clinicaltrials.gov_NCT05655312, S2.2.14.3-p0.65] (p=0.65, c=M/P/O) "- US Therapeutic Dose Finding Trial recruiting currently throughout the US -- https://clinicaltrials.gov/study/NCT05655312?term=vmt01"
  [S2.1.12] https://www.uchicagomedicine.org/find-a-clinical-trial/clinical-trial/irb230670 [2024-06-04]
    - [uchicagomedicine_trial_uchicago, S2.1.12.0-p0.85] (p=0.85, c=H/P/A) "This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors"
  [S2.2.13] https://trials.braintumor.org/trials/NCT05655312 [2022-08-31]
    - [braintumor_clinicaltrials.gov_NCT05655312, S2.2.13.5-p0.85] (p=0.85, c=H/P/PR) "This study will be conducted in 3 parts: Part 1: Monotherapy Dose-Escalation: [212Pb]VMT01 is administered alone in escalating doses to determine the Maximum Tolerated radioactivity Dose (MTD), Maximum Feasible radioactivity Dose (MFD), and potential recommended Phase 2 doses (RP2Ds) Part 2: Combination-Therapy Dose-Escalation: [212Pb]VMT01 and Nivolumab are administered in escalating doses to determine MTD, MFD, and RP2Ds."
    - [braintumor_clinicaltrials.gov_NCT05655312, S2.2.13.6-p0.85] (p=0.85, c=H/P/PR) "Enrolled subjects will be treated with increasing doses of [212Pb]VMT01 (up to 15 mCi) to determine MTD, MFD, and RP2D."
    - [braintumor_clinicaltrials.gov_NCT05655312, S2.2.13.7-p0.85] (p=0.85, c=H/P/PR) "Enrolled subjects will be treated with increasing radioactive doses of [212Pb]VMT01 (up to 15 mCi) in combination with nivolumab to determine MTD, MFD, and RP2D."
    - [braintumor_clinicaltrials.gov_NCT05655312, S2.2.13.8-p0.85] (p=0.85, c=H/P/PR) "Up to 2 monotherapy expansion cohorts of up to 25 subjects will be enrolled at previously identified RP2D to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort."
    - [braintumor_clinicaltrials.gov_NCT05655312, S2.2.13.9-p0.85] (p=0.85, c=H/P/PR) "Up to 2 Combination Therapy expansion cohorts of up to 25 subjects will be enrolled at RP2Ds previously identified to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort."
  [S2.2.15] https://www.lacnets.org/clinical-trials-1/alpha-prrt-with-pb-212-vmt [2016-01-01] [WARNING: Lower Quality Source (p=0.65)]
    - [lacnets_clinicaltrials.gov_NCT05636618, S2.2.15.3-p0.65] (p=0.65, c=M/P/O) "**IDENTIFIER (** **ClinicalTrials.gov** **)**: NCT05636618"

Q1.3: "VMT02 clinical trial phase"
  [S2.1.7] https://perspectivetherapeutics.com/pipeline/vmt01-02 [2025-05-19]
    - [perspectivetherapeutics_vmt01-phase_1/2a, S2.1.7.2-p0.85] (p=0.85, c=M/P/O) "Ongoing multi-center Phase 1/2a dose-escalation/expansion trial (NCT05655312) evaluating ["
  [S2.1.11] https://www.perspectivetherapeutics.com/pipeline/vmt01-02 [2025-05-19] [WARNING: Lower Quality Source (p=0.85)]
    - [perspectivetherapeutics_phase_imaging, S2.1.11.3-p0.85] (p=0.85, c=H/P/PR) "- Phase 1 imaging study at Mayo Clinic Rochester indicates feasibility of patient"
    - [perspectivetherapeutics_phase-1, S2.2.14.4-p0.65] (p=0.65, c=M/P/O) "- Phase 1 imaging study at Mayo Clinic Rochester indicates feasibility of patient"
  [S2.1.12] https://www.uchicagomedicine.org/find-a-clinical-trial/clinical-trial/irb230670 [2024-06-04]
    - [uchicagomedicine_phase_study, S2.1.12.1-p0.85] (p=0.85, c=H/P/A) "This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors"
  [S2.2.13] https://trials.braintumor.org/trials/NCT05655312 [2022-08-31]
    - [braintumor_phase-2, S2.2.13.10-p0.85] (p=0.85, c=H/P/PR) "This study will be conducted in 3 parts: Part 1: Monotherapy Dose-Escalation: [212Pb]VMT01 is administered alone in escalating doses to determine the Maximum Tolerated radioactivity Dose (MTD), Maximum Feasible radioactivity Dose (MFD), and potential recommended Phase 2 doses (RP2Ds) Part 2: Combination-Therapy Dose-Escalation: [212Pb]VMT01 and Nivolumab are administered in escalating doses to determine MTD, MFD, and RP2Ds."
    - [braintumor_phase-2, S2.2.13.11-p0.85] (p=0.85, c=H/P/PR) "Enrolled subjects will be treated with increasing doses of [212Pb]VMT01 (up to 15 mCi) to determine MTD, MFD, and RP2D."
    - [braintumor_phase-2, S2.2.13.12-p0.85] (p=0.85, c=H/P/PR) "Enrolled subjects will be treated with increasing radioactive doses of [212Pb]VMT01 (up to 15 mCi) in combination with nivolumab to determine MTD, MFD, and RP2D."
    - [braintumor_phase-2, S2.2.13.13-p0.85] (p=0.85, c=H/P/PR) "Up to 2 monotherapy expansion cohorts of up to 25 subjects will be enrolled at previously identified RP2D to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort."
    - [braintumor_phase-2, S2.2.13.14-p0.85] (p=0.85, c=H/P/PR) "Up to 2 Combination Therapy expansion cohorts of up to 25 subjects will be enrolled at RP2Ds previously identified to confirm the RP2D and regimen for the Phase 2 dose-expansion cohort."
  [S2.2.15] https://www.lacnets.org/clinical-trials-1/alpha-prrt-with-pb-212-vmt [2016-01-01] [WARNING: Lower Quality Source (p=0.65)]
    - [lacnets_phase-1/2a, S2.2.15.4-p0.65] (p=0.65, c=M/P/O) "**PHASE**: 1 / 2A"
    - [lacnets_phase-1/2a, S2.2.15.5-p0.65] (p=0.65, c=M/P/O) "Perspective Therapeutics is sponsoring a phase 1 / 2A prospective, multi-center open-label dose escalation, dose expansion study of [212Pb]VMT01 in up to 52 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT). During phase 1, there is a dose escalation period testing up to 4 escalating radioactivity dose cohorts of up to 8 subjects (administered at approximately 8-week intervals) at the assigned cohort radioactivity dose."
    - [lacnets_phase-1, S2.2.15.6-p0.65] (p=0.65, c=M/P/O) "During phase 1, there is a dose escalation period testing up to 4 escalating radioactivity dose cohorts of up to 8 subjects (administered at approximately 8-week intervals) at the assigned cohort radioactivity dose."

## Synthesis Instructions


SYNTHESIS DEPTH: Low Context (Concise & Direct)

Guidelines:
- Provide direct, focused answers
- Cover the main points without extensive elaboration
- Use 3-5 key facts
- Keep explanations brief and clear
- Minimal contextual background
- Focus on answering the specific question asked

SOURCE PRIORITY:
- **Prioritize HIGH reliability sources** (H) over MEDIUM (M) and LOW (L)
- Only use MEDIUM/LOW sources if HIGH sources don't cover that aspect

Target: Concise, fact-focused response


## Your Task

Generate a structured comparison answering the query, then self-assess.

**Citation Format:** Use [verbal_handle, snippet_id] format for all citations.

**CRITICAL - COPY EXACT handles and IDs from snippets above:**
- Format: `[handle, S1.1.5.6-p0.95]` - FULL 4-part ID
- **DO NOT create your own handles** - COPY from snippet listings
- **DO NOT shorten IDs** - Use full 4-part format
- Example from listings: `[intermittent_fasting_weight_2, S1.1.1.0-p0.95]`
  - ❌ WRONG: `[if_weight, S1.1.1-p0.95]` - made up handle, shortened ID
  - ✅ CORRECT: `[intermittent_fasting_weight_2, S1.1.1.0-p0.95]` - exact copy
- **Look up the snippet in listings above, copy its [handle, ID] exactly**
- **REQUIRED:** Every factual claim must have citations

**Output Structure:** Use nested objects to avoid repetition.

**CRITICAL - Citation Placement:**
- **INLINE ONLY**: Citations must be embedded DIRECTLY in the text
- **NO separate citation fields**: Do NOT create fields like "citations": [...]
- **Format**: Include [handle, ID] at the END of each claim within the text itself

Example structure:
```json
{
  "comparison": {
    "current_value": "6.21% [mortgage_rate_dec2025, S1.1.1.0-p0.95]",
    "trend": "decreased from prior week [rate_change, S1.1.2.1-p0.85]"
  },
  "self_assessment": "A"
}
```

❌ WRONG - Separate citation fields:
```json
{
  "feature": {
    "description": "Feature description here",
    "citations": [["handle1, S1.1.1.0-p0.95"]]
  }
}
```

✅ CORRECT - Inline citations:
```json
{
  "feature": "Feature description here [handle1, S1.1.1.0-p0.95]"
}
```

Note: Use FULL 4-part IDs exactly as shown in snippets above.

## Self-Assessment

Imagine a client paid an expert researcher for this answer. Would they be satisfied?

**Expert answers have:**
- Direct response to what was asked (no tangents, no gaps)
- Specific facts (numbers, dates, names - not vague generalities)
- Claims backed by authoritative sources with citations
- Complete coverage (nothing important missing that's findable online)
- Clear and well-organized presentation

**Grade your synthesis (A+ to C-):**
- **A+/A**: Expert-quality - client would be satisfied, nothing important missing
- **B**: Acceptable but incomplete - missing information that's likely findable online
  - **Optional:** Provide `suggested_search_terms` ONLY if you have specific, concrete gaps that targeted searches would fill.
  - **Optional:** `request_capability_upgrade=true` if reasoning is too complex.
  - **Optional:** `note_to_self` for next attempt.
- **C**: Insufficient - cannot meaningfully answer, or information not available
  - **Optional:** Provide `suggested_search_terms` ONLY if specific searches would likely help.

**CRITICAL for suggested_search_terms:**
- ONLY suggest search terms when you have HIGH CONFIDENCE they will find new, useful information
- Do NOT suggest speculative or exploratory searches ("maybe there's more about X")
- Each term should target a SPECIFIC gap you identified (e.g., "Company Y Phase 3 trial results 2024")
- If you're unsure whether more searches would help, do NOT suggest any - just give your best answer
- Empty `suggested_search_terms` is preferable to low-confidence guesses

**CRITICAL:**
- You MUST always provide an answer that satisfies the schema structure, even if incomplete.
- We will only re-run searches if you provide `suggested_search_terms` OR set `request_capability_upgrade=true`.

Return JSON with 'comparison', 'self_assessment', and optional 'suggested_search_terms', 'request_capability_upgrade', and 'note_to_self' fields.

**⚠️ RESPONSE LENGTH LIMIT: Keep your total response under 24000 words.**
```

</details>

### Refinement Mode Activated (Iter 2) <small>(04:07:22)</small>

<details><summary>Click to expand</summary>

```json
{
  "Refining": "Iteration 1 answer (Grade: B)",
  "Strategy": "3-tier cost-optimized refinement",
  "Tier 1": "Patches (fast, cheap)",
  "Tier 2": "Cheap model full implementation",
  "Tier 3": "Primary model full generation (fallback)"
}
```

</details>

### Refinement Success (Tier 1) <small>(04:07:34)</small>

```json
{
  "Method": "Patches (patches)",
  "Cost": "$0.0029",
  "Tier Breakdown": {
    "Tier 1": "$0.0029"
  },
  "Patches Applied": 4
}
```

### Synthesis Result (Iter 2) <small>(04:07:34)</small>

<details><summary>Click to expand</summary>

```json
[
  [
    "Owner",
    "Ratio Therapeutics",
    "H",
    "H",
    "T",
    "Confirmed as the developer of VMT02 [1]"
  ],
  [
    "Target / Indication",
    "MC1R / MC1R-positive melanoma",
    "H",
    "L",
    "T",
    "VMT01/02 targets the melanocortin subtype 1 receptor (MC1R) for MC1R-positive melanoma [1]"
  ],
  [
    "Development Stage",
    "Phase 1/2a",
    "H",
    "L",
    null,
    "ClinicalTrials.gov lists VMT02 as an imaging agent in a Phase 1/2a trial (NCT05655312) for MC1R-positive melanoma [clinicaltrials_nct05655312_vmt02, S2.1.6.0-p0.95]"
  ]
]
```

</details>

<p align='right'><small>Step duration: 11.51s</small></p>
</details>
